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ABSTRACT 
Dementia is the top global public health threat of the twenty first century. Within the 
dementia spectrum, Alzheimer’s disease (AD) is the most common type of dementia that occurs 
with aging and accounts for about 60% - 80% of diagnosed cases. But currently available 
discoveries failed to develop disease-modifying therapies for all patients living with AD. Recent 
discoveries can only partially slow down cognitive decline in a small subset of patients with limited 
effectiveness. The heterogeneity and complexity of the pathophysiology of AD indicate that a 
single drug approach may not be sufficient to prevent disease onset and progression. Human 
umbilical cord blood cells (HUCBC) and lithium treatment have shown promise against numerous 
neurological conditions, including AD.  Yet, they also show significant unwanted, adverse effects. 
To address this barrier to yield successful treatments, we employed two key modifications to these 
two treatment strategy. We used human umbilical cord blood derived serum (HUCBS, also labeled 
as CBS) rather than HUCBC. We also utilized ionic cocrystal of lithium salicylate l-proline 
(LISPRO, also labeled as LP) instead of usual lithium salt. Both HUCBS and LISPRO have been 
shown to have strong neuroprotective, anti-inflammatory properties in separate studies conducted 
in transgenic AD mouse models. The studies detailed herein independently investigated the 
effectiveness of biological (HUCBS) and pharmacological (LISPRO) approaches in modulating 
the pathology and cognitive impairments in AD mouse models (e.g., 5XFAD, 3XTg-AD, 
APPswe/PS1dE9, and Tg2576).  
 xi 
 
While administration of HUCBC stimulate anti-inflammatory pathways shown in previous 
studies, we found that HUCBS markedly promoted neurotrophic soluble amyloid precursor protein 
alpha (sAPPα) through non-amyloidogenic amyloid precursor protein (APP) processing pathway 
compared to adult (ABS) and aged blood serum (AgBS) in Chinese hamster ovary cells expressing 
wild type APP (CHO/APPwt). Using chromatographic fractionation, mass-spectrometry, and 
targeting complement proteins in cord blood serum fraction (αCBSF), we discovered the source 
of sAPPα in HUCBS as C1 complement protein. Further, intraperitoneal administration of αCBSF 
via osmotic minipump for 6 weeks showed prevention of cognitive impairment in 5XFAD mice 
assessed by novel object recognition, and Y-maze test.  
A series of recent studies have shown that lithium can prevent both AD- and age-associated 
cognitive decline. But, current United States Food and Drug Administration-approved lithium 
pharmaceutics (carbonate and citrate forms) have a narrow therapeutic window and unstable 
pharmaceutics that can cause toxicity without monitoring. Here we investigated the safety, 
pharmacokinetics, and therapeutic efficacy of LISPRO (LP), lithium salicylate (LS), and lithium 
carbonate (LC) in cell culture and mouse (B6129SF2/J, Tg2576, and 3xTg-AD) models. Cytokine 
profiles from the brain, plasma and splenocytes demonstrated that 8-week oral treatment with 
LISPRO downregulates pro-inflammatory cytokines, upregulates anti-inflammatory cytokines and 
suppress renal cyclooxygenase 2 (COX2) expression in Tg2576 mice. Pharmacokinetic studies 
indicated that LISPRO provides significantly higher brain and more steady plasma lithium levels 
in both B6129SF2/J and transgenic Tg2576 mice compared with lithium carbonate. Oral 
administration of LISPRO for 28 weeks significantly reduced β-amyloid plaques and tau 
phosphorylation. In addition, LISPRO significantly elevated pre-synaptic (synaptophysin) and 
post-synaptic protein (post synaptic density protein 95) expression in brains from transgenic 
 xii 
 
3XTg-AD mice. Moreover, female APPswe/PS1dE9 mice at 4 months of age were orally treated 
with LP, LS, or LC for 8- to 9- months at 2.25 mmol lithium/kg/day followed by measuring body 
weight, internal organs’ growth, and cognitive and non-cognitive function. LISPRO treatment 
prevented cognitive decline compared with transgenic APPswe/PS1dE9 cohort, as shown by 
shorter escape latency during training and probe trials in the Morris water maze and longer 
contextual freezing time during fear conditioning.  As expected, LISPRO treatment also reduced 
depression assayed by tail suspension test and irritability assessed with the touch escape test.  But, 
lithium treatment did not alter anxiety or locomotor activity as assessed by open field, elevated 
plus maze or accelerated rotarod tests.  
Taken together, these data indicate that both biological HUCBS and pharmacological 
LISPRO treatment may prove to be viable effective strategy for ameliorating Alzheimer’s like 
pathology and cognitive impairment in preclinical models. 
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CHAPTER 1 
INTRODUCTION 
 
 
Note to reader: 
Portion of this chapter has been previously published in Journal of Neuroscience Research, 
Habib et al., (2017) 95(4): 971–991 (Restoring Soluble Amyloid Precursor Protein α Functions as 
a Potential Treatment for Alzheimer’s Disease) and has been reproduced with permission from 
Wiley Periodicals, Inc. 
 
Alzheimer’s disease (AD): Overview 
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that severely affects 
cognition with no disease modifying treatments.  The pathological features of AD currently 
include: (a) extracellular amyloid plaques composed largely of amyloid-β (Aβ) peptides [1], (b) 
intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated microtubule 
associated protein tau (p-tau) [2], (c) dysmorphic synapses, (d) inflammation, and (e) neuronal loss 
[3]. The clinical symptoms of AD comprise difficulties with thinking, internalizing information, 
memory, language, and other cognitive skills that affect the ability to live independently. These 
cognitive-processing difficulties occur, because neurons in different parts of the brain associated 
with cognition have become irreversibly damaged. Changes in mood and personality may be an 
initial, early sign of AD following a gradual decline in memory. With more substantial memory 
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decline, individuals often become disoriented to time and space and show disrupted sleep-wake 
cycle. People with more prominent memory decline begin to forget recent conversations, names 
or events at early stages, while later stages show additional symptoms including impaired verbal 
communication, poor judgment, losing or misplacing things, lose the ability to work, and 
ultimately unable to carry out activities of daily living, such as speaking and walking. A person in 
the final stage of the disease is bed-bound and usually requires intensive care. AD accounts for the 
sixth-leading cause of death in the United States. According to Alzheimer’s association data, an 
estimated 5.7 million Americans of all ages are currently living with AD in 2018. The percentage 
of people with AD increases with age with a prevalence rising from 3% at the age of 65 and 32% 
at the age of 85. Total number of AD cases will be nearly 14 million in the United States, as the 
older population is expected to double by 2050.  Although five drugs have U.S. federal approval 
to manage AD symptoms, there still remains no permanent cure for AD. Therefore, the 
management cost of the disease will exceed 20 trillion USD in 2050, if we do not find effective 
treatments [4]. 
Alzheimer’s disease (AD): Pathology   
The major pathological hallmark of AD is amyloid plaque, which is an extracellular deposit 
of a short peptide called Aβ.  According to amyloid cascade hypothesis, the proteolytic cleavage 
of APP by two different enzymes, β- (also called beta-site amyloid precursor protein cleaving 
enzyme 1, BACE1) and γ-secretases, is a critical step to develop AD.  In the non-amyloidogenic 
pathway, most APP is cleaved at the plasma membrane by α-secretase, which precedes Aβ 
formation but produces a large secreted, 105-125 kDa N-terminal ectodomain of APP (sAPPα) 
and small membrane-bound α-C-terminal fragment (CTF) [5]. Alpha (α) secretase proteolytic 
enzymes are members of a disintegrin and metalloproteinase domain (ADAM) family that cleaves 
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numerous cell surface proteins including APP. Then, the membrane-bound α-CTF is cleaved by -
secretase complex (presenilin-1, nicastrin, anterior pharynx-defective 1, presenilin enhancer 2) 
inducing release of P3 peptide (3 kDa) and AICD (APP intracellular domain). In the 
amyloidogenic pathway, the remaining uncleaved APP is processed into endosomal-lysosomal 
compartments by β-secretase, producing soluble sAPPβ and membrane-bound β-CTF [6]. 
Subsequent action of γ- secretase on β-CTF produces Aβ 1-40/42 peptides and AICD.  In addition to 
α-, β- and γ- secretase cleavage, some studies have identified that APP can be cleaved by the 
metalloprotease meprin β, which generates soluble N-terminal truncated APP (N-APP) and N-
terminally truncated Aβ2-x peptide variants [7][8][9]. These latter proteins show increased 
aggregation potential compared to non-truncated Aβ40 peptides.  Cleavage of APP by meprin β 
occurs prior to endocytosis, and different APP mutants affect the catalytic properties of the 
enzyme.  More specifically, Swedish mutant APP does not undergo this cleavage and is unable to 
produce these truncated Aβ variants. One recent study showed that APP can also be cleaved by 
matrix metalloproteinases such as MT5-MMP, referred to as -secretase, which releases a long-
truncated ectodomain (sAPPη) and a membrane-bound CTF, termed CTFη. The membrane-bound 
CTFη is further cleaved by α- and β-secretases releasing both a long (Aη-α) and a short (Aη-β) 
peptide, respectively.  The cleavage of η occurs far from the N-terminus of the β-secretase cleavage 
site and produces fragments of 92 or 108 amino acids, which end at either the β- or α- secretase 
site, respectively [10] [Figure 1-1]. 
The major pathological hallmark of AD is amyloid plaque, which is an extracellular deposit 
of a short peptide called Aβ. A number of in vitro and in vivo studies demonstrated the toxic 
properties of Aβ peptides, since the APP gene was first identified in 1987 [6][11][12].  
Administration of Aβ peptides [13], their structural mimetics, and anti-Aβ antibodies [14] have 
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supported the toxic functions of the peptide in terms of promoting cognitive deficits. Yankner et 
al., (1989) showed that Aβ-expressing PC-12 cells grow normally without any cellular 
degeneration. Interestingly, after treatment with nerve growth factor (NGF), these Aβ-expressing 
PC-12 cells differentiated into neuronal cells and started to degenerate slowly. Further, cultured 
neuronal cells treated with conditioned medium collected from Aβ-expressing PC-12 cells also 
degenerated at a slower rate. Pre-treatment with the anti Aβ antibody blocked the Aβ-induced 
degeneration in PC-12 cells. This findings indicated that Aβ peptide induces neurodegeneration 
and eventual cell death [15]. Subsequently, other studies confirmed that this was the same 
oligomeric Aβ peptides cause neuronal cell death in vitro and in vivo. Further, substantial evidence 
demonstrates that elevated levels of soluble Aβ can initiate the disruption of synaptic connections 
between neurons, which then lead to neuronal loss and cognitive impairment (reviewed by 
[16][17]).  No strong correlation exists between the total number of plaques and degree of cognitive 
impairment in AD patients [18], however a series of recent studies demonstrated that prefibrillar 
soluble Aβ are found to be more toxic than their insoluble Aβ fibril forms [19][20].  
The other hallmark of AD is neurofibrillary tangles, which form inside the neurons and are 
composed of abnormally hyperphosphorylated tau [2]. The primary component of the 
neurofibrillary tangle is the microtubule-associated protein tau. In the central and peripheral 
nervous system, microtubules participate in many cellular processes such as cell structure, 
division, motility, and intracellular transport of proteins [21].  Tau, a highly expressed axonal 
protein responsible for maintaining physiology and stability of microtubule structure [22], 
becomes modified in AD [23]. Among different modifications of tau, phosphorylation rigorously 
affects its normal physiological functions in the brain. The tau phosphorylation state influences its 
ability to bind and stabilize microtubules, as hyperphosphorylation produces detachment and self-
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aggregation of tau into neurofibrillary tangles and microtubule depolymerization [24][25]. Several 
independent studies have extensively characterized the tangle pathology over the past few decades. 
As AD progresses, the number and size of tangles increase throughout the whole brain. The extent 
and distribution pattern of tangles well correlate with the stage and degree of cognitive impairment 
in AD [26][18]. The detail findings of those study fall beyond the scope of this study herein. 
 
Alzheimer’s disease (AD): Risk Factors  
The exact etiology of AD remains unclear. Only 1% of AD cases arise from known genetic 
mutations in three predominant genes such as APP, presenilin 1, and 2 (reviewed by [27]). Down 
syndrome patients, who have an extra APP molecule at chromosome 21, often get AD at a very 
early age (reviewed by [28]). The remaining 99% of patients have no genetic component and 
presumably arise through unknown environmental factors. It is thought that interaction among 
genetic, environmental, and lifestyle factors for many years with the aging likely trigger changes 
in the brain. Evidences suggest that the brain is particularly vulnerable to the effects of aging, as 
increasing age is the greatest known risk factor for AD to date.  It is generally believed that AD is 
not a part of normal aging, rather the risk for AD onset increases significantly after age 65. After 
age 85, the probability of AD onset is nearly 40%. Early-onset AD, or familial AD, comprises 1-
5% cases and arises through mutations in three predominant genes. In contrast, the greatest known 
risk factor for late-onset sporadic AD is older age. Most studies confirmed that a family history 
and carrying the ApoE4 allele increases the risk of AD. Genome-wide association studies have 
identified multiple genes with single nucleotide polymorphisms or variants associating with AD, 
including ABCA7, BIN1, CASS4, CD33, CD2AP, CELF1, CLU, CR1, DSG2, EPHA1, 
FERMD4A, FERMT2, HLA-DRB5/DRB1, INPP5D, MS4A, MEF2C, NME8, PICALM, PLD3, 
PTK2B, SLC24H-RIN3, SORL1, TRIP4, TREM2, and ZCWPW1 (reviewed by [29]). Data also 
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indicates an association between AD and head injury. Yet, other data demonstrate an association 
between AD and infection. Cardiovascular disease risk factors, such as high cholesterol and high 
blood pressure, also increase the risk to develop AD. 
 
Alzheimer’s disease (AD): Treatment 
No pharmacological treatments or therapeutic strategies delay or stop the progression of 
AD. Evidence suggests that AD begins over a decade before clinical symptoms appear which 
supports the importance of early intervention to modify disease progression. Current FDA-
approved drugs acetylcholinesterase inhibitor and NMDA-receptor antagonist for AD, e.g., 
donepezil, galantamine, tacrine, rivastigmine, and memantine, partially improve symptoms in 
small subset of patients. Acetylcholinesterase inhibitor is used for mild to moderate cases while 
NMDA-receptor antagonist used for moderate to severe dementia. Although these drugs have 
demonstrated significant clinical benefit, they are unable to stop, inhibit, or reverse the core 
neuropathology of AD. According to clinical trial registry, a total of 244 drugs have been tested in 
clinical trial between 2002 and 2012. Among all of these drugs, only one drug received approval 
from the FDA (reviewed by [30][31]). This indicates that we must develop new therapeutic targets 
and develop novel treatments to address this health crisis [4].  
 
Alzheimer’s disease (AD): Biological and pharmacological treatments 
Human umbilical cord blood derived serum (HUCBS) treatment as a biological approach to 
modulate AD  
HUCBS: Isolation  
Human umbilical cord blood-derived serum (HUCBS) was collected from umbilical cord 
blood and is blood that remains in the placenta and in the attached umbilical cord, after the cord 
has been detached from the newborn at the time of childbirth. HUCBS is separated from umbilical 
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cord blood by allowing clotting for 5-10 h in red top tubes with no anticoagulation followed by 
centrifugation at 3500 rpm for 5-10 min at 4 0C. Before treatment, all the samples were passed 
through a 0.22 µm pore size filter. In a recent study, we found that HUCBS produce increased 
levels of sAPPα compared to the adult (ABS, 25-30 years old) or aged (AgBS, >75 years old) 
blood serum in Chinese hamster ovary cells overexpressing wild-type APP (CHO/APPwt). First, 
we examined the enzymatic activity of α-secretase-like enzyme in HUCBS, ABS, and AgBS by 
comparing the levels of sAPPα upon treating CHO/APPwt cells. We hypothesized that HUCBS 
may contain novel enzyme protein that is responsible for this effect. In order to identify the source 
of the enzyme, we enriched a fraction (termed as αCBSF) with highest sAPPα producing capacity 
using multi-step chromatographic separation techniques. Further investigation using LC-MS/MS 
analyses showed that HUCBS-derived APP -secretase cleavage activity is mediated by C1 
complement. Infusion of αCBSF via intraperitoneal osmotic minipump ameliorates cognitive 
impairments and associated-amyloid pathology in transgenic 5XFAD mouse model. 
 
HUCBS: Anti-AD therapeutic properties of sAPPα, HUCBC, and HUCBS  
HUCBC induce embryonic, post-natal, and adult neurogenesis in preclinical models [32] 
and clinical study [33], and has been recommended as a treatment option for specific conditions.  
A series of recent study in HUCBC in treating different neurological conditions [34][35] opened 
new opportunities for AD research [36]. In our prior work in an AD mouse model, we found that 
multiple low-dose peripheral infusions of HUCBC reduced amyloid plaques, cerebral vascular Aβ 
astrocytosis, and improved cognition [37]. In a subsequent study, we demonstrated that HUCBC-
derived monocytes ameliorate amyloid pathology and cognitive impairment in Tg2576 AD mouse 
model [38]. Nevertheless, the possibility of causing graft versus host disease [39] and low yield of 
HUCBC makes the use of this cell-based therapy less attractive in many circumstances. In a recent 
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work using a sophisticated parabiosis experiment, Wyss-Coray and his colleagues have showed 
that blood plasma from old mice reduces neurogenesis and impairs cognitive functions in young 
mice brain [40]. In a follow-up study, the same group has reversed age-related impairments by 
infusing plasma from young mice into old mice [41]. We also believe that HUCBS possess anti-
AD therapeutic potential for reducing inflammation, pathology, and cognitive deficits. In our prior 
study, we found that sAPPα can inhibit amyloid [42] and tau pathology [43] by modulating BACE1 
and GSK3β enzyme activity. 
 
HUCBS: Neuroprotective effect of sAPPα and HUCBS  
                  
The level of sAPPα in the cerebrospinal fluid (CSF) and brain often serves as a predictive 
biomarker for AD patients. Almost all of the animal and human studies reported lower levels of 
sAPPα in AD brain compared to age-matched controls [44][45]. Many studies have reported the 
protective function of sAPPα against a variety of extracellular insults in cell cultures and in vivo 
models. However, the exact neuroprotective mechanisms of sAPPα that provide protection are 
unclear. Overall, sAPPα contributes to numerous protective functions in the brain including 
neuroprotection [46][47], increase long-term potentiation (LTP) [48], synaptic plasticity [49], 
stimulate neurite outgrowth [50][51], and proliferation of neuronal [52][53], and non-neuronal 
cells [54][55], which appear to be disrupted in Alzheimer’s patients [56]. Initial studies on cultured 
rat hippocampal slices showed neuroprotection against glucose-deprivation and glutamate 
mediated toxicity [57]. This finding indicates that sAPPα can protects cultured neuronal cells from 
excitotoxicity; this fact is further supported by increased secretion of sAPPα in response to 
electrical depolarization on rat hippocampal slices. Subsequently, the sAPPα-mediated 
neuroprotective mechanism in neuronal environment was identified. Using whole-cell patch-
clamp and imaging techniques, Furukawa and his colleagues have shown that sAPPα activates K+ 
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channel and suppress N-methyl-D-aspartate (NMDA) currents, which subsequently prevents 
neuronal excitability and glutamate-induced excitotoxicity [58][59].  Barger and Mattson have 
found that sAPPα decreases Ca2+ and NMDA currents in hippocampal neurons by elevating cyclic 
guanosine monophosphate, which protect against hypoglycemic damage and glutamate-induced 
excitotoxicity [60]. In line with the cell culture findings, in vivo studies confirmed the protective 
function of sAPPα. One study showed that ventricular administration of sAPPα in a rat model 
reduced hippocampal neuronal cell death against ischemic [61], spinal cord [62] and traumatic 
brain injury (TBI) [63][64]. Surviving neuronal cells synthesized new proteins visualized by amino 
acid autoradiography in the cell bodies of hippocampal neuronal cells [64]. Another study found 
that sAPPα treatment attenuated amyloid pathology, improved cognition, and motor functions in 
a moderately brain-injured APP knockout mouse model [65]. Subsequent studies by the Cappai 
group showed that the heparin binding site of sAPPα (amino acid residues 96-110) provides 
protection against TBI [66]. In addition, signaling pathway activation followed by gene 
transcription is another mechanism by which sAPPα elicits its protective function. A number of 
different studies demonstrated that sAPPα activates several signaling pathways involving 
phosphatidylinositol-3-kinase (PI3K)-PKB/Akt [67][68][69], nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κβ) [70], extracellular signal regulated kinase (ERK) [71][67] 
and inhibits stress-induced inhibition via c-Jun N-terminal kinase [72]. Moreover, sAPPα also 
activates several neuroprotective genes, such as insulin-like growth factor 2, manganese 
superoxide dismutase, catalase, and transthyretin [73]. To identify the downstream effector 
molecules, Hartl and his colleagues have analyzed sAPPα-induced proteome changes in primary 
neuronal cell culture. The study demonstrated that sAPPα downregulates cyclin-dependent kinase 
5 expression and induces cytoprotective chaperone 150-kDa oxygen regulated protein as a 
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protective response [74]. Furthermore, a recent study found that sAPPα can activate an Akt 
survival pathway by interacting with G-protein-coupled receptors and cell surface APP [69]. 
Increasing research demonstrates that blood plasma factors play an important role in age-
associated diseases, particularly in dementia and AD. In previous work, a research team led by Dr. 
Wyss-Coray from Stanford University demonstrated that administration of young mouse plasma 
via tail vein injection into old mice improved hippocampal learning and memory function [40]. 
They concluded that young blood could be a source of growth factors that might have benefited 
the old mice. In a new study by the same group demonstrated that older mice received human 
umbilical cord blood plasma showed improved hippocampal learning and memory function. They 
then identified the specific factor in umbilical cord blood plasma that makes the old mice brain 
young, and found that tissue inhibitor of metalloproteases 2 is responsible for rejuvenating 
hippocampal spatial memory function in older mice [75]. Wyss-Coray and his colleagues further 
compared umbilical, adult (19- to 24 year-olds) and aged (61- to 82 year-olds) blood plasma, and 
found an age-associated change in several proteins. They found that these age-associated changes 
in proteins might affect the hippocampal function in the brain. Recently, we found that HUCBS 
contain α-secretase-like enzyme that either directly or indirectly activates α-secretase and produces 
sAPPα significantly in cell culture and cell free system. 
 
HUCBS: Anti-inflammatory effects of HUCBC  
Microglia, the main immune cells in the brain, play a critical role in the etiology of several 
neuroinflammatory conditions [76]. Preclinical and postmortem analyses implicate inflammatory 
process as causative factor in neuronal cell death in a number of neurodegenerative diseases, such 
as Multiple sclerosis [77], Parkinson’s disease [78], Bipolar disorder [79], Alzheimer’s disease 
[80]. Activated microglia typically removes damaged cells from the brain either by recruiting 
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soluble factors or phagocytosis [81]. But, it remains unclear whether microglia plays a beneficial 
or detrimental role in diseased conditions. Current proposals state that acute microglial activation 
is beneficial to eliminate pathogens and damaged cells. But, chronic microglial activation cause 
damage through secretion of proinflammatory cytokines, complement proteins, and reactive 
species [82]. So, suppressing inflammatory cytokines released by microglia are considered an 
effective therapeutic approach in neuroinflammatory diseases. Several neuroprotective and anti-
inflammatory approaches can suppress microglial activation in the brain following inflammation. 
Our prior work showed that flavonoid compounds such as luteolin [83], diosmin [84], and 
epigallocatechin-3-gallate [85], have disease modifying properties through modulation of 
inflammatory pathways. In recent years, our lab and others have identified the immunomodulatory 
properties of HUCBCs in several neurodegenerative conditions particularly in AD [37]. The exact 
molecular mechanism behind these immunomodulatory effects of HUCBC remains unclear. More 
recently, HUCBC–derived stem cells have the potential to differentiate into neuronal and glial 
cells in experimental conditions. HUCBC opposes pro-inflammatory T helper cell type 1 response 
and stimulate anti-inflammatory T helper cell type 2 responses in a rat stroke model [86]. HUCBC 
can also reduce proinflammatory CD40-CD40 ligand interaction, which reduces Aβ deposition in 
Tg2576 and PSAPP AD mouse models [37]. Furthermore, HUCBC reduces proinflammatory 
reactive microgliosis, associated astrocytosis, and increased anti-inflammatory cytokines IL-10, 
transforming growth factor β1 (TGF-β1), and NGF in the brain [37]. Like HUCBC, we believe 
that HUCBS will also demonstrate its AD-modulating properties through anti-inflammatory 
function. 
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Ionic co-crystal of lithium salicylate l-proline (LISPRO) treatment as a pharmacological 
approach to modulate AD  
 
LISPRO: Formulation  
The active pharmaceutical ingredient of LISPRO is lithium. Briefly, lithium salicylate salt 
and l-proline were dissolved in hot deionized water. The resulting solution was maintained at 75-
90 0C on a hot plate. The colorless crystal formed in the plate after slow evaporation of solvent. 
Lithium is a divalent cation with the anion being salicylic acid, which is a derivative of acetyl 
salicylic acid (aspirin). The amino acid l-proline works as a coformer. In vivo pharmacokinetics 
data showed that LISPRO produced very steady lithium plasma and brain lithium levels for 48 h 
compared to lithium carbonate in Sprague Dawley rat model [87]. 
 
LISPRO: Anti-AD therapeutic properties of lithium  
Diverse preclinical studies provide consistent evidence supporting the neuroprotective 
effects of lithium to prevent neurodegenerative diseases, including AD. Several mechanisms may 
underlie lithium’s potential neuroprotective efficacy for AD. One important mechanism is that 
lithium inhibits certain enzymes in a noncompetitive manner by displacing the required divalent 
cation, magnesium [88]. Klein and Melton identified GSK3β as a key molecular target of lithium 
[89]. In the context of AD, this enzyme phosphorylates tau at most of the serine and threonine 
residues in the paired helical filaments.  GSK3 activity contributes both to Aβ production and Aβ-
mediated neuronal cell death [90]. Therapeutic doses of lithium block production of Aβ by 
interfering with APP cleavage at the -secretase step without inhibiting Notch processing by 
targeting GSK3α [91].  Lithium also blocks Aβ accumulation in brains of mice overexpressing 
APP by inhibiting GSK3β, which further implicates its requirement to process APP [92]. Since 
GSK3β also phosphorylates the tau protein, inhibition of GSK3β offers a new approach to reduce 
the formation of both β-amyloid plaques and neurofibrillary tangles. Interestingly, lithium 
 13 
 
treatment can prevent prefibrillar tau-aggregates in double transgenic mice that overexpress 
GSK3β and tau with a triple frontotemporal dementia with parkinsonism-17 (FTDP-17) mutation 
[93]. 
LISPRO: Neuroprotective effects of lithium 
Lithium induces its cellular and molecular effects by activating neurotrophic and 
neuroprotective pathways and its associated signaling mechanisms [94]. These neuroprotective 
effects are secondary to the two main effects, inhibition of GSK3β and inositol phosphatase. As 
GSK3β induces amyloid and tau pathology, lithium-induced inhibition of GSK3β offers a novel 
approach to modulate formation of both amyloid plaques and neurofibrillary tangles. More 
specifically, lithium inhibits GSK3β in a noncompetitive fashion by displacing the divalent cation, 
Mg2+ [95]. Lithium can modify cyclic adenosine monophosphate (cAMP)-mediated signaling by 
increasing adenylyl cyclase and protein kinase A (PKA), which subsequently activates the nuclear 
transcription factor cAMP response element binding protein (CREB) and increases brain derived 
neurotrophic factor (BDNF) expression. In addition, it has been demonstrated that chronic 
administration of lithium upregulates BDNF expression in rat and human studies. Increased BDNF 
activity may restore learning and memory function through neurogenesis and LTP. Binding with 
tropomyosin receptor kinase B receptor, BDNF activates extracellular signal-regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway which inhibit GSK3β 
and pro-apoptotic Bcl-2-associated death promoter protein (BAD). This signaling further increases 
nuclear CREB expression, which subsequently stimulates expression of anti-apoptotic bcl-2 and 
neuroprotective BDNF through feedback mechanisms. Mitochondrial bcl-2 inhibits BAD protein 
and also inhibits calcium and cytochrome c release into the cytoplasm. Lithium exerts 
neuroprotection by inhibiting inositol phosphatase enzymes, which regulate cellular inositol 
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triphosphate (IP3) levels. IP3 acting as a second messenger regulates several cellular processes 
through calcium signaling pathways. Lithium also downregulates calcium release from the 
endoplasmic reticulum (ER) via the IP3 pathway, which increases bcl-2 levels and prevents 
activation of apoptotic pathways. Another neuroprotective mechanism of lithium is attenuating 
pro-inflammatory cytokine generation, like IL-1β and TNFα, in activated microglia. This is 
particularly significant since inflammation commonly occurs in AD (reviewed by [94]) [Figure. 
1-2]. 
LISPRO: Anti-inflammatory effects of lithium 
Increasing evidence suggests that inflammation plays a key role in the pathological 
processes in AD. Among multiple mechanisms of action that underlie lithium’s therapeutic 
efficacy, anti-inflammatory effects of lithium play a critical role in preventing several 
inflammatory brain diseases including AD. As lithium has multiple targets in the brain, it is unclear 
which target mediates its therapeutic efficacy in a specific condition. The arachidonic acid-
prostaglandin pathway contributes to brain inflammation and anti-inflammatory treatment of AD 
[96]. Several lines of evidence demonstrated anti-inflammatory properties of lithium by 
modulating prostaglandin pathways [97]. Lithium can reduce COX2 expression and 
lipopolysaccharide induced prostaglandin E2 production and also increases anti-inflammatory 17-
hydroxy-docosahexanoic acid in different parts of the brain in preclinical models and primary cell 
cultures [98][99][100].  However, other studies reported either no effect or increased COX2 
expression in other tissue sites of action [101][102]. Nitric oxide (NO) is an important signaling 
molecule involved in multiple cellular processes. The NO pathway is implicated in brain 
inflammation [103]. Other studies showed that lithium treatment enhances nitric oxide synthase 
expression and NO production [104][105]. However, most studies demonstrated that lithium 
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inhibits nitric oxide synthase-nitric oxide inflammatory pathway [106][107]. Tumor Necrosis 
Factor-α (TNF-α), IL-1β, IL-4 and IFN-γ are major pro-inflammatory cytokines involved in neural 
inflammatory processes. Some studies indicate that lithium stimulates TNF-α production 
[108][109]. However, most studies showed that lithium significantly inhibits TNF-α synthesis in 
the brain [110][111][112]. Similar to TNF-α, most of the studies showed that lithium can inhibit 
IL-1β [113], IL-4 [114] and IFN-γ [115] synthesis. IL-2 and IL-10 are important anti-inflammatory 
cytokines found in the human immune system. Numerous studies found that lithium increases IL-
2 [116][117], and IL-10 [118] synthesis, indicating a profound anti-inflammatory effect for 
lithium. Lithium also can modulate other inflammatory markers, such as IL-1α, IL-1 receptor 
antagonist, IL-3, IL-6 and IL-17. As very few studies have investigated the effect of lithium on 
these mediators, no conclusive findings available in this context. Several studies investigated the 
effects of lithium on microglial expression and function in the brain [119][120]. Lithium inhibits 
microglial and astrocytes activation in a mouse model of AD [121]. GSK3β dysregulation plays a 
critical role in the development of several inflammatory diseases including AD [122]. The exact 
anti-inflammatory therapeutic mechanism of action of lithium remains unclear. Accumulating 
evidence suggests that GSK3β enhances the activity of transcription factor NF-κβ, which increased 
inflammatory processes in animal models [123]. Pharmacological inhibition of GSK3β attenuated 
inflammatory NF-κβ activity and pro-inflammatory cytokine production under different 
experimental conditions [124]. In fact, GSK3β phosphorylates NF-κβ and accelerates proteasomal 
degradation of this transcription factor. Inhibiting NF-κβ activation by GSK3β further suppressed 
LPS-induced TNF-α, COX2 and nitric oxide synthase expression [110][125]. Inhibiting GSK3β 
activity by lithium downregulates the pro-inflammatory cytokine signal transducer and activator 
of transcription (STAT) pathway [126]. Taken together, the above findings indicate that lithium 
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suppresses inflammatory pathways in many experimental conditions. Despite these anti-
inflammatory potential, many other studies show that lithium has pro-inflammatory effects in the 
cells. Further studies will elucidate the effects of lithium on inflammation. Our studies should also 
investigate the inflammatory effects of the related compound, salicylic acid, a derivative of aspirin 
and further investigate whether it will enhance the anti-inflammatory effects of LISPRO in AD. 
 
Rationale: GSK3β is a target for both sAPPα and lithium 
GSK3 is a serine/threonine protein kinase initially identified as playing a key role in 
glycogen metabolism [127]. The phosphorylation state and growth factor signaling regulate 
GSK3β activity, as phosphorylation at tyrosine 216 increases [128] and serine 9 residue decreases 
[129] its activity. GSK3β kinase has many different kinds of physiological functions in neuronal 
cells. GSK3β has specific functions during neuronal development [130], neuronal apoptosis 
[131][132], and synaptic dysfunction [133].  Partial inhibition of GSK3β using various approaches 
showed positive effects in different pathologies including psychiatric disorders and is now 
recommended as treatment for specific conditions [134][135]. Since GSK3β induces both amyloid 
formation and tau hyperphosphorylation [136], it acts as a bridge between amyloid and tau 
pathology [137][138]. Partial inhibition of GSK3 signaling significantly reduced Aβ deposition, 
plaque formation, and rescued memory deficits in a double transgenic AD mouse model [134]. 
GSK3β also induces tau phosphorylation in various different conditions [139]. So, inhibition of 
GSK3β emerged as a putative therapeutic target option for AD. Numerous studies identified 
different modulators that can modulate Aβ and tau hyperphosphorylation. However, in vitro and 
in vivo studies show that not many of these modulators can reduce both amyloid and tau 
pathologies together. A potential agent that modulates both amyloid and tau pathologies together 
will be a promising therapeutic tool for the treatment of AD. 
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Our recent laboratory data demonstrated that sAPPα producing capacity of HUCBS is not 
mediated by ADAM and ADAM17 (TACE) metalloprotease function in cell culture and cell free 
system. Alpha (α) -secretases are members of the ADAM family of proteins with cysteine-rich, 
disintegrin, and zinc metalloproteinase domains in their ectodomain [140]. Two members of this 
family e.g., ADAM10 and ADAM17 are primarily responsible for the α-secretase activity [141]. 
Both ADAM10 and ADAM17 can cleave several transmembrane proteins and promote tumor 
growth in the cell [142]. ADAM10, in particular, cleaves various transmembrane proteins in the 
vascular system, including the platelet-activating collagen receptor glycoprotein VI [143][144] 
and endothelial transmembrane proteins CX3CL1 and CXCL16 [145]. Inhibition of ADAM10 is 
a potential therapeutic target for prevention of cancer and inflammation. ADAM17 is responsible 
for TNFα secretion [146], and act as a therapeutic target in cancer, inflammatory, and vascular 
diseases.  AD is the only disease where increasing α-secretase activity is favorable. The cleavage 
of substrates other than APP seems the primary obstacle to enhance α-secretase enzymatic activity 
in AD therapeutics [147]. Thus, we hypothesized that HUCBS treatment as a novel biological 
approach will modulate pathology and cognitive impairments in cell culture and AD mouse models 
by restoring sAPPα, and other neurotrophic growth factors. Our prior work and others have 
demonstrated that sAPPα-mediated inhibition of BACE1 activity reduces -amyloid [42], and 
GSK3β-mediated inhibition of BACE1 expression reduces AD-like pathology. Further, a recent 
study using human primary neurons from sporadic AD patients showed that purified neurons 
treated with β-secretase inhibitors, but not γ-secretase inhibitors, significantly reduced phospho-
tau (Thr 231) and GSK3β levels. These results suggest a direct relationship between APP 
proteolytic processing, but not Aβ, in GSK3β activation and tau phosphorylation in human neurons 
[148].  Additionally, we have demonstrated that sAPPα reduces GSK3β-mediated tau 
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phosphorylation in cell culture and transgenic mouse overexpressing sAPPα crossed with PSAPP 
mice [43]. As sAPPα can reduce both amyloid and tau pathology, we hypothesized that restoring 
sAPPα with HUCBS will reduce both amyloid and tau pathology in AD preclinical mouse models. 
Taken together, we believe that HUCBS-derived α-secretase will provide a novel therapeutic tool 
to treat AD through production of sAPPα, and other neurotrophic factors [Figure 1-3]. 
              Lithium inhibits GSK3β activity by competitively inhibiting magnesium (Mg2+) [95] and 
increasing inhibitory GSK3 (Ser9) phosphorylation through activation of protein kinase B/Akt 
signaling pathway. One of the main limitations of lithium pharmaceutics (carbonate and citrate) is 
that they have narrow therapeutic window 0.6-1.5 (mmol/L or mEq/L). The therapeutic ranges are 
based on the steady-state plasma lithium concentrations found 12 h after a dose. In addition, a 
plasma lithium level of (≥ 1.5 mmol/L) or more is associated with serious toxicity. To improve 
therapeutic efficacy and reduce inflammation, one of our collaborators at University of South 
Florida investigated the pharmacokinetics of lactate, salicylate, and carbonate salts of lithium 
[149]. The study data indicated that lithium carbonate produces a very sharp peak and rapid 
elimination with undetectable levels at 48 h in Sprague Dawley rat model. This results explains 
the required multiple administrations of lithium carbonate to reach the target therapeutic 
concentration. In contrast, lithium salicylate produced elevated plasma and brain levels of lithium 
at 48 h after administration without any sharp peak. The hygroscopic property of parent lithium 
salicylate inspired to modify this salt using crystal engineering technology, and made an ionic 
cocrystal of lithium salicylate with amino acid l-proline (abbreviated as LISPRO or LP) [87]. 
Together, we believe that LISPRO will ameliorate Alzheimer’s like β-amyloid and associated 
pathologies through inhibition of GSK3β and anti-inflammatory cytokines stimulation [Figure 1-
4]. 
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Hypothesis and project aims 
 
In this study, we propose to explore the therapeutic efficacy of biological HUCBS (Aim 1 
& 2) and pharmacological LISPRO (Aim 3 & 4) treatment in cell culture and AD mouse models 
in stated aim below.  
Aim 1, Identify and characterize novel APP specific α-secretase enzyme from HUCBS. Aim1 
outcome, we expect that the proposed studies using separation techniques such as chromatography, 
centrifugation, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) will 
isolate α-secretase enzyme from HUCBS. 
Aim 2, Investigate whether αCBSF derived from HUCBS ameliorates AD pathology and cognitive 
impairments in AD mouse models. Aim 2 outcome, we expect that αCBSF administration will 
ameliorate pathology and cognitive impairment in transgenic AD (5XFAD, 3XTg-AD) mice. 
Aim 3, Investigate and compare the safety, pharmacokinetics, and therapeutic efficacy of LISPRO 
treatment with carbonate and salicylate lithium salts in cell culture and rodent models. Aim 3 
outcome, we expect that LISPRO treatment will showed better safety profile compared to lithium 
carbonate through inhibition of inflammatory COX2. We also expect that LISPRO will show 
stable lithium levels in the blood plasma compared to lithium carbonate in rodent models. Finally, 
we also expect that LISPRO treatment will reduce amyloid and tau pathology in transgenic Tg2576 
and 3XTg-AD mouse models through inflammatory pathway inhibition. 
Aim 4, Examine and compare the effect of LISPRO treatment in improving cognitive- and non-
cognitive behavioral impairments in transgenic APPswe/PS1dE9 AD mice with carbonate, and 
salicylate salt of lithium. Aim 4 outcome, we expect that LISPRO treatment will prevent cognitive 
and non-cognitive functional decline in transgenic APPswe/PS1dE9 AD mouse model. 
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Figure 1-1 Schematic diagram of amyloid precursor protein (APP, middle) processing 
pathways and cleavage products.  
The non-amyloidogenic APP processing pathway (upper) involves cleavages by α- and γ-
secretases.  Sequential cleavage of APP by α-secretase generates sAPPα and c-terminal fragment 
C83 (not shown).  The subsequent cleavage of C83 by γ-secretase complex generate APP 
intracellular domain (AICD) and a short fragment called P3. The amyloidogenic APP processing 
pathway (lower) involves cleavages by β- and γ-secretases. Cleavage of APP by β-secretase 
generate sAPPβ and c-terminal fragment C99 (not shown).  Subsequent cleavage of C99 by γ-
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secretase complex generate toxic species Aβ (40 or 42, depends on the cutting site) and AICD.  
This is termed as amyloidogenic pathway due to generation and accumulation of Aβ species into 
plaque inside the brain. In addition to α-, β- and γ-secretases cleavage, APP is cleaved by 
metalloprotease meprin β, generating soluble N-terminal truncated APP (N-APP) or Aβ2-X 
variants. In addition to meprin β cleavage, the cleavage of APP by several matrix 
metalloproteinases such as MT5-MMP, referred to as -secretase, releases a long-truncated 
ectodomain (sAPPη) and a membrane-bound carboxy-terminal fragment (CTF), termed CTFη.  
The membrane-bound CTFη is further cleaved by α- and β- secretases and release a long (Aη-α) 
and a short (Aη-β) peptide, respectively. 
 
[Note to reader: Adapted from Habib et al., 2017 [56], Restoring Soluble Amyloid Precursor 
Protein α Functions as a Potential Treatment for Alzheimer’s Disease. Journal of Neuroscience 
Research 2017; 95(4):973-991 with permission from Wiley Periodicals, Inc. © Copyright 2016.] 
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Figure 1-2 Neurotrophic and neuroprotective pathways targeted by lithium. 
BDNF receptor (Trk-B) activation activates the ERK/MAPK pathway, which inhibits GSK3β and 
BAD protein. This activation increases the expression of CREB, which facilitates the expression 
of neuroprotective proteins such as bcl-2, and BDNF. Mitochondrial bcl-2 inhibits pro-apoptotic 
activation of BAD, and subsequent mitochondrial increases of calcium influx and cytochrome c 
release. Dysregulated intracellular calcium levels, may increases the risk of apoptosis, have been 
associated with the pathophysiology of bipolar disorder. Lithium downregulates endoplasmic 
reticulum (ER) calcium release via an IP3 receptor dependent pathway also increases bcl-2 
expression, which improves mitochondrial stability and prevents activation of apoptotic pathway. 
IMPase directly inhibited by lithium, recycles IP3.  In addition, cellular signaling through Wnt 
glycoproteins and frizzled receptors inhibits GSK3β. Lithium’s inhibition of GSK3β prevents β-
catenin phosphorylation and stimulates its translocation to the nucleus, and activating transcription 
of neurotrophic and synaptogenesis genes. Lithium also indirectly inhibits PKC. 
 
          [Note to reader: Adapted from Quiroz et al., 2010 [94]. Novel Insights into Lithium’s 
Mechanism of Action: Neurotrophic and Neuroprotective Effects; Neuropsychobiology (2010) 62 
(1):50-60; with permission from S. Karger AG, BASEL] 
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Figure 1-3 Hypothesized pathways for sAPPα-mediated reduction of amyloid and tau 
pathology 
Soluble amyloid precursor protein alpha (sAPPα) increases GSK3β inhibitory phosphorylation 
(decrease GSK3β activity) by inhibiting BACE1 and followed by reduction of tau 
phosphorylation. sAPPα mediated BACE1 inhibition also results in a decrease of Aβ production 
and amyloid plaque load. 
 
[Note to reader: Adapted from Deng & Habib et al., 2015 [43], Soluble Amyloid 
Precursor Protein α Inhibits Tau Phosphorylation through Modulation of GSK3β Signaling 
Pathway. Journal of Neurochemistry 2015; 135: 630-637 with permission from John Wiley & 
Sons, Inc. Copyright © 1999-2018.] 
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Figure 1-4 Schematic illustration of the lithium targeted cellular and molecular mechanism 
by activating several neurotrophic and associated signaling in Alzheimer’s disease.  
Lithium inhibit GSK3 (both α and β isoforms) and inositol mono/polyphosphatase (IMPase, 
IPPase) activity. The inhibition of GSK3 by lithium reduces tau phosphorylation and production 
of Aβ peptides by interfering γ-secretase cleavage of APP processing. In addition, inhibition of 
inositol monophosphatase by lithium may regulate clearance of aggregated phosphorylated tau and 
Aβ peptides. Moreover, lithium increases the expression of BDNF, which activates the 
ERK/MAPK pathway and further increases the expression of nuclear transcription factor cAMP 
response element (CREB). Accordingly, activation of BDNF may up-regulates neurogenesis and 
down-regulates pro-inflammatory responses (IL-1β, and TNFα) in Alzheimer’s disease 
 
[Note to reader: Adapted from Habib et al., 2017 [150], LISPRO mitigates β-amyloid and 
associated pathologies in Alzheimer’s mice. Cell Death & Disease 2017; 8(6): e2880] 
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CHAPTER 2 
Human umbilical cord blood serum derived α-secretase: Functional testing in 
Alzheimer’s disease mouse models 
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Chapter synopsis  
Alzheimer’s disease (AD) is an age-related disorder that affects cognition.  Our previous 
studies showed that the neuroprotective fragment of amyloid procurer protein (APP) metabolite, 
soluble APPα (sAPPα), interferes with β-site APP cleaving enzyme 1 (BACE1, β-secretase) 
cleavage and reduces amyloid-β (Aβ) generation.  In an attempt to identify approaches to restore 
sAPPα levels, we found that human cord blood serum (CBS) significantly promotes sAPPα 
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production compared with adult blood serum (ABS) and aged blood serum (AgBS) in Chinese 
hamster ovary cells stably expressing wild-type human APP (CHO/APPwt).  Interestingly, CBS 
selectively mediated the α-secretase cleavage of human neuron-specific recombinant APP695 
(fAPP695) in a cell-free system with independent from TNFα converting enzyme (TACE) [a 
disintegrin and metalloproteinase domain-containing protein 17 (ADAM17)] and ADAM. 
Subsequently, using three-step chromatographic separation techniques (i.e., diethylaminoethanol, 
size exclusion, and ion-exchange chromatography), we purified and ultimately identified a CBS 
specific fraction with enhanced α-secretase catalytic activity (termed αCBSF), and found that 
αCBSF has more than 3,000 fold increased α-secretase catalytic activity compared with the 
original pooled CBS.  Furthermore, intracerebroventricular injection of αCBSF markedly 
increased cerebral sAPPα levels together with significant decrease in cerebral Aβ production and 
abnormal tau (Thr231) phosphorylation compared with AgBSF treatment in 3XTg-AD mice.  
Moreover, aged blood serum fraction with enhanced α-secretase activity administered 
intraperitoneally to 5XFAD mice via an osmotic mini pump for 6 weeks ameliorated β-amyloid 
plaques and reversed cognitive impairment measures.  Together, our results propose necessity for 
the further study aimed at identification and characterization of the-α-secretase in CBS for novel 
and effective AD therapy. 
Background 
The neuropathological hallmarks of AD that differentiate it from other dementia include: 
extracellular β-amyloid plaques composed largely of amyloid-β (Aβ) peptides [1] and intracellular 
neurofibrillary tangles (NFTs) composed of the hyperphosphorylated microtubule associated 
protein tau [2]. Successive cleavage of APP by β- and γ-secretases produce Aβ peptides of variable 
length (Aβx-40, 42), soluble APPβ (sAPPβ), membrane-bound β-C-terminal fragment (β-CTF, C99), 
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and APP intracellular cytoplasmic/C-terminal domain (AICD) [6]. The Aβ peptide fragments, 
which accumulate as plaques in the brain, induce neuroinflammation, synaptic dysfunction, and 
neuronal cell death that affects cognitive function [11]. In contrast, most of the APP is cleaved by 
α- and γ-secretases which not only precludes Aβ generation but also produce a secreted soluble 
APPα (sAPPα), membrane-bound α-C-terminal fragment (α-CTF, C83), P3 peptide and AICD [5].  
Overall, sAPPα has been shown to be involved in numerous physiological functions in the brain, 
which appear to be interrupted in AD. Several studies have shown that neurotrophic fragment 
sAPPα not only prevents Aβ generation [42] and tau phosphorylation [43] but is also known to be 
a neuroprotective APP metabolite, including but not limited to proliferation, neurite outgrowth, 
and long term potentiation [56][151][152]. Thus, we hypothesized that therapeutic interventions 
or approaches that has potential to produce sAPPα markedly could improve AD pathology and 
cognitive function. 
Several studies have shown that human umbilical cord blood cell (HUCBC) has therapeutic 
potential in numerous age-related neuroinflammatory conditions, including AD.  In line with those 
studies, we showed that single as well as multiple low-dose infusion of HUCBC significantly 
reduced amyloidogenic APP processing, Aβ and β-amyloid plaque accumulation, glial 
neuroinflammation, and cognitive impairments in preclinical AD mice models [37][153].   
Additionally, HUCBC treatment changed microglial phenotypes from pro-inflammatory to anti-
inflammatory, increased microglial Aβ phagocytosis, increased anti-inflammatory cytokines in the 
brain [i.e., interleukin-10 (IL-10), transforming growth factor β1 (TGFβ1), and nerve growth factor 
(NGF)], and reduced CD40-CD40L interaction that is important for Aβ-induced pro-inflammatory 
microglial activation [38].  To identify the specific HUCBC responsible for this neuroprotective 
effect, we found that cord blood-derived monocyte reduces β-amyloid pathology and improves 
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cognition with much more effectively than monocyte-deficient cord blood in AD mouse model 
[38]. In line with the findings of above studies, several recent reports underscored the role of young 
blood and/or plasma in aging and age-associated neurodegenerative conditions.  Among those, 
Wyss-Coray and other labs have reported that exposing old mice to a young systemic environment 
by parabiosis increased synaptic plasticity, improved pathology, and behavioral recovery such as 
contextual fear conditioning and spatial learning in old mice. More interestingly, they also found 
that it is not the blood cells rather the soluble factors are getting into the mice brain. They pooled 
plasma from young mice as well as young human and injected into old mice, which successfully 
rejuvenated old mice brain structure and cognition tested by Barnes maze memory test 
[41][154][155][156][157]. In a follow-up study, they showed that human cord blood plasma as 
well as plasma enriched in tissue inhibitor of metalloproteinases 2 improves synaptic plasticity and 
hippocampal dependent cognitive function in old mice [75].  
Based on our preliminary laboratory findings, we hypothesized that human cord blood 
serum (CBS) possesses novel APP-specific α-secretase-like enzyme, reflected by marked 
production of sAPPα level. As CBS contains many different small molecules, growth factors, 
proteins, inhibitors, hormones, enzymes, and other unknown substances, we also hypothesized that 
infusion of characterized CBS fraction will ameliorate AD-like pathology and cognitive 
impairments in mouse models. Here, we show that CBS markedly enhanced sAPPα production in 
Chinese hamster ovary (CHO) cells stably expressing wild-type human APP (CHO/APPwt cells) 
as well as mediated α-secretase cleavage of human neuron-specific APP695 (fAPP695) in a cell-free 
system, which effects are not seen with normal adult or aged blood serum (ABS or AgBS).  
Additionally, we have been successfully able to characterized a CBS fraction with enhanced α-
secretase-like catalytic activity (refer to αCBSF) using sequential DEAE-affinity column, size-
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exclusion, and anion-exchange chromatographic fractionation processes. Moreover, we found that 
αCBSF infusion increased sAPPα levels, decreased Aβ production/β-amyloid plaque formation, 
prevent neuronal loss and abnormal tau (Thr231) phosphorylation in the cortex, and improved 
cognitive function in Alzheimer’s mouse models.  Our findings indicate that CBS fraction with 
enhanced α-secretase-like activity holds immense therapeutic potential for treatment of AD. 
 
Materials and methods 
Reagents and antibodies 
CBS was obtained from Lee Biosolutions (St. Louis, MO, USA) and human umbilical cord 
blood plasma (CBP) was obtained from STEMCELL Technologies Inc. (Vancouver, BC, V5Z 
1B3, Canada).  Human Cord Blood is aspirated from the umbilical cord vein into a cord blood 
collection bag containing citrate-phosphate-dextrose as an anticoagulant. Individual lot of cord 
blood plasma (CBP) is prepared from a single cord blood sample. Three to five different lots of 
CBP samples were pooled in as “pooled cord blood plasma”. CBP is separated from umbilical 
cord blood centrifugation at 3500 rpm for 5-10 min. CBP is aliquoted and frozen at -20°C first, 
and then transferred to a -80°C freezer after 24 h at 4°C. There is no placement into -80°C for a 
snap freeze. Frozen CBP are not heat inactivated. There is no analysis performed to determine the 
number of platelets in each sample, therefore the plasma cannot be specifically characterized as 
'low platelet' or 'platelet poor' plasma. Frozen CBP samples were thawed in a 37°C water bath 
before used in experiment. Cord blood serum (CBS) was collected from umbilical cord blood and 
is blood that remains in the placenta and in the attached umbilical cord, after the cord has been 
detached from the newborn at the time of childbirth. CBS is separated from umbilical cord blood 
by allowing clotting for 5-10 h in red top tubes with no anticoagulation followed by centrifugation 
at 3500 rpm for 5-10 min at 4°C. CBS sample was passed through a filter membrane with a pore 
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size of 0.22 µm. Individual CB serum was prepared from a single sample. More than ten serum 
samples of CBS were pooled in as “pooled cord blood serum”. Normal human adult blood serum 
(ABS, 25-30 years old) and aging blood serum (AgBS, >75 years old) as well as their plasma (ABP 
and AgBP, respectively) were obtained from Florida Blood Services (Tampa, FL, USA).  
Antibodies include: specific anti-sAPPα monoclonal antibody (2B3; IBL, Minneapolis, MN, USA, 
Cat# 11088 RRID: AB_494690), anti-APP C-terminal polyclonal antibody (pAb751/770; EMD 
Millipore, La Jolla, CA, USA, Cat# 171610, RRID: AB_211444), anti-APP N-terminal 
monoclonal antibody (22C11; Merck Millipore, Billerica, MA, USA, Cat# MAB348B, RRID: 
AB_11204540), anti-N-terminal A monoclonal antibody (6E10; Covance Research Products, 
Emeryville, CA, USA), anti-Aβ16–26 monoclonal antibody (4G8; Covance Research Products, Cat# 
SIG- 39200, RRID: AB_10175149), anti-phospho-tau antibody (Thr231; Merck Millipore, Cat# 
AB9668, RRID: AB_570891), anti-DDK antibody (Cell Signaling Technology, Danvers, MA, 
USA, Cat# 2908, RRID: AB_1905079), anti-NeuN antibody (Merk Millipore, Cat# ABN90, 
RRID: AB_11205592), and anti-β-actin monoclonal antibody (Sigma-Aldrich, St. Louis, MO, 
USA, Cat# A5316, RRID: AB_476743).  Human recombinant full-length APP695 (fAPP, 100 ng)-
tagged with C-terminal MYC/DDK was purchased from OriGene Technologies, Inc. (Rockville, 
MD, USA). 
 
Cell culture 
Chinese hamster ovary (CHO) cell line with stable expression of human wild-type APP 
(CHO/APPwt) was a generous gift from Drs. Stefanie Hahn and Sascha Weggen (University of 
Heinrich Heine, Düsseldorf, Germany).  At the beginning of the experiment, CHO/APPwt cells 
were genotyped and confirmed the genetic make-up. The cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS), 1 mM sodium pyruvate 
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and 100 U/mL of penicillin/streptomycin.  For treatment, the cells were plated in a 24-well plate 
at 2 x 105 cells /well for overnight incubation, washed and treated with CBS (0-10%), Inact CBS 
(5%), ABS (0-10%), AgBS (0-10%), or αCBSF (0-1%) in DMEM.  After treatment, supernatants 
were collected and the cells were washed with ice cold PBS 3X and lysed with cell lysis buffer (20 
mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM 
sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, and 1 mM 
PMSF) (Cell Signaling Technology).  Both cell supernatants and lysates were used for sAPPα 
analysis by ELISA.  For immunoprecipitation, 100 ng of fAPP695 was incubated with αCBSF at 
37oC for 1 h and then the sAPPα/αCBSF-derived immune complex was immunoprecipitated using 
2B3 sAPPα specific antibody or anti-DDK antibody.  The supernatants were then collected and 
used for treatment of CHO/APPwt cells. 
 
Cell-free -secretase assay 
In order to determine the -secretase activity of CBS reflected by sAPPα level, human 
recombinant full-length APP695 tagged with C-terminal MYC/DDK (fAPP695, 100 ng; OriGen 
Biomedical, Austin, TX, USA) was incubated with CBS, heat inactivated CBS (inact CBS, 56oC 
for 30 minutes), AgBS, fetal bovine serum (FBS), or αCBSF at 37ºC for 5 h in the presence or 
absence of protease inhibitor cocktail (PI, 1X; Sigma-Aldrich), TNFα converting enzyme (TACE) 
inhibitor [(TAPI-0, 1 µM; abcam, Cambridge, MA, USA), or a disintegrin and metalloproteinase 
domain-containing protein (ADAM) inhibitor (GM6001, 1 µM; Sigma-Aldrich)].  The reaction 
mixtures were then subjected to Western blot (WB) analysis for APP α-secretase processing.  In 
addition, TACE and ADAM10 cleavage activity of αCBSF was determined using TACE 
(AnaSpec, Fremont, CA, USA) and ADAM10 cleavage activity kits (AnaSpec), according to 
manufacturer’s instructions. 
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CBS fractionation 
Next, in order to purify and characterize the α secretase in - CBS or AgBS, the Econo-Pack 
Serum IgG purification kit, and 10DG columns (Bio-Rad, Philadelphia, PA, USA) were initially 
employed to remove highly abundant IgG and salts.  The desalted serum was applied to DEAE 
Affi-Gel blue columns and residual IgG was eluted according to the instructions.  Then 20 
additional protein fractions were collected by eluting with an ionic strength gradient of NaCl buffer 
ranging from 0.1 M to 2.0 M.  The remaining proteins on the column were eluted by the 
regeneration buffer included in the kit and collected as the regeneration fraction.  The 0.8 M NaCl 
eluted protein fractions were combined together and sent to Moffitt Cancer Center Protein 
Purification Core for further separation by size exclusion chromatography, employing analytic 
Superdex 200 columns and eluting with PBS, and ion-exchange chromatography, employing Q-
Sepharose columns and eluting with 500 mM NaCl, 50 mM Tris, pH 7.6.  The final enzyme 
containing fractions were exchanged to PBS buffer by Ultracel-10 membranes (10 kDa, Merck 
Millipore) for further experimentation and referred to as CBSF or AgBSF. 
 
Animal models 
Both 5XFAD [MMRC Stock No: 34840-JAX; RRID IMSR_JAX: 006554] and 3xTg 
[MMRC Stock No: 34830-JAX] mice of male and female were purchased from Jackson laboratory 
(Bar harbor, Maine, USA).  In this preclinical study to investigate whether CBS fractionation 
changes AD-like pathology and associated behavioral deficits, five-month old 5XFAD mice were 
used that harbor five mutations [APP KM670/671NL (Swedish), APP I716V (Florida), APP V717I 
(London), PSEN1 M146L, and PSEN1 L286V] [158], rapidly develop AD-like pathology 
including accumulation of high levels of extracellular β-amyloid plaques, neurodegeneration, and 
behavioral impairments. In order to investigate whether CBS fractionation administration changes 
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both Aβ and tau phosphorylation, 3XTg-AD mice were used which harbor presenilin-1 
(PS1/M146V), APP (KM670/671NL), and tau (P301L) mutants. These mice progressively 
develop β-amyloid and NFT pathology which potentially synergize to accelerate 
neurodegeneration by 6 months of age [159].  At the beginning of the experiment all mice were 
confirmed as mutant by PCR. One male and four female mice were housed in a single cage 
separately. All animal experiments were performed in accordance with the guidelines of the 
National Institutes of Health and were approved by USF Institutional Animal Care and Use 
Committee (IACUC reference number: IS00000438). Transgenic mice used for aging studies may 
exhibit signs such as ruffled hair coat, hair loss, excessive weight gain and/or loss. When one of 
these signs is observed, mice will be monitored more closely and will be weighed twice weekly. 
Mice exhibiting multiple clinical signs or showing >20% weight loss will be excluded from the 
study. As per our previous practice, if a mouse appears overtly sick or in pain as indicated by 
ruffled, matted, or dull hair, hunched back or head pressing, failure to move about the cage, failure 
to respond to stimuli, rapid, shallow, labored breathing, twitching or trembling, or to experience 
seizure, a veterinarian will be consulted in order to ensure timely intervention and treatment, or 
removal from the study. All mice were maintained on a 12-h light/12-h dark cycle at ambient 
temperature and humidity and housed in the Morsani College of Medicine Animal Facility at the 
University of South Florida (USF) with ad libitum access to food and water.   
 
Stereotaxic intracerebroventricular injection 
In order to determine whether αCBS fraction could modify Aβ and tau pathology, cohorts 
of seventeen (n = 17, 9♂/8♀) triple transgenic 3XTg-AD mice were arbitrary anesthetized with 
isoflurane (2 - 3% induction, 1% maintenance).  After reflexes were checked to ensure that mice 
were unconscious, they were positioned on a stereotaxic frame (Stoelting Lab Standard™, Wood 
 34 
 
Dale, IL, USA) with ear-bars positioned and jaws fixed to a biting plate.  The axis coordinates 
were taken from a mouse brain atlas, and the needle of a Hamilton microsyringe was implanted 
into the left lateral ventricle delimited from the stereotaxic coordinates (coordinates relative to 
bregma: −0.6 mm anterior/posterior, +1.2 mm medial/lateral, and −3.0 mm dorsal/ventral) using 
the stereotaxic device.  αCBSF (0.5 µg/mouse, n = 6, 3♂/3♀),), AgBSF (0.5 µg/mouse, n = 6, 
3♂/3♀),) and PBS (1 µL/mouse, n = 5, 3♂/2♀),) were administered at 1 μL/minute.  After 
administration, the syringe was removed slowly to prevent bleeding and further brain damage.  
The lesions were closed with 1-2 staples and observed until anesthesia had cleared.  Seventy two 
hour after the intracerebroventricular (i.c.v.) injections animals were sacrificed with isoflurane, 
then transcardially perfused with ice-cold PBS, and brains were harvested for biochemical, 
histochemical, and immunohistochemical analyses. 
 
Intraperitoneal administration with an osmotic mini pump 
Mice were labeled using tail tattooing by veterinarian who was blinded about the entire 
experiment.  In order to determine whether CBS fractionation changes AD-like pathology and 
associated behavioral deficits, cohort of even-number labeled 5XFAD mice were randomly 
assigned into two experimental groups of six mice each, receiving CBSF (n = 6, 3♂/3♀), or 
AgBSF (n = 6, 3♂/3♀) treatment by an Alzet® osmotic mini pump (Alzet 2004, DURECT 
Corporation, Cupertino, CA, USA).  A third group of WT control mice was received to CBSF (n 
= 6) by the same administration route.  Mice were briefly anesthetized with isoflurane as 
previously, an area of the abdomen was shaved, a 1-cm abdominal incision was made and an 
Alzet® osmotic mini pump filled with 100 L of CBSF, or AgBSF was implanted intraperitoneally 
(i.p.).  The pump delivered these fractionated sera at a constant rate of 0.15 µL/h for 6 weeks, 
yielding a treatment dose of 1 mg/kg/day or 30 μg/mouse/day.  At the end of 4-5 weeks treatment 
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(6 months of age), cognitive evaluations were conducted in these mice with our established 
behavioral battery.  After 6 weeks treatment, mice were sacrificed with isoflurane, then 
transcardially perfused with ice-cold PBS, and brains were removed to assess β-amyloid plaque 
pathology. 
 
Behavioral assessments 
Novel object recognition test  
Novel object recognition is based on the spontaneous tendency of a mouse to explore a 
new object compared with an old object.  At first, during the habituation phase (day 1), each mouse 
was acclimatized with the testing apparatus box for 10 minutes.  Next, during the training day (day 
2) each mouse was familiarized with two similar objects (4 cm x 4 cm x 4 cm) for 10 minutes.  
Finally, during the testing day (day 3) one of the objects was replaced with a new object and tested 
for 10 minutes.  The amount of time spent exploring the new and old objects during the test phase 
was quantified by video tracking (ANY-Maze; Stoelting Lab Standard™) and provides an index of 
recognition memory.  Discrimination index was calculated as frequency of exploration of new 
versus original objects. 
 
Y-maze test  
Y-Maze testing was performed as described previously [160]. This task was used to assess 
basic mnemonic processing by spontaneous percent alternation and exploratory activity of mice 
placed into a black Y-maze.  The arms of this maze were 21 cm-long and 4 cm-wide with 40 cm-
high walls.  Each mouse was placed in one of the arms and allowed one five-minute trial of free 
exploration of the three alleys in the maze.  The number of total arm choices and sequence of arm 
choices were recorded. 
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Histochemical and immunohistochemical analyses 
Mice were euthanized with isoflurane and then transcardially perfused with ice-cold PBS.  
Brains were rapidly isolated, and one hemisphere was frozen immediately in liquid nitrogen and 
stored at -80°C.  For molecular analysis, brain hemispheres were sonicated in RIPA buffer (Cell 
Signaling Technology), centrifuged at 14,000 rpm for 1 h at 4°C and supernatants were isolated 
for WB analyses.  The other hemisphere was placed in 4% paraformaldehyde for cryostat 
sectioning.  The 25-μm free-floating coronal sections were collected and stored in PBS with 100 
mM sodium azide at 4°C.  Immunohistochemical staining was performed using various primary 
antibodies in conjunction with the VECTASTAIN Elite ABC kit (Vector Laboratories, 
Burlingame, CA, USA) coupled with diaminobenzidine substrate.  A set of sections without adding 
primary antibody were used as negative staining control.  Sections were also stained with Congo 
red dye and Thioflavin-S fluorescence dye for detecting fibrillary Aβ species as described 
previously [161][85].  Images of five 25-μm sections (150 μm apart) through hippocampus and 
neocortex were captured and a threshold optical density was obtained that discriminated staining 
from background.  Data are reported as percentage of immunolabeled area captured (positive 
pixels divided by total pixels captured).  Quantitative image analysis was performed by a single 
examiner (T.M.) blinded to sample identities. 
 
 
WB analysis and ELISA 
WB analyses and quantification were performed as previously described [84]. Briefly, the 
proteins from the cell-free suspensions, cell lysates, and homogenized tissue were 
electrophoretically separated using 10% bicine/tris gel (8 M urea) for proteins less than 5 kDa or 
10% tris/SDS gels for larger proteins.  Electrophoresed proteins were transferred to nitrocellulose 
membranes (Bio-Rad), washed and blocked for 1 h at room temperature in tris-buffered saline 
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containing 5% (w/v) nonfat dry milk (TBS/NFDM).  After blocking, membranes were hybridized 
overnight with various primary antibodies, washed and incubated for 1 h with the appropriate 
HRP-conjugated secondary antibody in TBS/NFDM.  Blots were developed using the luminol 
reagent (Thermo Fisher Scientific, Waltham, MA, USA).  sAPPα ELISA (IBL) was performed 
according to manufacturer’s instruction. 
 
Statistical analysis 
Comparisons between two groups were performed by Student's t-test analysis. For more 
than two groups, one-way analysis of variance (ANOVA) followed by LSD post hoc analysis was 
used to compare each other for statistical significance. Alpha was set at 0.05 for all analyses.  The 
significance level of p value was set at p < 0.05 for all analyses. All the mice experiment were 
repeated three times in parallel to attain the above significant difference. Data are expressed as 
mean ± SEM. The statistical package for the social sciences release IBMSPSS 23.0 (IBM, Armonk, 
NY, USA) was used for all data analyses. 
Results 
 
CBS dose-dependently promotes α-cleavage in CHO/APPwt cells 
Our previous studies indicate that both single and multiple low-dose infusions of HUCBC 
as well as HUCBC-derived monocytes can significantly reduce β-amyloid plaques and cognitive 
impairments in AD mouse models.  Having shown that HUCBC can reduce β-amyloid pathology, 
we next set out to determine whether human umbilical-derived CBS could also reduce β-amyloid 
pathology through alteration of APP processing.  CHO/APPwt cells were treated with different 
concentrations (0-10%, six different doses) of CBS, ABS, or AgBS for 4 h (Figure 2-1a and b, left 
panels).  The conditioned media were collected and subjected to sAPPα ELISA and also sAPPα 
WB analysis using 2B3 sAPPα specific antibody.  CBS dose-dependently promoted sAPPα levels 
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with greater than that elicited by ABS and AgBS.  Similarly, CHO/APPwt cells were treated with 
5% CBS, ABS, or AgBS for six different time points (0-4 h, Figure 2-1a and b, right panels).  CBS 
time-dependently promoted sAPPα levels with greater than that elicited by ABS and AgBS.  To 
see whether the factor present in the serum mediating α-secretase activity is proteinaceous in 
nature, we treated CHO/APPwt cells with heat inactivated serum (inact CBS) for 4 h.  As expected, 
heat inactivation limited the sAPPα producing capacity of CBS, as shown by ELISA (Figure 2-1c, 
upper panel) and WB (Figure 2-1c, lower panel).  Therefore, CBS possesses α-secretase, reflecting 
sAPPα level in a dose- and time-dependent fashion and the factor mediating this activity is heat 
labile and most likely a protein. These results confirm that FBS also contains a heat sensitive -
secretase.   
 
CBS mediates α-cleavage of neuron specific APP695 independent of ADAM activity 
Next, we tested whether the α-secretase in CBS is mediated by TACE (ADAM17) or 
ADAM. Human recombinant full-length APP695 (fAPP, 100 ng)-tagged with C-terminal 
MYC/DDK was incubated with CBS, inactivated CBS (inact CBS), or AgBS at 37ºC for 5 h in the 
presence or absence of different inhibitors [protease inhibitor cocktail (PI, 1X), TACE inhibitor 
(TAPI-0, 1 µM), or ADAM inhibitor (GM6001, 1 µM)] (Figure 2-2a).  The reaction mixtures were 
subjected to sAPPα WB analysis using 2B3 sAPPα specific antibody (Figure 2-2a, upper panel) 
and total APP analysis using 6E10 anti-Aβ1-17 antibody (Figure 2-2a, lower panel).  PI cocktail 
significantly limited CBS derived α-secretase catalytic activity, as reflected by sAPP695 level, but 
this activity was not limited by TACE or ADAM inhibitors (Figure 2-2a, upper panel).  In addition, 
full-length APP (fAPP695, 100 ng) was incubated with 5% CBS, FBS, or inactivated CBS for 1, 5, 
or 24 h.  CBS α-secretase increased the level of sAPP695 in a time-dependent manner, measured 
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by 2B3 antibody (Figure 2-2b, upper panel).  As shown, the level of sAPP770 represents 
endogenous sAPPα. 
 
Removal of high and low abundance proteins increases activity of CBS α-secretase 
To purify and ultimately identify the target protein/complex mediating CBS -secretase 
catalytic cleavage, three-step chromatographic separation techniques were employed.  Initially, 
removal of highly abundant immunoglobulins and desalting were performed using Bio-Rad 
Econo-Pack Serum IgG purification kit and 10DG columns.  Desalted CBS was then applied to 
DEAE Affi-Gel blue columns to completely remove IgGs and collect 20 additional protein 
fractions, and eluted with increasing strengths of NaCl buffer.  CHO/APPwt cells were treated 
with each fraction for 2 h to determine -secretase activity by ELISA.  In addition, unfractionated 
whole and desalted CBS (dCBS) positive control as well as PBS negative control was used to treat 
cells.  These sequential approaches significantly increased -secretase, with the fractions 
showing the highest α-secretase catalytic activity, as reflected by sAPPα level eluting around 0.6-
0.9 M NaCl concentrations (Figure 2-3a).  As shown in Figure 2-3c, 0.7-0.9 M NaCl fractions 
from 10 CBS lots increased sAPPα levels at least with maximum fivefold higher than the whole 
CBS.  In addition, the fractionated and whole CBS were run in SDS-PAGE, demonstrating 
numerous proteins remaining in each CBS fraction (Figure 2-3c, right upper panel).  Therefore, 
we selected the 0.8 M NaCl eluted fraction for further purification. As shown in Figure 2-3b, the 
level of total protein concentration represents in (mg/mL) in CBS fraction. 
 
Further purification of CBS α-secretase using size-exclusion and anion-exchange 
chromatography 
 
The 0.8 M NaCl eluted fraction of CBS was subjected to size-exclusion chromatography 
using Superdex 200 prep grade columns (XK 16/40, GE Healthcare, USA) packed with cross-
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linked agarose and dextran.  The mobile phase was 20 mg/mL acetone in distilled water, and 
detection was performed at UV280 nm.  Approximately 100 mg of protein from the 0.8 M NaCl 
fraction was applied to the column and 48 fractions were eluted with PBS.  The catalytic activity 
of α-secretase was greatly enhanced, as tested on CHO/APPwt cells by measuring sAPPα 
production.  Fractions #11 and 12 produced sAPPα > fivefold higher compared with the original 
0.8 M NaCl eluted fraction as well as all other fractions, as determined by WB (upper panel) and 
ELISA (lower panel, Figure 2-4a).  To confirm the enhancement of α-secretase, we determined 
the sAPPα in fractions #8-18 along with the original 0.8 M NaCl eluted fraction from three 
different CBS lots.  Fractions #10-13 showed α-secretase activity 15 fold more than the original 
0.8 M NaCl eluted fraction, as measured by ELISA (Figure 2-4c).  As determined by SDS-PAGE, 
the molecular mass of the #10-13 fractions was 177-275 kDa (Figure 2-4c). 
To examine the charge of α-secretase protein/complex in CBS, the size exclusion fractions 
containing the highest α-secretase catalytic activities, as reflected by sAPPα levels (#10 to 13) 
were further subjected to anion-exchange chromatography using Q-Sepharose columns.  Protein 
from the size exclusion fractions were applied to the column and 82 fractions were eluted with 0.5 
M NaCl.  Fractions #53-56 showed > eightfold higher α-secretase catalytic activity, as reflected 
by sAPPα level than the original size-exclusion fraction, as determined in CHO/APPwt cells by 
WB and ELISA (fractions #2-4 in Figure 2-5a, upper and lower panels, respectively).  To further 
compare the enzymatic activity of CBS samples before and after anion-exchange chromatography, 
we collected fractions #1-5 and #23 from three different samples and determined the sAPPα level 
in each, indirect measurement of CBS α-secretase activity.  Combined fractions #2-4 produced 
sAPPα > 50 fold higher than the original eluted (#23) fraction, as measured by ELISA (Figure 2-
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5c).  Combined fractions #2-4, referred to hereafter as αCBSF, were therefore used for further 
analysis. 
 
αCBSF promotes non-amyloidogenic APP processing 
Human recombinant full-length APP (fAPP695) was incubated with five different 
concentrations (0-1%) of αCBSF at 37ºC for 2 h.  The reaction mixtures were subjected to sAPPα 
WB analysis using 2B3 antibody as well as full length APP and αCTF analyses using 
pAPP751/770 antibody (an anti-APP C-terminal antibody, Figure 2-6a).  This analysis showed 
that αCBSF increases sAPPα as well as α-CTF fragments and decreases (full-length) holo APP 
with increasing doses. 
In order to confirm that αCBSF mediates novel α-secretase cleavage independent of TACE 
or ADAM, fAPP695 was incubated with αCBSF in t3e absence or presence of ADAM (GM6001, 
1 µM) or TACE inhibitor (TAPI-0, 1 µM) for 1 h. αCBSF treatment alone increased the levels of 
APP-processing fragments such as sAPPα and α-CTF, and decreased the level of holo APP as 
determined by WB, which effects did not alter significantly by GM6001 and TAPI-0 combined 
treatment with αCBSF (Figure 2-6b).  In addition, TACE and ADAM10 enzymatic activities of 
αCBSF were measured by TACE and ADAM10 cleavage activity kits.  TACE (25 μg/mL) in the 
presence or absence of TACE inhibitor (TAPI-0, 1 µM) and ADAM10 (50 μg/mL), in the presence 
or absence of ADAM inhibitor (GM6001, 1 μM), were included as positive controls.  Results 
suggest that CBSF has very little TACE or ADAM10 activity (Figure 2-6c and d). 
 
Immunoprecipitation of fAPP695/CBS specifically limits APP α-secretase cleavage 
To determine whether immunoprecipitation could specifically limit α-secretase of αCBSF, 
100 ng of fAPP695 was incubated with 0.125 μg of αCBSF at 37°C for 1 h and the sAPPα/αCBSF 
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immune complex was immunoprecipitated using anti-DDK antibody, 2B3 or nonspecific IgG.  
CHO/APPwt cells were treated in the FBS free condition for 2 h with the supernatants collected 
from the immune complex or PBS as reference control, and then conditioned media were analyzed 
by sAPPα WB using anti-N-terminal APP antibody (22C11, Figure 2-7a) and sAPPα ELISA 
(Figure 2-7b) to determine α-secretase in CBS.  Immunoprecipitation of the sAPPα/αCBSF with 
anti-DDK antibody significantly reduced α-secretase activity of αCBSF, indicating that 
immunoprecipitation limits the CBS-mediated APP α-secretase cleavage.  In contrast, 
immunoprecipitation of sAPPα/αCBSF with 2B3 did not reduce CBS -secretase, indicating that 
αCBSF does not form an immune complex with sAPPα.  In addition, there was no notable or 
significant difference in sAPPα production elicited by 0.5% supernatant from αCBSF IP with 
control IgG and 2.5 % (equivalent to 0.5% Super.) αCBSF alone (data not shown). 
 
CBSF reduces β-cleavage, promotes α-cleavage of APP, and stabilizes tau phosphorylation 
in 3XTg-AD mice 
 
To test whether αCBSF suppresses β-site APP cleaving enzyme 1 (BACE1)-mediated APP 
processing in vivo, four-month old 3XTg-AD mice were treated αCBSF, AgBSF (0.5 μg/mouse), 
or PBS control (1 μL/mouse) with i.c.v. injections.  After 72 h of treatment, in homogenates 
prepared from the right hemisphere (non-injection side), WB analysis using Aβ1-17 antibody (6E10) 
shows that αCBSF reduced A (Figure 2-8a) and -CTF production (Figure 2-8c), whereas 
enhancing sAPPα production (Figure 2-8b), compared with AgBSF and PBS control.  Compared 
with AgBSF and PBS, αCBSF also reduced tau (Thr231) phosphorylation in these mice (Figure 2-
8d). 
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CBSF ameliorates β-amyloid pathology in 5XFAD mice 
 
To determine the effect of CBSF on -amyloid pathology, transgenic 5XFAD mice at 
five months of age were continuously treated with αCBSF or AgBSF via i.p. osmotic mini pump 
for 6 weeks.  Immunohistochemical staining using 4G8 antibody showed that αCBSF treatment 
substantially decreases cortical and hippocampal β-amyloid plaques (Figure 2-9a, upper panel), 
and reduces fibrillary Aβ species visualized by Thioflavin-S histochemical staining (Figure 2-9a, 
lower panel) compared with AgBSF treatment.  Moreover, the CBSF-treated cohort also revealed 
less β-amyloid plaque pathology than the AgBSF-treated cohort, as determined by Congo red 
histochemical staining (Figure 2-9a, middle panel).  Quantitative analysis disclosed that CBSF 
therapy significantly ameliorated -amyloid pathology, as determined by 4G8 antibody staining 
in both neocortex and hippocampus regions compared with AgBSF treatment (Figure 2-9b). 
 
Neuroprotective effects of αCBSF 
 
5XFAD mice undergo neuronal loss in the neocortex and hippocampus that is associated 
with behavioral deficits.  We examined whether continuous delivery of αCBSF by i.p. osmotic 
mini pump can elicit a neuroprotective effect in 5XFAD mice.  Treatment with αCBSF partially 
prevented neuronal loss in the neocortex region compared with AgBSF treatment, as demonstrated 
by NeuN antibody immunohistochemical staining, thus indicating that αCBSF may confer 
neuroprotective ability for AD brain (Figure 2-10a and b). 
 
αCBSF improves learning, memory, and cognitive function in 5XFAD mice 
 
5XFAD mice were received to continuous treatment with αCBSF or AgBSF via i.p. 
osmotic mini pump for 4 weeks, and evaluated for cognitive function by Novel object recognition 
and Y-maze tests.  Novel object recognition test showed that αCBSF-treated 5XFAD mice spent 
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more time with the novel versus old objects, whereas AgBSF-treated 5XFAD mice spent the same 
period of time with both novel and old objects (Figure 2-11a).  Thus, discrimination index (%) was 
enhanced by αCBSF compared with AgBSF treatment (Figure 2-11b).  Notably, improvement was 
complete, because there was no significant difference (p > 0.05) from WT control mice (NTg).  In 
addition, αCBSF treatment significantly increased the number of entries (Figure 2-11c) and 
spontaneous alterations in 5XFAD mice compared with the AgBSF-treated cohort (Figure 2-11d), 
as determined by Y-maze test, thus confirming that αCBSF treatment improved learning and 
working memory in this AD mouse model. 
 
Discussion 
 
Recent progress in HUCBC therapy for different neurological diseases [34][35] opened 
new opportunities for AD research [36]. We have previously found that multiple low-dose 
peripheral infusion of HUCBC reduced cerebral -amyloid plaques, cerebral amyloid angiopathy, 
and astrocytosis, whereas these treatments improved cognitive impairments in the PSAPP AD 
mouse model [37] and enhanced neurogenesis in the aged rat brain [32].  In a subsequent study, 
we have reported that HUCBC-derived monocytes reduced cerebral -amyloid pathology and 
cognitive impairments [38].  In addition, we have shown that HUCBC-derived monocyte more 
effectively removed A by phagocytosis than the aged-blood monocyte, whereas sAPPα enhanced 
A phagocytosis by the aged monocyte by forming a complex with Aβ via the help of monocyte 
scavenger receptor [38].   In support of these findings, we demonstrated that overexpression of 
sAPPα significantly reduces both cerebral -amyloid [42] and tau pathology in crossing Tg-sAPPα 
with PSAPP mice [43]. Meanwhile, using a sophisticated parabiosis mouse model, Wyss-Coray 
and colleagues showed that blood serum from old mice reduces neurogenesis and impairs cognitive 
functions when administered into young mice [40]. Subsequently, several groups reversed age-
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related cognitive impairments in aged mice by infusing plasma from young into old mice 
[41][154][155] as well as AD pathology [157].   More specifically, Wyss-Coray group have 
published several articles over the last few years [41][75] showing the potential of young and/or 
umbilical cord plasma in ameliorating aged-associated cognitive impairments. In those 
experiments, they have either joined the young and aged mice thorough parabiosis or injected 
young and/or umbilical cord blood derived plasma into aged mice via tail vein injection. 
Interestingly, only three to four injections within 3-4 weeks period of time improved cognitive 
impairments in those experiments. These results encouraged us to determine whether human CBS 
could effectively reduce AD pathology in vitro (i.e., cell culture and cell-free systems) as well as 
in vivo (i.e., 3X-TgAD and 5XFAD mouse models) by enhancing sAPPα production. 
Our preliminary findings indicate that CBS possesses α-secretase-like enzyme in cell 
culture and cell-free systems.  In CHO/APPwt cells, CBS produces greater amount of sAPPα 
production compared with ABS and AgBS in a concentration- and time dependent manner (Figure 
2-1a and b).  Since α-secretase is proteinaceous and heat-labile, we hypothesized that α-secretase-
like enzyme displayed by CBS is also inactivated by heat treatment.  As expected, heat inactivation 
significantly limited the sAPPα producing capacity of CBS (Figure 2-1c).  These results suggest 
that α-secretase-like enzyme of CBS is most likely a single complex protein that interacts with and 
cleaves APP.  Subsequent study indicated that CBS mediates α-secretase cleavage of neuron-
specific APP695 in a cell-free system, further suggesting that this activity is mediated by an 
endogenous enzyme (Figure 2-2a and b). 
To purify, characterize, and ultimately identify this α-secretase-like content in CBS, we 
employed three-step affinity column, size-exclusion, and anion-exchange chromatography 
techniques in a sequential manner (Figure 2-3, 2-4, and 2-5).  These sequential purification steps 
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enhanced the catalytic activity more than 3,000 fold compared with original CBS.  The fractions 
containing highest α-secretase catalytic activity, as reflected by sAPPα level were combined and 
termed as “αCBSF” for the further study.  SDS-PAGE analysis of the fractions from size-exclusion 
and anion-exchange chromatography yielding the highest α-secretase indicated size of our 
unknown enzyme could be around 177-275 kDa (Figures 2-4 and 2-5). It is not easy for a 177-275 
kDa protein to cross the blood brain barrier through intraperitoneal mini pump administration 
without any inhibition. However we do not believe the protein is larger than 275 kDa based on the 
markers in for our gels. However, the SDS-PAGE also showed some low molecular-weight 
compounds which cannot be ruled out as well, which warrant further investigation. Interestingly, 
TACE (ADAM17) and ADAM inhibitors did not alter α-secretase in CBS, indicating that the 
enzyme is not TACE or ADAM, whereas the activity was dramatically reduced by protease 
inhibitor/cocktail, confirming that the activity is mediated by a protease (Figures 2-2 and 2-6).  
Moreover, immunoprecipitation of αCBSF with 2B3 antibody (anti-C-terminal of sAPPα) showed 
significant reduction of sAPPα levels, indicating that α-secretase-like enzyme αCBSF physically 
interacts with sAPPα (Figures 2-7). 
Previously, we and others have shown that sAPPα reduces β-amyloid pathology via 
inhibition of BACE1 [42]. In a recent article, we have shown that sAPPα decreases tau 
phosphorylation via BACE1 inhibition and GSK-3β-mediated inhibitory phosphorylation [43]. 
This study prompted us to investigate the functional efficacy of fractionated CBS (αCBSF) in 
5XFAD and 3XTg-AD mouse models. We have shown that αCBSF significantly reduced Aβ and 
tau phosphorylation (p-tau-Thr231) in 3X-Tg AD mice, whereas αCBSF enhanced α-secretase 
cleavage products (i.e., sAPPα and α-CTF), indicating that α-secretase-like content in CBS 
promotes APP non-amyloidogenic processing in vivo (Figure 2-8b and c).  In 5XFAD mice being 
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aggressive -amyloid deposition and plaque formation, αCBSF reduced -amyloid plaque 
pathology in both neocortex and hippocampus regions, and reduced neural loss in the neocortex 
region, compared with AgBSF-treated mouse brains (Figures 2-9 and 2-10). By carrying-out 
sequential fractionation, we markedly enhanced CBS derived α-secretase (termed αCBS) and 
infused into 5XFAD mice via osmotic mini pump over the period of 6 weeks. Behavioral analyses 
in 5XFAD mice indicate that αCBS treated mice showed improved episodic memory, as 
determined by novel object recognition test (Figure 2-11a and b) as well as spatial working 
memory, as determined by Y-maze test (Figure 2-11c and d) compared with AgBSF treatment. 
Our work is in line with the work of Villeda et al. 2014 [41] and Castellano et al. 2017 [75] where 
improvement of performance in cognitive impairment was found in aged-mice treated with young 
plasma. Notwithstanding, we are not quite sure how CBS fraction (αCBSF) ameliorates β-amyloid 
pathology and cognitive functioning in 5XFAD and tau pathology in 3XTg-AD mouse model. The 
effect we observe may or may not be from CBS α-secretase-like enzyme. One of the plausible 
explanation of this effects are may be a direct action from CBS α-secretase-like enzyme or could 
be an indirect effect through peripheral sink hypothesis which demand further investigation. 
Although we do not know the exact molecular mechanism, however, we believe that human cord 
blood derived serum and/or plasma protein functions as a master regulator of several genes 
involved in the proliferation of cells, and blood vessels that might reduce neuroinflammation, Aβ, 
and improve synaptic plasticity by affecting multiple pathways. Overall, our results show 
beneficial effects of αCBSF in ameliorating β-amyloid pathology and cognitive functioning in 
5XFAD and reducing tau phosphorylation in 3XTg-AD mouse model. 
It is well known that members of the membrane-bound zinc-dependent metalloproteinase 
ADAM family are α-secretase enzymes that cleave APP for the non-amyloidogenic pathway.  In 
 48 
 
particular, three different members of this family, ADAM9, ADAM10, and ADAM17, possess 
APP α-secretase activity [141].  The ADAM family constitutes a large family of multidomain 
membrane proteins that have both cysteine-rich, disintegrin, and zinc metalloprotease domains in 
their ectodomain [140]. The main function of ADAM family is to shed the ectodomain of different 
membrane proteins, and has growth factors-like function via intracellular signaling cascade.  
However, it should be noted that numerous other substrates also have been linked to these ADAM 
family.  These functions of ADAM family either protect against AD or promote AD pathogenesis 
via activation of different cytokines.  One of the enzymes, ADAM17 is also known as TACE, 
responsible for secreting the main pro-inflammatory cytokine, TNFα [146]. Thus, TACE 
(ADAM17) is a therapeutic target for multiple diseases.  Additionally, both ADAM10 and 
ADAM17 cleave various other membrane proteins and promote tumor in the cell [142]. ADAM10, 
in particular, cleaves many different kinds of transmembrane proteins in the vascular system, 
including the platelet-activating collagen receptor glycoprotein VI, [144][143] and endothelial 
proteins, including transmembrane chemokines (i.e., CX3CL1 and CXCL16) [145]. These two 
chemokines are known for angiogenesis, inflammation, and immune cell recruitment [162][163]. 
Likewise, ADAM9 cleaves and releases a number of molecules with important roles in 
tumorigenesis and angiogenesis.  Taken together, whereas the known α-secretase enzymes, mainly 
ADAM10 and ADAM17 (TACE) and in some degree ADAM9, are involved in APP α-secretase 
cleavage, they are not APP specific and cleave various substrates associated with inflammation, 
tumor formation, and progression.  Thus, whereas AD is the only pathology in which an increased 
α-secretase activity has been proposed to be favorable, the nonspecific nature of the known -
secretases has made this strategy for AD treatment thus far unsuitable [147]. 
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In sum, our study has presumably discovered an umbilical cord blood derived α-secretase 
which is independent on TACE or ADAM, thus making it a suitable candidate for the further study 
as a therapeutic target for AD treatment.  This α-secretase-like enzyme activity either directly or 
indirectly activates α-secretase or produce sAPPα in cell culture and AD animal models.  In 
addition, we believe this α-secretase appears to be mediated by novel enzymes residing within the 
sera which decline with age.  We expect that our study using fractionation, chromatographic 
separation and mass-spectrometry (MS) techniques would identify the target enzyme as well as 
other interacting partners from CBS.  However, identification of a target protein or enzyme with a 
particular function from a complex mixture of serum is a challenging task due to multiple factors, 
including the high complexity and wide dynamic range of proteins as well as the presence of 
contaminating proteins of high abundance.  Despite this, here we show that our purification 
techniques significantly enhanced the α-secretase of CBS.  Further MS based sophisticated 
purification techniques will completely purify, identify, and characterize the factor mediating this 
α-secretase in CBS. 
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Figure 2-1 CBS, but not ABS or AgBS, markedly promotes APP α-cleavage in a time-, dose- 
and temperature-dependent manner. 
(a) CHO/APPwt cells were treated with 0, 0.25, 0.5, 1, 5 and 10% CBS, ABS, or AgBS (left panel).  
In addition, CHO/APPwt cells were treated with 5% CBS, ABS, or AgBS between 0 and 4 h, as 
indicated (right panel).  (b) CHO/APPwt cells were treated with CBS at different concentration (0-
10%) for 4 h (left panel) or treated with 5% CBS for different time point (0 - 4) h, as indicated 
(right panel).  Conditioned media were subjected to sAPPα ELISA (Figure 2-1A and B, top panel) 
and WB analyses (Figure 2-1B, bottom panel) with 2B3 antibody (c) CHO/APPwt cells treated 
with heat inactivated serum (inact CBS) or CBS for 4 h.  Conditioned media were subjected to 
sAPPα ELISA (Figure 2-1C, top panel) and WB analyses (Figure 2-1C, bottom panel) with 2B3 
antibody.  Data are presented as mean (± S.D.) of sAPPα produced (ng/mg) from 5 independent 
experiments in triplication.  Human umbilical cord blood plasma (CBP) produced similar results 
(data not shown).  APP α-secretase activity of pooled CBS or CBP or individualized CBS or CBP 
was similar (data not shown). 
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Figure 2-2 CBS directly mediates α-cleavage of neuron specific APP695, but this activity is 
not mediated by ADAM and TACE. 
CBS directly mediates α-cleavage of neuron specific APP695, but this activity is not mediated by 
ADAM and TACE.  (a) Human recombinant full-length APP695 tagged with C-terminal 
MYC/DDK (fAPP695, OriGen, 100 ng) was incubated with 5% CBS, inact CBS, or AgBS at 37ºC 
for 5 h in the presence or absence of a protease inhibitor cocktail (PI, 1 X), TACE (ADAM17) 
inhibitor (TAPI-0, 1 µM), or ADAM inhibitor (GM6001, 1 µM).  Lane 1-4 represent CBS (1), 
inact CBS (2), AgBS (3), and FBS (4) sample only control without substrate fAPP695. Lane 5 
represent fAPP695 (5) substrate only control without any serum sample. Lane 6-11 represent 
substrate fAPP695 with CBS (6), inact CBS (7), CBS with PI (8), CBS with TAPI-0 (9), CBS with 
GM6001 (10), and AgBS (11). Lane 12-14 represent (lane 12-14; PI (12), TAPI-0 (13), and 
GM6001 (14) inhibitor and substrate control respectively, without any serum sample.  The reaction 
mixtures were subjected to sAPPα WB analysis using 2B3 antibody (top panel) and total APP 
using 6E10 (an anti-Aβ1-17 antibody; lower panel).  sAPP770 refers to the endogenous α-secretase 
cleavage product of CBS or AgBS, whereas sAPP695 refers to the α-secretase cleavage product of 
fAPP695. (b) 100 ng of fAPP695 was incubated with 5% CBS for 1, 5, or 24 h, or 5% FBS or inact.  
FBS for 24 h, and then subjected to sAPPα and total APP WB analysis using 2B3 (top panel) and 
6E10 (lower panel), respectively.  sAPP770 refers to the endogenous α-secretase cleavage product 
of CBS or AgBS, whereas sAPP695 refers to the α-secretase cleavage product of fAPP695. 
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Figure 2-3 Fractionation of APP specific α-secretase activity in CBS.   
To purify and eventually identify the α-secretase activity in CBS, the Econo-Pack Serum IgG 
purification kit (Bio-Rad) was initially employed to remove highly abundant IgG.  CBS was then 
desalted using Econo-Pack 10DG columns.  The desalted serum was applied to DEAE Affi-Gel 
blue columns to remove residual IgG and collect 20 additional protein fractions, by eluting with 
an increasing ionic strength gradient of NaCl buffer ranging from 0.1 M to 2.0 M.  The remaining 
proteins on the column were eluted by the regeneration buffer included in the kit and collected as 
the regeneration fraction (Reg).  (a) CHO/APPwt cells were cultured in 24-well plates and treated 
with 10 μL of each protein fraction for 2 h.  Conditioned media were then collected and analyzed 
by sAPPα WB (upper panel) and ELISA (lower panel).  10 μL CBS, desalted CBS (dCBS), and 
phosphate buffered saline (PBS; Ctrl) were included under the same cell culture conditions as 
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positive and negative controls respectively.  Cell lysates were also prepared from each fraction-
treated cell culture as an additional reference to evaluate sAPPα production levels (data not 
shown).  (b) Protein concentration of each fraction.  (c) CHO/APPwt cells were treated with the 
0.6 to 1.0 M NaCl eluted fractions from 10 different CBS lots, as well as whole CBS and PBS 
(Ctrl), for 2 h and the conditioned media were collected for sAPPα ELISA.  The results were 
presented as mean (± S.D.) sAPPα produced (ng/mg protein).  In addition, each protein fraction 
was also subjected to SDS PAGE to assess total protein fractionation (c, right panel). 
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Figure 2-4 Protein size-exclusion chromatography by preparative-grade Superdex 200 
column. 
The 0.8 M NaCl eluted protein fraction of CBS was further subjected to size exclusion 
chromatography by analytic Superdex 200 column.  Approximately 100 mg of protein from the 
0.8 M NaCl fraction was applied to the column and 48 fractions were eluted with PBS.  (a) 
CHO/APPwt cells were cultured in 24-well plates and treated with 40 μL of each protein fraction 
for 2 h.  The conditioned media were collected and analyzed by sAPPα WB (upper panel) and 
ELISA (lower panel).   In parallel, the 0.8 M NaCl eluted fraction (#31) and PBS (#32) were 
included under the same cell culture conditions as positive and negative controls respectively.  Cell 
lysates were also prepared from each fraction-treated cell culture as an additional reference to 
evaluate sAPPα production levels.  (b) Protein concentration of each size fraction.  (c) 
CHO/APPwt cells were treated with #8 to 18 size fractions prepared from 3 independent 
experiments, as well as the original 0.8 M NaCl fraction (#31) and PBS (#32), and then conditioned 
media were collected and analyzed by sAPPα ELISA.  The results were presented as mean (± S.D.) 
sAPPα produced (ng/mg protein).  In addition, each size fraction was subjected to SDS PAGE 
analysis to assess total protein fractionation (C, right panel). 
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Figure 2-5 Further fractionation by anion-exchange chromatography.   
The size exclusion fractions containing the highest APP α-secretase activities (#10 to 13) were 
further subjected to anion-exchange chromatography using Q-Sepharose columns.  Approximately 
10 mg of protein from the size exclusion fraction(s) was applied to the column and 82 fractions 
were eluted with buffer containing 50 mM Tris, 500 mM NaCl, pH 7.6.  (a) CHO/APPwt cells 
were treated with 40 μL of each protein fraction for 2 h and conditioned media and cell lysates 
were analyzed by sAPPα WB (upper panel) and ELISA (lower panel).   The original size exclusion 
eluted fraction (#23) and PBS (#24) were included as positive and negative controls respectively.  
In addition, SDS-PAGE of #2-4 anion-exchange fractions showed the presence of multiple 
proteins (middle panel).  (b) Protein concentration of each fraction.  (c) CHO/APPwt cells were 
treated with the #1 to 4 anion-exchange fractions prepared from 3 independent experiments and 
then conditioned media were subjected to sAPPα ELISA.  The results are presented as mean (± 
S.D.) sAPPα produced (ng/mg protein).  The original size exclusion eluted fraction (#23) was 
included as a positive control.  Combined fractions #2 to 4, referred to as CBSF, and were used 
for further analysis. 
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Figure 2-6 αCBSF directly mediates α-cleavage of neuron specific APP695, but this activity 
is not mediated by ADAM or TACE.  
(a) Human recombinant full-length APP695 (fAPP695, 100 ng) was incubated with 0, 0.125, 0.25, 
0.5, or 1 µg of αCBSF. at 37ºC for 2 h.  The reaction mixtures were subjected to sAPPα WB 
analysis using 2B3 (top panel) and holo APP and α-CTF analysis using pAPP751/770 antibody 
(lower panel).  (b) fAPP695 (100 ng) was incubated with 0.125 µg of αCBSF in the absence or 
presence of ADAM (GM6001, 1 µM) or TACE inhibitor (TAPI-0, 1 µM) for 1 h and then subjected 
to sAPPα, holo APP and α-CTF WB analysis using 2B3 (top panel) and pAPP751/770 (lower 
panel).  α-CTF of APP was further confirmed by an additional WB using an antibody specifically 
against Aβ17-26 (4G8).  In addition, incubating human recombinant full-length APP751 with αCBSF 
produces similar results (data not shown).  (c) The TNFα converting enzyme (TACE or ADAM17) 
activity of αCBSF was measured by TACE cleavage activity kit.  TACE (25 μg/mL) secretase in 
the presence or absence of TACE inhibitor (TAPI-0, 1 µM) was included as positive control.  (d) 
In parallel the ADAM10 activity of the αCBSF was measured by ADAM10 cleavage activity kit.  
ADAM10 (50 μg/mL) secretase, in the presence or absence of ADAM inhibitor (GM6001, 1 μM), 
was included as positive control.  TACE, ADAM17, and ADAM10 cleavage activities were 
determined for 1 h and expressed as relative fluorescence units (RFU).  These results are presented 
as mean (± S.D.) of three independent experiments with triplicates for each condition. 
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Figure 2-7 Immunoprecipitation of fAPP695/αCBSF specifically limits APP α-secretase 
activity of αCBSF. 
To determine whether immunoprecipitation could limit the ability of αCBSF to promote APP α-
cleavage, we incubated 100 ng of fAPP695 with 0.125 μg of αCBSF at 4°C for overnight and then 
immunoprecipitated (IP) the sAPPα/αCBSF immune complex using an anti-DDK antibody 
(DDKAb), an sAPPα specific antibody (2B3), or nonspecific IgG.  CHO/APPwt cells were treated 
with the supernatants (Super.) from each immune complex, or PBS as control, in the FBS free 
condition.  Two h after treatment, conditioned media were collected and analyzed by sAPPα WB 
using anti-N-termnal APP antibody (22C11, a) and sAPPα ELISA (b).  For (b), the results were 
presented as mean (± S.D.) of sAPPα production (ng/mL) in the conditioned media from three 
independent experiments with triplicates for each condition.  There was no notable or significant 
difference in sAPPα production elicited by 0.5% supernatant from αCBSF immunoprecipitated 
with control IgG (Ctrl) and 2.5 % (equivalent to 0.5% Super.) of αCBSF alone, as determined by 
sAPPα WB and ELISA analysis (data not shown). 
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Figure 2-8 αCBSF promotes APP α-secretase processing in vivo. 
3XTg-AD female mice at 4 months of age were treated with αCBSF, AgBSF (0.5 μg/mouse; n = 
6), or PBS control (1 μL/mouse; n = 5 female) by i.c.v. injection and euthanized 72 h later.  Mouse 
brain homogenates were then prepared from the right half of the brain (non-injection side).  (a) 
WB analysis using Aβ1-17 antibody (6E10) shows total APP and Aβ species.  (b) WB analysis using 
an sAPPα specific antibody (2B3) or anti-N-terminal APP antibody (22C11) shows sAPPα or total 
APP, respectively.  (c) WB analysis using pAb751/770 shows full-length APP (holo APP) and two 
bands corresponding to β-CTF and α-CTF.  (d) Mouse brain cortices from each treatment group 
were stained with anti-phospho-tau [p-tau (Thr231)] antibody.  In addition, percentages [p-tau 
(Thr231) positive area/total area; mean ± S.D.] of anti-p-tau antibody positive cells were quantified 
by image analysis (p < 0.005) (data not shown).  WB data presented here are representative of 
results obtained from 5 to 6 female mice per group. 
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Figure 2-9 αCBSF reduces β-amyloid plaques in 5XFAD mice.   
Five month old 5XFAD female mice were treated i.p. with αCBSF (n = 5 to 7) and AgBSF (n = 5 
to 6) via osmotic mini pump at 30 g/mouse/day for 6 weeks.  (a) Mouse brain sections from each 
group were stained with 4G8, Congo red, and Thio-S.  (b) Percentages of 4G8 positive areas were 
quantitatified by image J analysis for neocortex and hippocampus, showing that αCBSF treatment 
significantly reduced plaque area compared with AgBSF treatment (t-test for independent samples; 
*p < 0.05, **p < 0.01). 
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Figure 2-10 Neuroprotective Effects of CBSF.   
5XFAD female mice at 5 months of age were treated i.p. with αCBSF (n = 7) or AgBSF (n = 6) 
via osmotic mini pump for 6 weeks.  (a) Mouse brain sections from αCBSF and AgBSF treated 
groups were stained with NeuN.  (b) Quantification of NeuN positive cells in the CA1, CA3, and 
neocortex revealed that CBSF treatment significantly increased NeuN positive cells compared 
with AgBSF treatment in neocortex (t-test for independent samples; *p < 0.05). 
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Figure 2-11 αCBSF improves cognitive function in 5XFAD mice.   
5XFAD female mice at 5 months of age were treated with αCBSF and AgBSF (30 μg/mouse/day) 
i.p. by osmotic mini pump for 6 weeks.  Each treatment groups as well as nontransgenic WT 
controls (NTg) were subjected to Novel Object Recognition and Y-maze behavioral testing.  (a) 
Times spent exploring old and novel objects during the test phase of NOR was recorded for each 
treatment group.  (b) Discrimination index, calculated as the frequency of exploring new object 
vs. original objects, was significantly reduced in 5XFAD mice treated with AgBSF, but not in 
those treated with αCBSF, compared with NTg controls.  (c) Total number of arm entries for Y-
maze was recorded for each treatment group.  (d)  Percent alternations was significantly reduced 
in 5XFAD mice treated with AgBSF, but not in those treated with αCBSF, compared with NTg 
controls.  Significance level determined by ANOVA for a total of n = 5 NTg mice, n = 7 αCBSF 
treated 5XFAD mice, and n = 6 AgBSF treated 5XFAD mice (***p < 0.001). 
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CHAPTER 3 
Human cord blood serum-derived APP -secretase cleavage activity  
is mediated by C1 complement 
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Chapter synopsis 
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly.  In healthy 
individuals amyloid precursor protein (APP) is cleaved by α-secretase generating soluble alpha 
amyloid precursor protein (sAPP), which contribute neuroprotective functions in the neuronal 
environment.  In contrast, in the neurodegenerative environment of AD patients, amyloid-β-
peptide (Aβ) of either 40 or 42 residues are generated by increased activity of beta and gamma 
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secretase.  These proteins amalgamate in specific regions of the brains, which disrupt neuronal 
functions and lead to cognitive impairment. Our most recent work studied the impact of umbilical 
cord blood serum (CBS) on modulation of sAPP production.  Heat-sensitive CBS significantly 
promoted sAPP production indicating heat-sensitive factor(s) plays a role in this process.  Liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) analysis was used to determine the 
molecular source of -secretase in purified CBS and aged blood serum (AgBS) fraction.  Of the 
proteins identified, the subunits of C1 complex (C1q, C1r, and C1s) and alpha-2-macroglobulin 
showed significantly greater levels in purified CBS fraction (CBSF) compared with AgBS 
fraction (AgBSF).  Specifically, C1 markedly increased sAPP and alpha-carboxyl-terminal 
fragment (-CTF) production in a dose-dependent fashion, whereas C1q alone only minimally 
increased and C3 did not increase sAPP production in the absence of sera.  Furthermore, C1q 
markedly increased sAPP and CTF, while decreasing A, in CHO/APPwt cells cultured in the 
presence of whole sera.  These results confirm our initial assumption that APP -secretase activity 
in human blood serum is mediated by complement C1, opening a potential modality of therapeutic 
for the future of AD.   
 
Background 
AD is the most common neurodegenerative disorder characterized by the presence of 
intracellular neurofibrillary tangles, extracellular β-amyloid plaques and neuronal loss throughout 
the entire brain.  Aβ, a 4 kDa peptide, is one of the major components of β-amyloid plaques. Under 
physiological conditions, -secretase cleaves APP within the Aβ domain, thereby preventing 
generation of Aβ and releasing soluble neurotrophic sAPP [56]. sAPP has been shown to reduce 
Aβ generation and plaque deposition by interfering with beta-site APP cleaving enzyme 1 
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(BACE1), also known as beta (β)-secretase [42][164]. In addition, sAPP has also been shown to 
inhibit tau phosphorylation through modulation of GSK3β signaling pathway [43]. In 
neurodegenerative environment of AD, sequential cleavage of APP by β- and gamma (γ)-
secretases generate Aβ peptides, comprising either 40 or 42 residues in length and which aggregate 
in the brain [1]. Eventually, these protein aggregates trigger neuroinflammation and 
neurodegeneration ultimately leading to cognitive impairment and memory dysfunction [165]. 
One of the prominent facets of AD neuropathology is the colocalization of activated inflammatory 
proteins of the complement pathways with the disease pathology [166]. 
Human umbilical cord blood cells (HUCBC) have emerged as a potential 
immunomodulatory therapy in various diseases, including ischemia and neurodegeneration [167].  
The many benefits of HUCBC include attenuation of amyloidogenic APP processing and reduction 
of Aβ levels in PSAPP and Tg2576 mice models of AD [37].  Importantly, multiple low-dose 
HUCBC infusion have also been shown to improve cognitive functions in transgenic PSAPP mice 
[153].  Our most recent work showed that CBS significantly promoted sAPP production whereas 
heat-inactivation eliminated this effect. Furthermore, sAPP production was found to be increased 
by the removal of serum immunoglobulins and salts.  To further understand what exactly in CBS 
was promoting sAPP, we isolated the specific fraction of CBS found to have the highest α-
secretase activity (CBSF) by a three step chromatographic process.  The proteolytic -secretase 
activity in CBSF was found to not be mediated by TNF-α converting enzyme (TACE) or a 
disintegrin and metalloproteinase domain-containing protein (ADAM)10. Immunoprecipitation 
studies indicated the presence of α-secretase-like enzyme, which physically interacts with APP 
[168].  As first reported, following the administration of CBSF by intracerebroventricular (icv) 
injection, both Aβ levels and tau phosphorylation were reduced in 3XTg-AD mice.  Amyloid 
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plaque numbers were decreased in the neocortex and hippocampus of 5XFAD mice through 
CBSF intraperitoneal minipump administration in comparison with mouse brain treated with the 
corresponding AgBSF.  Furthermore, icv administration of CBSF enhanced non-amyloidogenic 
APP processing in 3xTg-AD mouse, providing a neuroprotective effect.  These results combined 
with reduced neuronal loss in the neocortex of the 5XFAD mice model following CBSF 
administration reveal a therapeutic potential for improving synaptic plasticity and 
neuroinflammation [168]. 
The complement system is a major part of the innate immune system involved in 
neuroprotection via activation of immunomodulatory pathways [169].  In fact, a growing body of 
evidence suggests that complement proteins have neuroprotective effects in the developing and 
adult brain [170][171]. Neurogenesis and synapse elimination are heavily influenced by the 
complement system, particularly in the early stages of the neurodevelopment [170][172].  
Complement protein C1 complex is most commonly known for its neuroprotective role in 
enhancing and refining the neural network through phagocytosis of apoptotic cells and immune 
complexes [173]. The C1 complex is composed of a C1q and two each of C1r and C1s molecules. 
C1q, the largest subcomponent of the cascade initiator of C1 pathway, is composed of 6 of each 
A, B and C chains comprising 18 polypeptide chains [174]. In addition to a role in synaptic 
elimination, complement protein subcomponent C1q has been shown to increase neuronal survival 
and branching in absence of other complement components [175] and this effect could be mediated 
via upregulation of genes associated with neurotrophic factors (neural growth factor, and 
neurotrophin 3), cytoskeletal (syntaxin-3), and cholesterol metabolism (cholesterol-25-
hydroxylase) [176]. During development C1q is expressed in synaptic regions, and synapse 
elimination is mediated by C1q during the period of synaptic pruning.  Therefore deficiencies in 
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C1q or downstream complement components can lead to neuronal defects and other detrimental 
effects [172]. These data confirm a direct neuroprotective role of C1q in the physiological 
condition. In peripheral phagocytes C1q downregulates proinflammatory cytokine expression and 
supports the overall clearance of cellular debris. C1q binds to apoptotic cells flagging them to be 
cleared out before they release neurotoxic components [177]. Despite several physiological 
functions, dysregulated activation of the complement pathways in the central nervous system 
(CNS) have been usually considered detrimental in various conditions including AD [178]. 
Treatment with a cyclic hexapeptide C5a receptor antagonist (PMX205) has been shown to reduce 
fibrillary amyloid deposition and glial activation, while rescuing cognitive impairment in passive 
avoidance task in Tg2576 Swedish mutant mice [179]. Neuronal C1q is normally down-regulated 
in adult CNS, but is found to be upregulated in the advent of injury or early stages of disease [170]. 
Interestingly, C1q is found to be induced in the brain in response to neuronal injuries in AD and 
blocks fibrillary forms of Aβ neurotoxicity in vitro [180]. Benoit et al. demonstrated that C1q 
protect both immature and mature primary neurons against fibrillary and oligomeric Aβ toxicity 
[181]. Depending on the timing and environment, C1q can either be neuroprotective or induce an 
inflammatory environment leading to neurodegeneration in adult brain. Loeffler et al., reported 
that C3b and iC3b (i.e., proteolytically inactive product of C3b which prevent complement cascade 
activation) are also accumulated on AD-affected neurons, much like C1q [182]. 
Given that sAPP has anti-amyloidogenic properties, the primary known -secretases 
which cleave APP are non-specific and stimulating them could generate unwanted off-target 
effects. Our preliminary data show that α-secretase-like enzymatic activity in CBS is not mediated 
by ADAM10 or TACE, the major α-secretases that cleave APP in AD. In addition, we purified 
and identified a CBS specific fraction CBSF, with more than thousand fold increased -secretase 
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activity, which markedly increased cerebral sAPP, decreased A production and abnormal tau 
phosphorylation and ameliorated cognitive impairment in two (3xTg-AD and 5XFAD) AD mouse 
models [168]. In support of this hypothesis, we have tested further for the identification of the 
heat-sensitive protein factor(s) exerting this novel enzymatic function. Here, we have recently 
identified a novel role for complement protein C1 complex in the CNS. Multi-step fractionations 
followed by LC-MS/MS analyses of CBS have identified several proteins compared to AgBS, each 
of which could potentially generate sAPP by cleaving APP in cellular system. Utilizing in vitro 
CHO/APPwt, N2a/APPwt, and TgAPPwt primary neuronal cell lines, we found that α-secretase-
like enzymatic activity promoting sAPP may be in part mediated by complement protein C1 
complex. These results point to a novel neurotrophic function of complement protein C1 complex 
which requires further investigation. 
 
Materials and methods  
Reagents and antibodies 
CBS was obtained from Lee Biosolutions (St. Louis, MO, USA).  CBS was separated from 
umbilical cord blood by allowing clotting for 5-10 h in tubes without anticoagulant followed by 
centrifugation at 3,500 rpm for 5-10 min and filtration through a membrane with a pore size of 
0.22 µm.  Individual CBS samples were prepared from a single lot of cord blood, and more than 
ten samples of CBS were combined as “pooled CBS”.  Normal human aged blood serum (AgBS, 
>75 years old) were obtained from Florida Blood Services (Tampa, FL, USA).  All sera were heat-
activated.  Heat inactivation of human sera was conducted at 56 0 C for 30 min.  Complement 
proteins, complement depleted sera, and complement inhibitors were acquired from the following 
sources.  Human complement protein C1 inhibitor (Cat# GF178), complement protein C1 from 
 68 
 
human serum (Cat# 204873), complement protein C3-depleted human serum (Cat# 234403), and 
complement protein C1q-depleted human sera (Cat# 234401) from MilliporeSigma, St. Louis, 
MO, USA.  Complement protein C3 from human serum (Cat# A113), and complement iC3b from 
human serum (Cat# A115) are from Complement Technology, Inc. Tyler, Texas, USA.  
Complement protein C1q from human serum (Cat# 204876) from Calbiochem, UK.  Compstatin, 
complement protein C3b inhibitor human (Cat# SB 431542) was acquired from Tocris Bioscience, 
Minneapolis, MN, USA.  Sera from C1qa deficient (def) mice (129P2/OlaHsd, 3 months age) were 
kindly provided by Dr. Andrea J. Tenner (University of California, Irvine, USA). Antibodies used 
in this studies include: specific anti-sAPP monoclonal antibody (2B3; IBL, Minneapolis, MN, 
USA, Cat# 11088 RRID: AB_494690), anti-APP C-terminal polyclonal antibody (pAb751/770; 
EMD Millipore, La Jolla, CA, USA, Cat# 171610, RRID: AB_211444), anti-N-terminal A 
monoclonal antibody (6E10; Covance Research Products, Emeryville, CA, USA), and anti-β-actin 
monoclonal antibody (Cat# A5316, RRID: AB_476743) from MilliporeSigma, St. Louis, MO, 
USA.  Human sAPP ELISA assay kit was purchased from IBL AMERICA, MN, USA. 
 
CBS and AgBS fractionation  
 
In order to purify and characterize the α-secretase in CBS or AgBS, the Econo-Pack Serum 
IgG purification kit, and 10 DG columns (Bio-Rad, Philadelphia, PA, USA) were initially 
employed to remove highly abundant IgG and salts.  The desalted serum was applied to DEAE 
Affi-Gel blue columns and residual IgG was eluted according to the instructions.  Then 20 
additional protein fractions were collected by eluting with an ionic strength gradient of NaCl buffer 
ranging from 0.1 M to 2.0 M.  The remaining proteins on the column were eluted by the 
regeneration buffer included in the kit and collected as the regeneration fraction.  The 0.8 M NaCl 
eluted protein fractions were combined together and sent to Moffitt Cancer Center protein 
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purification core for further separation by size exclusion chromatography, employing analytic 
Superdex 200 columns and eluting with PBS, and ion-exchange chromatography, employing Q-
Sepharose columns and eluting with 500 mM NaCl, 50 mM Tris, pH 7.6.  The final enzyme 
containing fractions were exchanged to PBS buffer by Ultracel-10 membranes (10 kDa, Merck 
Millipore) for further experimentation and referred to as CBSF or AgBSF (Figure 3-1). 
 
LC-MS/MS 
 
Briefly each lane gel slices were destained using acetonitrile and subjected to tris 2-
carboxyethy-phosphine (TCEP) reduction and iodoacetamide alkylation followed by in-gel trypsin 
digestion, extraction and vacuum centrifugation concentration.  A nanoflow liquid chromatograph 
(U3000, Dionex, Sunnyvale, CA) coupled to an electrospray ion trap mass spectrometer (LTQ-
Orbitrap, Thermo, San Jose, CA) was used for tandem mass spectrometry peptide sequencing 
experiments.  Total 5 µL sample was first loaded onto a pre-column (5 mm x 300 µm ID packed 
with C18 reversed-phase resin, 5 µm, 100Å) and washed for 8 min with aqueous 2% acetonitrile 
and 0.04% trifluoroacetic acid.  Next, the trapped peptides were eluted onto the analytical column, 
(C18, 75 µm ID x 15 cm, Pepmap 100, Dionex, Sunnyvale, CA).  The 120-min gradient was 
programmed as: 95% solvent A (2% acetonitrile + 0.1% formic acid) for 8 min, solvent B (90% 
acetonitrile + 0.1% formic acid) from 5% to 50% in 90 min, then solvent B from 50% to 90% B 
in 7 min and held at 90% for 5 min, followed by solvent B from 90% to 5% in 1 min and re-
equilibrate for 10 min (60-min gradient setup).  The flow rate on analytical column was 300 nl/min.  
Five tandem mass spectra were collected in a data-dependent fashion following each survey scan.  
The MS scans were performed in Orbitrap to obtain accurate peptide mass measurement and the 
MS/MS scans were performed in linear ion trap using 60 second exclusion for previously sampled 
peptide peaks.  The LC-MS/MS data were submitted to a local MASCOT server Swiss-Prot 
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Human database for MS/MS protein identification search via ProteomeDiscoverer software.  Two 
trypsin missed cleavages were allowed, the precursor mass tolerance was 1.08 Da.  The MS/MS 
mass tolerance was 0.8 Da.  The incorrect detection rate in each LC-MS/MS analysis was set to be 
less than 1%. 
 
Cell culture  
 
Chinese hamster ovary (CHO) cell line with stable expression of human wild-type APP 
(CHO/APPwt) was a generous gift from Drs. Stefanie Hahn and Sascha Weggen (University of 
Heinrich Heine, Düsseldorf, Germany).  These cells were initially genotyped to confirm their 
genetic make-up.  The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 
10% fetal bovine serum (FBS), 1 mM sodium pyruvate and 100 U/mL of penicillin/streptomycin.  
For treatment, the cells were plated in 24-well plate at 2 x 105 cells /well for overnight incubation, 
washed and treated with CBS, heat inactivated (56 0C, 30 min) CBS, AgBS, or CBSF, AgBSF 
in DMEM.  After treatment, supernatants were collected and the cells were washed with ice cold 
PBS 3X and lysed with cell lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 1 mM 
EGTA, 1% v/v Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerolphosphate, 1 mM 
Na3VO4, 1 µg/mL leupeptin, and 1 mM PMSF; Cell Signaling Technology).  Both cell 
supernatants and lysates were used for sAPP analysis by ELISA.  In addition, murine N2a cells 
transfected with APPwt (N2a/APPwt) and primary neuronal cells were obtained from cerebral 
cortices of TgAPPwt mouse embryos, between 15 and 17 days in utero, as described previously 
[85].  For TgAPPwt mouse-derived cortical neurons, cerebral cortices were isolated from 
TgAPPwt mice between 15 and 17 days in utero  and mechanically dissociated in trypsin (0.25%) 
individually after incubation for 15 min at 37 0C. Cells were collected after centrifugation at 1200 
g, suspended in DMEM supplemented with 10% fetal calf serum, 10% horse serum, uridine (33.6 
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mg/ml, Sigma-Aldrich), and fluorodeoxyuridine (13.6 mg/ml, Sigma-Aldrich) and seeded in 24-
well collagen-coated culture plates at 2.5 x 105 cells per well. After reaching confluence (~70–
80%). these cells were treated with purified human complement C1 at 0, 5, 10, or 20 µg/mL for 
4h, supernatants were collected for sAPP measurement by ELISA and cells were washed with 
ice cold PBS 3X and lysed with cell lysis buffer followed by western blotting using 6E10 and 
pAb751/770 antibodies. 
 
Transgenic APPwt mice  
 
Transgenic wild-type B6.Cg-Tg (PDGFB-APP) 5Lms/J strain (TgAPPwt) male and female 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed 
in the Animal Facility in College of Medicine at the University of South Florida and maintained 
on a 12-h light/12-h dark cycle at ambient temperature and humidity with ad libitum access to food 
and water.  All animal experiments involving mice were performed in compliance with the US 
Department of Health and Human Services Guide for the Care and Use of Laboratory Animals and 
in accordance with the guidelines of the University of South Florida Institutional Animal Care and 
Use Committee.   
 
WB analysis and ELISA  
WB analyses and quantification were performed as previously described.  Briefly, the 
proteins from the cell-free suspensions, cell lysates, and homogenized tissue were 
electrophoretically separated using 10% bicine/tris gel (8 M urea) for proteins less than 5 kDa or 
10% tris/SDS gels for larger proteins. Electrophoresed proteins were transferred to nitrocellulose 
membranes (Bio-Rad), washed and blocked for 1 h at room temperature in tris-buffered saline 
containing 5% (w/v) nonfat dry milk (TBS/NFDM).  After blocking, membranes were hybridized 
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overnight with various primary antibodies, washed and incubated for 1 h with the appropriate 
HRP-conjugated secondary antibody in TBS/NFDM and developed using the luminol reagent 
(Thermo Fisher Scientific, Waltham, MA, USA).  Soluble sAPP in the media was quantified with 
the IBL human sAPP colorimetric sandwich ELISA kit according to the manufacturer’s 
instructions.  
 
Statistical analysis   
Comparison between two groups was performed by Student's t-test analysis.  For more than 
two groups, one-way analysis of variance (ANOVA) followed by LSD post hoc analysis was used 
to compare each other for statistical significance.  Alpha was set at 0.05 for all analyses.  All 
molecular analyses were repeated three times in parallel.  Data are expressed as mean ± SEM.  The 
statistical package for the social sciences release IBM SPSS 23.0 (IBM, Armonk, NY, USA) was 
used for all data analyses. 
 
 
Results 
Heat-sensitive APP -secretase activity in CBS  
In order to identify the source of -secretase in CBS, we initially confirmed that CBS 
possesses heat-labile -secretase activity.  CHO/APPwt cells were treated with CBS (2%) for 0, 
5, 10, 15, 30, 60, and 120 min, followed by determination of sAPP in conditioned medium by 
ELISA.  CBS caused a time-dependent increase in sAPP release from CHO/APPwt cells that was 
significantly greater than the control treatment (Figure 3-2a; *p < 0.05, **p < 0.01, ***p < 0.001).  
Similarly, CHO/APPwt cells were treated for 2 h with 0, 0.25, 0.5, 1, 2, and 5% CBS, followed by 
determination of sAPP in conditioned medium by ELISA.  CBS caused dose-dependent release 
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of sAPPα in culture medium from CHO/APPwt cells that was significantly greater than the control 
treatment (Figure 3-2b; *p < 0.05, **p < 0.01, ***p < 0.001). Next, we wanted to determine if heat 
inactivation of serum reduces sAPP producing capacity of CBS.  CHO/APPwt cells were treated 
with 2% whole or heat-inactivated CBS or AgBS (56 0C for 30 min) for 2 h followed by 
determination of sAPP in conditioned media by ELISA.  Both CBS and AgBS heat-inactivation 
significantly limited sAPP releasing capacity (Figure 3-2c; *p < 0.05, **p < 0.01, ***p < 0.001). 
Furthermore, CHO/APPwt cells were treated with 2% whole or heat-inactivated CBSF or AgBSF 
for 2 h followed by determination of sAPP in conditioned media by ELISA; Figure 3-2d; *p < 
0.05, **p < 0.01, ***p < 0.001).   As shown most recently, purification significantly enhanced the 
sAPP producing capacity of CBS and AgBS, which again was significantly limited by heat 
inactivation.  These results confirm that CBS possesses an enhanced level of heat-sensitive -
secretase activity. 
 
Proteomic analyses of CBSF and AgBSF 
Having shown that CBSF possesses an enhanced -secretase activity, we next set out to 
determine the molecular source of -secretase in CBSF and AgBSF by LC-MS/MS 
analysis.  From 142 major proteins identified, we selected those most likely to exhibit -secretase 
activity. Several of the major proteins identified in CBSF and AgBSF are shown in Figure 3-3.  
Of these proteins, the subunits of complement protein C1 complex (C1q, C1r and C1s) and alpha-
2-macroglobulin showed significantly greater levels in CBSF compared with AgBSF (Figure 3-
3; *p< 0.05, **p < 0.01).  Notably, the levels of complement proteins C3, C4, C5, C6 and C8 
complexes, ApoE, ApoB100 and full-length APP (fAPP) were not significantly different between 
CBSF and AgBSF (p > 0.05).  Complement proteins C1 and C3b complex have proteolytic 
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activity, which can be inactivated at 56 ºC for 30 min. These proteins play important roles in 
neurodevelopment and provide early protection against stress or disease, including AD. Thus, we 
hypothesized that the heat-labile -secretase activity in CBS is mediated in part by complement 
protein C1 complex or C3b. 
 
CBS-mediated -secretase-like cleavage of APP is independent of complement C3b  
In order to determine if α-secretase activity of CBS is mediated by activation of 
complement protein fragment C3b, we investigated whether depletion of complement protein C3 
could limit the α-secretase-like activity of CBS.  CHO/APPwt cells were treated with C3 depleted 
CBS (2%) for 0, 15, 30, 60, and 120 min followed by determination of sAPPα in conditioned 
medium by ELISA. Depletion of C3 complement protein did not change sAPPα producing 
capacity of CBS in CHO/APPwt cells (Figure 3-4d; *p < 0.05, **p < 0.01, ***p < 0.001).  In order 
to confirm that C3b complement does not mediate α-secretase activity in CBS, we pre-incubated 
whole or C3 depleted CBS (2 %) with the C3b inhibitor compstatin at 0, 6, 12, 25, 50, and 100 
µM for 15 min at 37 0C and then treated CHO/APPwt cells with these premix complexes separately 
for 2 h.  Compstatin did not alter sAPPα production significantly elicited by whole (Figure 3-4a; 
p > 0.05) or C3-depleted serum (Figure 3-4b; p > 0.05).  Therefore, CBS -secretase-like activity 
is independent of enzymatic activity of complement C3b protein. 
In order to determine if complement protein component C3b acts an inhibitor of CBS α-
secretase-like activity, CHO/APPwt cells were treated for 2 h with premixes of CBS (2%) and 
iC3b (0, 1.25, 2.5, 5, 10, and 20 µg/mL), the proteolytically inactive product of C3b which prevents 
complement cascade activation.  The sAPPα producing capacity of CBS was not altered by iC3b 
as determined by sAPPα ELISA (Figure 3-4c; p > 0.05), indicating that complement C3b protein 
does not act as a potent CBS -secretase inhibitor.  
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CBS -secretase-like activity is mediated in part by complement protein C1 complex 
To determine if -secretase-like activity in CBS is mediated by complement protein C1 
complex, we determined CBS -secretase activity in the presence of complement protein C1 
inhibitor.  CHO/APPwt cells were treated with αCBSF (1 and 2%) in the presence of complement 
protein C1 inhibitor at 0, 50, 100, and 200 µg/mL for 2 h.  C1 inhibitor markedly reduced sAPP 
released by αCBSF (1 and 2%) in a dose-dependent fashion, as determined by ELISA (Figure 3-
5a; *p < 0.05, **p < 0.01, ***p < 0.001) and WB (2% CBS; Figure 3-5b; *p < 0.05, **p < 0.01, 
***p < 0.001; quantification not shown), indicating that -secretase-like activity in CBS is 
mediated in part by complement C1 protein.  In addition, we determined the effect of purified 
human C1 complement protein on sAPP production in N2a/APPwt and TgAPPwt/primary 
neuronal cells in absence of sera. Complement protein C1 dose-dependently increased sAPP and 
-CTF production in N2a/APPwt cells (Figure 3-5c-e; **p < 0.01, ***p < 0.001) and 
TgAPPwt/primary neuronal cells (Figure 3-5f-h; *p < 0.05, **p < 0.01) in absence of serum, as 
determined by ELISA and WB.  These results indicate that complement protein C1 complex 
mediates -secretase-like activity in CBS. 
In order to confirm that complement C1 but not C3 protein has -secretase-like activity, 
CHO/APPwt cells were treated with purified human complement C1 or C3, or C1q subunit, at 0, 
2.5, 5, 10, and 20 µg/ml in serum free media for 2 h followed by determination of sAPP in 
conditioned medium by ELISA.  As expected, complement protein C1 significantly increased 
sAPP production in a dose-dependent fashion, whereas C1q alone minimally increased and 
complement protein C3 did not increase sAPP production in serum free medium (Figure 3-6a, 
*p < 0.05, **p < 0.01).  In contrast, both complement C1 and C1q protein component significantly 
increased sAPP production in CHO/APPwt cells cultured in C1q depleted sera (Figure 3-6b, **p 
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< 0.01, ***p < 0.001), and complement protein C1 significantly increased sAPP and -CTF 
level, while decreasing A and β-CTF level in CHO/APPwt cells in presence of whole sera as 
determined by WB (Figure 3-6c).   
In order to investigate the role of complement protein C1 in mediating α-secretase activity 
in whole blood plasma, CHO/APPwt cells were treated with plasma from C1qa deficient mice or 
age-matched wild-type littermates.  Interestingly, the production of sAPP elicited by plasma from 
male C1qa deficient mice was not significantly different (Figure 3-6d, p > 0.05) whereas that 
elicited by plasma from female C1qa deficient mice was significantly greater than that elicited by 
age- and gender-matched plasma from wild-type littermates (Figure 3-6d, **p < 0.01).  Therefore, 
plasma -secretase activity is not significantly altered by C1qa deficient in male mice but 
significantly enhanced by C1qa deficient in female mice.  These results are consistent with C1-
mediated -secretase playing an important role in male and female individuals but that other -
secretases compensate in its absence. In addition, the elevated sAPPα production capacity in 
female compared to male C1qa deficient mice indicate a unknown function of this neurotrophic 
fragment in the peripheral system of females. 
Altogether, these results confirm that APP -secretase-like activity in human blood serum 
is mediated by complement protein C1 complex.  The inability of C1q to rescue -secretase 
activity in serum free media is likely due to the absence of components C1s and C1r, which are 
required to complex with C1q in C1 for proteolytic activity.   
 
Discussion 
In our previous study, we have shown that peripheral administration of HUCBC [37] as 
well as HUCBC-derived monocytes [38] reduce cognitive impairments and β-amyloid plaques in 
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PSAPP AD mice.  In a subsequent study, we showed that human CBS also has -secretase-like 
activity which likewise reduces cognitive impairment, tau hyperphosphorylation and plaque 
deposition in AD mice [168] [183]. The present study further investigated the component of CBS 
that attenuates β-amyloid plaques, especially through the increased production of the neurotrophic 
sAPP.  Our results confirm the presence of -secretase-like enzyme activity within the CBS, 
reflected by elevated production of sAPP.  Interestingly, heat-inactivation of -secretase activity 
of CBS at 56 0C for 30 min inspired us to assume that -secretase-like activity is mediated by a 
complement protein.  This is further reinforced by the result of LC-MS/MS data, which indicate 
the dominance of complement protein C1 subcomponents (C1q, C1r, and C1s), C3b, and C4 
proteins in CBSF as well as AgBSF (Figure 3-3).  Further investigations using complement 
inhibitors and C1 complement protein depleted serum reveal that endogenous C1 complex 
enhances sAPP production in cell culture and primary neuronal cell line, including CHO/APPwt 
(Figure 3-5b), N2a/APPwt (Figure 3-5c-e), and TgAPPwt/primary neuronal cells (Figure 3-5f-h).  
As previously mentioned, complement protein C1 is composed of a C1q, and two each of C1r and 
C1s. C1q is composed of 6 of each A, B and C chains comprising 18 polypeptide chains [174].  
Modifying various factors revealed that C1q depleted serum elicited less sAPP production in 
comparison with the whole serum, highlighting the crucial nature of C1q-mediated -secretase 
activity in CBS (Figure 3-6a-c).  Interestingly, our results indicate that the inability of C1q to 
rescue -secretase-like activity in serum free media is likely due to the absence of C1s and C1r 
subcomponents, which are required to form complex with C1q in C1 for proteolytic activity (Fig 
3-6a).  It should be noted that C1r and C1s, are serine proteases, which form the complete initiation 
complex of C1qC1r2C1s2 when activated by C1q binding to an immune complex [184]. 
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Initially, C1q synthesis serves to be protective by aiding in clearance of apoptotic cells and 
regulating the environment to prevent further neurotoxicity from spreading [180].  It has been 
proposed that C1q and C3 opsonisation [185][186] accelerate clearance of Aβ. In addition, C1q-
mediated protection against Aβ is associated with expression of low-density lipoprotein receptor-
related protein 1B and G-protein-coupled receptor 6 as early as 2 months of age in 3XTg-AD 
mouse model [181]. Despite the critical role C1q plays in immune regulation and neuroprotection, 
evidence has also suggested that C1q could potentially be proinflammatory [187].  C1q is 
synthesized when there is an injury in the CNS [188].  By binding with β-sheet fibrillary plaques, 
C1q activates the complement cascade that can have detrimental inflammatory consequences via 
production of the chemotactic factor C5a and recruitment and activation of microglial cells to the 
site of injury. This activation requires association of C1q with C1r and C1s as in the C1 complex. 
As the disease pathology continues to progress, it causes more of the complement pathways to be 
activated [189].  High density of negative charges in various regions, can activate the complement 
system through an electrostatic interaction independent of antibodies [190]. This can be seen with 
β-amyloid fibrils binding to arginine-rich segments within the β chain of C1q [191]. Consequently, 
the fragments not only create further inflammation attracting glial cells, but can also activate 
classical pathway triggering the release of more pro-inflammatory components.  In a study done 
with APPQ-/- mice, those lacking C1q are unable to activate the classical pathway because the 
fibrillary Aβ interaction with C1q is not possible [192].  In AD pathology, factors leading to 
neurodegenerative pathways of complement activation include C1q interaction with not only the 
β-sheet fibrils, but also hyperphosphorylated tau [190].  Though these fibrils would normally be 
cleared by microglia, binding of C1q to Aβ1-42 peptide strands make it increasingly difficult for 
microglia to clear out neurotoxic debris [193].  The general trend toward increased complement 
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activation causes the activated microglia to further exacerbate inflammation as C1q upregulation 
positively correlates with the quantity of reactive astrocytes making the blood-brain barrier 
vulnerable [183].  
Collectively, our results indicate that CBS contains proteins that promote α-secretase like 
enzymatic activity (Figure 3-2).  LC-MS/MS analysis in CBSF and AgBSF revealed the presence 
of 142 proteins of which complement protein C1 subunits and alpha-2-macroglobulin showed 
significantly greater levels in CBSF compared with AgBSF (Figure 3-3).  Upon further study, 
complement protein C1 subunits showed enhanced sAPPα production and Aβ reduction in cell 
culture studies (Figure 3-5 & 3-6).  As discussed previously, C1q is known to have 
proinflammatory and detrimental effect on neuronal tissue, which will limit the therapeutic 
application of C1q. There may be other components in αCBSF contributing the beneficial effects 
observed in transgenic AD mice. In addition, C1 has α-secretase activity, which may also compete 
with amyloidogenic β-secretase pathway and reduce β-cleavage of APP when αCBSF was 
administered in mice. There is much to be learned about the exact mechanisms of action of C1q, 
especially how its neurotrophic effects may shift in AD pathology and instead lead to further 
acceleration of neuro-detrimental inflammation.  Nevertheless, our research identified an 
additional and novel function in CBS by enhancing α-secretase-like activity and that the overall 
reduction in β-amyloid plaques incites a therapeutic potential for attenuating AD pathology. 
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Figure 3-1 Work-flow for αCBSF and AgBSF fractionation. 
Initially, CBS and AgBS were desalted followed by sequential chromatographic separation using 
DEAE column, size-exclusion, and ion-exchange chromatography. Each fraction was collected 
followed by efficacy testing by treating CHO/APPwt cells for sAPPα release. Eventually a fraction 
(αCBSF) was chosen based on the highest capacity for sAPPα generation. LC-MS/MS was 
performed to identify the source of the protein function. 
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Figure 3-2 CBS significantly enhances APP α-cleavage in CHO/APPwt cells. 
(a) Chinese hamster ovary cells overexpressing human wild-type APP (CHO/APPwt cells) were 
treated for 0 - 120 min with CBS (2%). (b) Chinese hamster ovary cells overexpressing human 
wild-type APP (CHO/APPwt cells) were treated for 2 h with CBS (0, 0.25, 0.5, 1, 2, and 5) %. (c). 
Chinese hamster ovary cells overexpressing human wild-type APP (CHO/APPwt cells) were 
treated for 2 h with CBS (0%, Ctrl), heated-inactivated CBS (2%), heated-inactivated AgBS (2%), 
AgBS (2%), and CBS (2%). (d) Chinese hamster ovary cells overexpressing human wild-type APP 
(CHO/APPwt cells) were treated for 2 h with CBS (0%, Ctrl), heated-inactivated CBSF (2%), 
heated-inactivated AgBSF (2%), fraction isolated from AgBS (AgBSF, 2%), and fraction isolated 
from CBS (αCBSF, 2%) after purification as briefly described under “Materials and Methods”. 
Then sAPPα release into the conditioned medium was analyzed by ELISA as described under 
“Materials and Methods”. Data are presented as mean (± SEM.) of sAPPα produced (ng/mL or 
ng/mg) from 3 independent experiments performed in triplicate where the asterisk (*) represent 
following: *p < 0.05, **p < 0.01, ***p < 0.001), indicating a significant difference from control 
treatment. 
 
 
 
 82 
 
 
 
Figure 3-3 Identification of proteomic profile of αCBSF and AgBSF.   
The proteome of αCBSF and AgBSF were analyzed by LC-MS/MS.  From 142 major proteins 
identified, those exhibiting proteolytic and therefore potential α-secretase-like activity were 
selected.  Of these proteins, the subunits of complement protein C1q (**p < 0.001), C1r (*p < 
0.05) and C1s (*p < 0.05) and alpha-2-macroglobulin (*p < 0.05) showed significantly greater 
levels in αCBSF compared with AgBSF.  Data are presented as mean (± SEM.) of number of 
peptide hits from 3 independent experiments where the asterisk (*) represent following: *p < 0.05, 
**p < 0.001, ***p < 0.01), indicating a significant difference. 
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Figure 3-4 CBS mediated sAPPα release by CHO/APPwt cells is independent of complement 
protein C3b.   
C3b inhibitor at indicated concentration (0, 6, 12, 25, 50, and 100 µM) pre-incubated with CBS 
(2%) as well as C3 depleted CBS (2%) for 15 min.  (a). CHO/APPwt cells were treated for 2 h 
with CBS (2%) + Compstatin (C3b inhibi). (b) CHO/APPwt cells were treated for 2 h with C3 
depleted CBS (2%) + Compstatin (C3b inhibi). Then sAPPα release into the conditioned medium 
was analyzed by ELISA as described under “Materials and Methods”. (c) In addition, CBS (2%) 
incubated with iC3b at indicated concentration (0, 1.25, 2.5, 5, 10, and 20 µg/mL) and treated 
CHO/APPwt cells for 2 h followed by sAPPα determination in the medium by ELISA.  (d). 
CHO/APPwt cells were treated with C3 depleted CBS (2%) for indicated time (0, 15, 30, 60, and 
120) min. The sAPPα ELISA results are presented as mean (± SEM.) of sAPPα produced (ng/mL 
or ng/mg of total intracellular protein) from 3 independent experiments performed in triplicate 
where the asterisk (*) represent following: *p < 0.05, **p < 0.01, ***p < 0.001), indicating a 
significant difference from control treatment. 
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Figure 3-5 A specific complement C1 protein inhibitor significantly reduces APP α-cleavage 
induced by CBS.    
(a) CHO/APPwt cells were treated for 2 h with CBS (1 and 2%) in the presence of C1 inhibitor at 
indicated concentration (0, 50, 100, and 200) μg/mL, followed by analysis of sAPPα in conditioned 
media by ELISA.  (b). In addition, cell lysates from CHO/APPwt cells treated for 2 h with CBS 
(2%) in the presence of complement protein C1 inhibitor at indicated concentration (0 - 200 
μg/mL) were subjected to WB analysis of sAPPα levels.  (c) N2a/APPwt cells and (f) 
TgAPPwt/mouse primary neuronal cells were treated with purified human complement C1 protein 
complex at indicated dose (0, 5, 10, and 20) µg/mL in serum free condition for 4 h followed by 
analysis of holo APP, sAPP and CTF in cell lysates by WB (c & f).  The levels of sAPPα in 
conditioned media as determined by ELISA (d & g) and band density radios of α-CTF to (full-
length) holo APP (e & h) are presented below each blot.  The sAPPα ELISA results were presented 
as mean (± SEM., ng/mL or ng/mg of total intracellular protein, *p < 0.05, **p < 0.01, ***p < 
0.005).            
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Figure 3-6 The purified human complement C1 protein complex promotes APP α-cleavage.     
(a) CHO/APPwt cells were treated for 4 h with purified human complement C1q subcomponent, 
C1, and C3, at indicated concentration (0, 2.5, 5, 10, and 20) µg/mL in serum free media followed 
by analysis of sAPPα in conditioned media by ELISA. (b) CHO/APPwt cells were treated for 2 h 
with purified human complement C1q subcomponent, C1, and C3, at indicated concentration (0, 
2.5, 5, 10, and 20) µg/mL in C1q depleted serum followed by analysis of sAPPα in conditioned 
media by ELISA. (c) In order to further determine the effect of complement C1 protein on APP 
processing, CHO/APPwt cells were treated for 2 h with purified complement C1 protein at 
indicated concentration (0, 2.5, 5, 10, and 20) µg/mL in the absence of whole serum and cell lysates 
were prepared from each treated cell culture for analysis of holo APP, sAPPα, Aβ and α- and β-
CTF by WB.  The sAPPα ELISA results are presented as mean (± S.E.M) (ng/mL). (d) Evaluation 
of C1qa deficient mouse sera in APP α-cleavage processing.  CHO/APPwt cells were treated for 
2 h with plasma (2%) obtained from C1qa knockout mice or wild-type littermates at 3 months of 
age (n = 5 males or 3 females for each group) followed by determination of sAPPα in conditioned 
media by ELISA.  The sAPPα ELISA results were presented as mean (± SEM., ng/mL or ng/mg 
of total intracellular protein, *p < 0.05, **p < 0.01, ***p < 0.005).       
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CHAPTER 4 
 
Ionic co-crystal of lithium salicylate proline (LISPRO) mitigates β-amyloid 
and associated pathologies in Alzheimer’s mice 
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Chapter synopsis 
Lithium has been marketed in the United States of America since the 1970s as a treatment 
for bipolar disorder.  More recently, studies have shown that lithium can improve cognitive decline 
associated with Alzheimer’s disease (AD).  However, the current United States Food and Drug 
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Administration-approved lithium pharmaceutics (carbonate and citrate chemical forms) have a 
narrow therapeutic window and unstable pharmacokinetics that, without careful monitoring, can 
cause serious adverse effects.  Here, we investigated the safety profile, pharmacokinetics, and 
therapeutic efficacy of LISPRO (ionic co-crystal of lithium salicylate and l-proline), lithium 
salicylate, and lithium carbonate (Li2CO3).  We found that LISPRO (8-week oral treatment) 
reduces β-amyloid plaques and phosphorylation of tau by reducing neuroinflammation and 
inactivating glycogen synthase kinase 3β (GSK3β) in transgenic Tg2576 mice.  Specifically, 
cytokine profiles from the brain, plasma, and splenocytes suggested that 8-week oral treatment 
with LISPRO down-regulates pro-inflammatory cytokines, up-regulates anti-inflammatory 
cytokines, and suppresses renal COX2 expression in transgenic Tg2576 mice.  Pharmacokinetic 
studies indicated that LISPRO provides significantly higher brain lithium levels and more steady 
plasma lithium levels in both B6129F2/J (2-week oral treatment) and transgenic Tg2576 (8-week 
oral treatment) mice compared to Li2CO3.  Oral administration of LISPRO for 28 weeks 
significantly reduced β-amyloid plaques and tau-phosphorylation.  In addition, LISPRO 
significantly elevated pre-synaptic (synaptophysin) and post-synaptic protein (postsynaptic 
density protein 95) expression in brains from transgenic 3XTg-AD mice.  Taken together, our data 
suggest that LISPRO may be a superior form of lithium with improved safety and efficacy as a 
potential new disease modifying drug for AD. 
 
Background 
Alzheimer’s disease (AD) affects memory and cognition irreversibly, and is one of the 
most critical public health concerns for the elderly.  Extracellular amyloid plaques (mostly 
amyloid-β, Aβ) [194] and intracellular neurofibrillary tangles (NFTs; paired helical filament of 
hyperphosphorylated tau) [195] are neuropathological hallmarks of AD which severely affect the 
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hippocampus and neocortex [196]. Currently, the United States Food and Drug Administration 
(FDA) has approved acetylcholinesterase inhibitors (i.e., donepezil, rivastagmine, and 
galantamine) and/or N-methyl D-aspartate antagonists (i.e., memantine) for AD intervention [197]. 
However, no pharmacological or non-pharmacological intervention is wholly-available that is 
effective in preventing or slowing the progression of the disease.  Therefore, large numbers of AD 
patients and their care givers urgently await better alternatives. 
Lithium has been used to treat mania and depression since the mid-20th century [198] and, 
despite the advent of newer medications, it is still considered the gold standard for the treatment 
of bipolar disorder [199][200].  While lithium is currently FDA approved as a mood stabilizer for 
the treatment of bipolar disorder, it is also commonly prescribed off-label for other 
neuropsychiatric symptoms including suicidality and impulsive aggression, [199] as well as 
neurodegenerative diseases such as AD [201].  Nunes and colleagues observed in a 18-month 
clinical study that AD patients treated daily with micro-doses of lithium performed at a consistent 
level on the mini-mental status exam (MMSE), indicating arrested cognitive decline compared to 
the placebo-group [202]. Moreover, Forlenza and colleagues reported in their 1-year clinical trial 
study that patients with amnestic mild cognitive impairment treated with chronic low-dose lithium 
progressed less to AD compared to the placebo-group [200]. The treated patients performed higher 
on the cognition subscale of the AD Assessment Scale and had decreased concentrations of 
phosphorylated tau in their cerebrospinal fluid (CSF), indicating lithium as a potential therapeutic 
for AD [200]. 
Several mechanisms may underlie lithium’s potential neuroprotective efficacy for AD.  An 
important mechanism of lithium is that it inhibits certain enzymes in a noncompetitive manner by 
displacing the required divalent cation, magnesium [88]. Klein and Melton identified glycogen 
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synthase kinase 3β (GSK3β) as one such molecular target of lithium [89]. In the context of AD, 
this enzyme phosphorylates tau at most serine and threonine residues in the paired helical 
filaments.  GSK3 activity contributes both to Aβ production and Aβ-mediated neuronal cell death 
[90]. Aβ is derived from amyloid precursor protein (APP) by sequential proteolysis, catalyzed by 
the aspartyl protease β-site amyloid precursor protein cleaving enzyme 1 (BACE1), followed by 
presenilin-dependent -secretase proteolysis [56].  Therapeutic doses of lithium block the 
production of Aβ peptides by interfering with APP cleavage at the -secretase step, without 
inhibition of Notch processing, by targeting GSK3α [91].  Lithium also blocks the accumulation 
of Aβ in brains of mice overexpressing APP by inhibition of GSK3β, implicating its requirement 
for maximal processing of APP [92].  Since GSK3β also phosphorylates tau protein, inhibition of 
GSK3β offers a new approach to reduce the formation of both β-amyloid plaques and NFTs.  
Interestingly, combined transgenic mice overexpressing GSK3β with transgenic mice expressing 
tau with a triple FTDP-17 mutation develop prefibrillar tau-aggregates that are averted by lithium 
[93].  
Despite its medicinal advantages, current lithium pharmaceutics (i.e., carbonate and citrate 
chemical form) approved by FDA are known to cause serious short- and long-term side effects in 
humans.  The drugs have a narrow therapeutic window (0.6-1.5 mM), as the commonly used 
lithium salts cross the blood-brain-barrier slowly, [203][204] requiring multiple doses throughout 
the day to reach safe therapeutic plasma levels.  Moreover, required therapeutic doses oftentimes 
lead to excess accumulation of lithium ions in peripheral organs, particularly the kidney and heart.  
Dehydration, in the setting of lithium therapy, may result in renal and cardiac toxicity, 
hypothyroidism, hyperparathyroidism, weight gain, and nephrogenic diabetes insipidus [205]. 
Lithium intoxication ensues with supratherapeutic serum concentrations, producing symptoms 
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such as loss of consciousness, muscle tremor, epileptic seizures, and pulmonary complications 
[206].  As such, lithium administration requires frequent monitoring of blood chemistry and 
lithium plasma levels, which can discourage physicians from prescribing lithium in favor of other 
therapeutics which do not require monitoring plasma levels to avoid the potential side-effects 
noted.  This is especially true in the elderly who often have an array of comorbidities that 
necessitate polypharmacy.  Hence, there is a demand for a safer and better lithium formulation to 
treat AD. 
We have previously reported the development of a novel ionic cocrystal of lithium with an 
organic anion, salicylic acid, and l-proline (LISPRO, LP).  The unique crystal structure of LISPRO 
does not negatively affect the bioactivity of lithium at several potential therapeutic targets related 
to AD treatment, namely induction of brain-derived neurotrophic factor (BDNF) from neurons, 
inhibition of lipopolysaccharide induced nitric oxide (NO) production from microglia, neural 
differentiation, and inhibition of GSK3 in neural stem cells.  While LISPRO either outperformed 
or matched the efficacy of equimolar concentrations of lithium salt controls at these targets in vitro, 
the cocrystal distinctly modulated lithium pharmacokinetics in vivo.  For example, rats 
administered with a single oral high dose of LISPRO had detectable brain lithium levels at 48 h, 
while those receiving the equimolar equivalent of conventional carbonate chemical form of lithium 
did not.  In addition, LISPRO produced a steady plasma lithium plateau over a 48-h period whereas 
carbonate chemical form of lithium produced the typical plasma lithium spike thought to be 
associated with adverse events [87][149].  Moreover, salicylic acid in the crystal reduces 
neuroinflammation associated with AD, being the active metabolite of aspirin.  These data point 
to the potential for increased safety and efficacy profile of LISPRO. 
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In this study, we more thoroughly evaluated the therapeutic efficacy and safety profile of 
LISPRO on ameliorating AD-like pathology in cell culture systems and transgenic AD mouse 
models (i.e., Tg2576 and 3XTg-AD mice).  We found that LISPRO has a superior pharmacokinetic 
and safety profile compared to traditional lithium chemical form, promoting us to further 
investigate the therapeutic efficacy for AD treatment. 
 
Materials and methods 
Reagents   
For preparation of LISPRO (LP), lithium salicylate (LS) [≥ 98% pure, anhydrous, 1 mM 
(Sigma-Aldrich, St. Louis, MO, USA)] and L-proline (≥ 99% pure, Sigma-Aldrich, 1 mM) were 
dissolved in 2.0 ml of hot deionized water.  The resulting solution was maintained on a hot plate 
(75-90 °C) to allow slow evaporation of solvent until colorless crystals had formed, which were 
collected and dried (evaporation at 1 atmospheric pressure).  For preparation of lithium carbonate 
(LC), [≥ 99% ACS grade, 1 mM (Sigma-Aldrich)] were suspended in 1-2% methylcellulose [12-
18 cP, 1-2% in H2O (20 °C) (Sigma-Aldrich)] solution. 
 
Antibodies  
Primary antibodies include anti-A1-16 (6E10, Covance Research Products, Emeryville, 
CA, USA), anti-A17-24 (4G8, Covance Research Products), anti-p-tau (Thr231, EMD Millipore, 
Billerica, MA, USA), anti-p-tau (Ser202, AT8, Thermo Fisher Scientific, Waltham, MA, USA), 
anti-p-tau (Ser404), anti-p-tau (Thr181, AT270, AnaSpec, Fremont, CA, USA), anti-total tau (tau46, 
Cell Signaling Technology, Danvers, MA, USA), anti-synaptophysin (Cell Signaling 
Technology), anti-GSK3 (Ser9, Thermo Fisher Scientific), anti-cyclooxygenase 2 (COX2) 
(Thermo Fisher Scientific), anti-light chain 3B (LC3B) (Thermo Fisher Scientific), anti--tubulin 
III (Thermo Fisher Scientific), anti-p-synapsin I (Thermo Fisher Scientific), anti- microtubule 
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associated protein 2 (MAP2) (Thermo Fisher Scientific), anti- glial fibrillary acidic protein 
(GFAP) (Thermo Fisher Scientific), anti- neuronal nuclei (NeuN) (Thermo Fisher Scientific), anti- 
post synaptic density protein 95 (PSD95) (Thermo Fisher Scientific), and anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (Thermo Fisher Scientific) antibodies.  Paired helical 
filament 1 (PHF1) antibody was kindly provided by Dr. Peter Davies (Albert Einstein University). 
 
Cell culture  
HeLa cells stably transfected with wild-type 4R0N human tau [HeLa/tau cells; kindly 
provided by Dr. Chad Dickey, University of South Florida (USF) (Tampa, FL, USA)], human 
neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA), murine neuroblastoma cells (N2a cells), 
murine neuronal stem cells (ATCC), human neural stem cells (H9-Derived, ATCC) were cultured 
in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum, 1 mM sodium 
pyruvate, and 100 U/ml of penicillin/streptomycin.  Kidney cells were cultured in InVitroGRO 
medium (BioreclamationIVT, ATCC).  Splenocytes from individual mice were prepared and 
treated as previously described [207]. Primary neuronal cells were obtained from cerebral cortices 
of Tg2576 mouse embryos, between 15 and 17 days in utero, as described previously [208][209]. 
These cells were treated with LP or LC at 0, 2.5, 5, 10, 20, or 30 mM for 12 h, supernatants were 
collected and cells were washed with ice cold PBS 3X and lysed with cell lysis buffer (20 mM 
Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 µg/ml leupeptin, and 1 mM PMSF) 
(Sigma-Aldrich). 
In addition, murine primary culture microglia was isolated from mouse cerebral cortices, 
as described previously [37][210].  Briefly, cerebral cortices from newborn mice (1-day old) were 
isolated under sterile conditions and mechanically dissociated at 4 °C.  Cells were grown in RPMI 
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1640 medium supplemented with 5% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, 0.1 
μg/ml streptomycin, and 0.05 μM 2-mercaptoethanol for 14 days, after which only glial cells 
remained.  Astrocytes were separated from microglial cultures using a mild trypsinization protocol 
as described [211]. Greater than 98% of these glial cells stained positive for anti-Mac-1 antibody 
(Roche Diagnostics, Indianapolis, IN, USA) by fluorescence activated cell sorting (FACS) 
analysis [212].  
 
Enzyme-linked immunosorbent assay 
 
Enzyme-linked immunosorbent assay (ELISA) was performed according to the 
manufacturer’s instruction.  Total Aβ species, including Aβ40,42 in cell conditioned media and brain 
homogenates were detected by Aβ1–40/42 ELISA kits (IBL America, Minneapolis MN, USA) 
according to the manufacturer’s instructions.  In addition, cytokines [TNFα, IL-10, and IL-12 (p70) 
levels in brain homogenates and or in cell conditioned media were measured by ELISA (R &D 
Systems, Minneapolis, MN) according to the manufacturer’s instructions.  Aβ levels are 
represented as pg/mg (mean ± SEM) of total cellular protein. 
 
Microglial inflammatory activity analysis 
To determine the effect of LP on microglial pro-inflammatory activity, primary microglial 
cells were treated with LP (0-20 mM) in the presence of interferon γ (IFNγ) (100 U/ml) and/or 
CD40 ligand (CD40L, 1 μg/ml) for 8 h, and then pro-inflammatory microglial activation was 
assessed by fluorescence-activated cell sorting (FACS) and ELISA analyses of CD40, tumor 
necrosis factor α (TNFα), and interleukin-12 protein 70 (IL-12p70). 
 
 
 
 
 94 
 
Phagocytosis analysis 
 
To determine the effect of LP on microglial A phagocytosis, primary microglia were 
pretreated with LP at 10 mM or vehicle (1% dimethyl sulfoxide) for 6 h followed by incubation 
with 1 μM fluorescein isothiocyanate (FITC)-Aβ42 for 1 h.  Cellular supernatants and lysates were 
analyzed for extracellular and cell-associated FITC-Aβ42 using a fluorometer and data were 
represented as the relative fold of mean fluorescence change, calculated as the mean fluorescence 
for each samples at 37 °C divided by mean fluorescence at 4 °C. 
 
Autophagy analysis 
 
In addition, the effect of LP and LC on microglial autophagy was determined by pretreating 
microglial cells with LP, LC (10 mM), or phosphate-buffered saline (PBS) for 18 h, followed by 
permeabilization, staining with autophagic marker LC3B antibody and determination of 
fluorescent intensity of autophagosome and cytosol by a Slidebook digital microscopy (Version 
5.0.0.1, Olympus America Inc., NY USA). 
 
Mice 
 
Triple transgenic (3XTg-AD) mice harboring APPSWE, PSEN1 (PS1/M146V) and tau (P301L) 
mutations (3XTg-AD, the Jackson Laboratory, Bar Harbor, ME, USA), Tg2576 mice harboring 
APPSWE (Taconic, Hudson, NY, USA) and wild-type B6129F2/J mice (the Jackson Laboratory) 
were housed under standardized 12 h-light/12-h dark cycle at ambient temperature and humidity 
with diet and water available ad libitum at the USF vivarium.  The mice were allowed to acclimate 
for a period of one week before any treatment.  All experiments were conducted in accordance 
with USF Institutional Animal Care and Use Committee approved protocols and guidelines of the 
National Institutes of Health. 
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Lithium treatment 
Adult male B6129F2/J mice (2-month old) were treated for 2 weeks (acute) with one of six 
diets, consisting of normal mice chow diet (Teklad 2018) containing low or high doses of LP ( 
0.18 or 0.35%; equivalent to 292 or 583 mg/kg/day), LS (0.10 or 0.20%; equivalent to 162 or 325 
mg/kg/day), or LC (0.025 or 0.05%; equivalent to 42 or 83 mg/kg/day), yielding 1.125 or 2.25 mM 
Li/kg/day, respectively, for all forms of lithium.  In addition, both male and female Tg2576 (8-
month old) and 3XTg-AD mice (5-month old) were fed for 8 and 28 weeks (chronic) with one of 
four diets respectively, consisting of normal mice chow alone or normal chow supplemented with 
LC (0.05%), LS (0.20%), or LP (0.35%).  These doses were chosen based on the literature and a 
pilot study conducted at our laboratory using low- and high-doses of lithium salts. 
 
Plasma and brain lithium measurement 
After LP, LS, or LC treatment, mice were anesthetized with isoflurane, blood was collected 
by cardiac puncture, the heart and vasculature were carefully perfused with ice-cold PBS 
containing heparin (10 U/ml) and brain tissue was removed for lithium determination using atomic 
absorption spectroscopy (AAS).  Blood was centrifuged at 1,600 x g at room temperature for 10 
min and 100 µl plasma was diluted 10 fold in 10% isopropyl alcohol containing 5% trichloroacetic 
acid (IPA), vortexed, and incubated for 10 min to precipitate proteins.  Supernatants were clarified 
at 3,000 x g for 30 min prior to measuring lithium content (AA-6200, Shimadzu, Kyoto, Japan at 
the Interdisciplinary Research Facility at USF).  Each brain was divided coronally, the front half 
was rinsed with PBS, weighed, suspended in an equal volume of concentrated HNO3, heated for 1 
h at 100 °C, cooled to room temperature, centrifuged at 3,000 x g for 1 h, and the supernatant was 
diluted 10 fold in 10% isopropyl alcohol prior to measuring lithium content using AAS (Shimadzu 
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AA-6200).  Peak absorbance were determined referring to values obtained for standards 1% HNO3 
lithium solution (HIGH-PURITY STANDARDS, Charleston, SC, USA) 
 
Western blot analysis 
The posterior half of each brain was equally divided sagittally and one portion (one-fourth 
of brain) was immediately frozen at liquid nitrogen, and stored at -80 °C for Western blot (WB) 
analyses.  Brains were homogenized (Minilys homogenizer, Bertin Technologies) in RIPA lysis 
buffer (Cell Signaling Technology) containing protease and phosphatase inhibitor cocktail 
(Thermo Fisher Scientific) and centrifuged at 14,000 rpm for 1 h at 4 °C.  For WB analyses, 
supernatants from cell lysates or homogenized tissue were electrophoretically separated using 10% 
bicine/tris gel (8 M urea) for proteins less than 5 kD or 10% tris/SDS gels for larger proteins.  
Electrophoresed proteins were transferred to nitrocellulose membranes (Bio-Rad, Richmond, CA, 
USA), washed and blocked for 1 h at room temperature in tris-buffered saline containing 5% (w/v) 
nonfat dry milk (TBS/NFDM).  After blocking, membranes were hybridized overnight with 
various primary antibodies, washed and incubated for 1 h with the appropriate HRP-conjugated 
secondary antibody in TBS/NFDM.  Blots were developed using the luminol reagent (Thermo 
Fisher Scientific) and densitometry analysis was performed using an ImageJ software (Java 
1.6.0_20, NIH, USA) as used previously.  
 
Immunohistochemical analysis 
The other posterior portion (one-fourth) of each brain was fixed in fresh 4% 
paraformaldehyde solution for cryostat sectioning and free-floating 25-μm coronal sections were 
collected and stored in PBS with 100 mM sodium azide at 4 °C.  Immunohistochemical (IHC) 
staining was conducted according to the manufacturer’s instruction using a Vectastain ABC Elite 
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kit (Vector Laboratories, Burlingame, CA, USA) coupled with the diaminobenzidine substrate.  
Biotinylated anti-phospho-tau antibodies against different phospho-tau residues were used as 
primary antibodies.  Images were acquired as digitized tagged-image format files to retain 
maximum resolution using a BX60 bright field microscope with an attached CCD camera system 
(Olympus DP-70, Tokyo, Japan).  Digital images were routed into a Windows PC for quantitative 
analyses using an ImageJ software after obtaining a threshold optical density that discriminated 
staining from background.  Each anatomic region of interest was manually edited to eliminate 
artifacts and selection bias was controlled for by analyzing each region of interest in its entirety. 
 
Immunocytochemical analysis   
After 30 min fixation with fresh 4% paraformaldehyde solution, immunocytochemical 
(ICC) staining was conducted by indirect method and visualized by appropriate 
immunofluorescence dye (i.e., FITC)-labeled secondary antibodies.  Images were acquired as 
digitized tagged-image format files to retain maximum resolution using a confocal microscope 
with an attached CCD camera system (Olympus DP-70). 
 
Statistical analysis 
All data were normally distributed; therefore, in instances of single mean comparisons, 
Levene’s test for equality of variances followed by the t-test for independent samples were used 
to assess significance.  In instances of multiple mean comparisons, one-way analysis of variance 
(ANOVA) with post hoc Fisher’s LSD test was used.  Alpha was set at 0.05 for all analyses.  The 
statistical package for the social sciences release IBM SPSS 23.0 (IBM, Armonk, NY) was used 
for all data analyses. 
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Results 
Lithium pharmacokinetics during chronic LP, LC, and LS treatment 
In our previous study, we monitored the pharmacokinetics of lithium following a single 
dose of LP and LC by oral gavage.  Using male Sprague-Dawley rats, the plasma and brain profiles 
measured by AAS indicated that LP produces a very steady level of lithium at 48 h after treatment, 
whereas the level of lithium was almost undetectable after 48 h of LC treatment [87]. In the present 
study, we investigated the plasma and brain pharmacokinetics of lithium upon chronic treatment 
with LP, LC, or LS to Tg2576 and 3XTg-AD mice, as well as wild-type B6129F2/J mice.  Low or 
high doses of LP, LC, or LS, yielding lithium at 1.125 or 2.25 mM/kg/day respectively, showed 
steady increases of lithium levels in the plasma and brain between 1 and 2 weeks of treatment in 
B6129F2/J mice, with the high dose yielding higher lithium levels (Figures 4-1a and b).  No 
statistically significant differences were found between treatments in plasma lithium levels at 
either dose.  By contrast, after 2 weeks of treatment, LP yielded significantly higher brain lithium 
levels compared to LC and LS. 
In Tg2576 mice, LP and LC treatment revealed steady increases of lithium levels in the 
plasma and brain over an 8-week treatment, with significantly higher plasma lithium levels by LC 
treatment compared to LP only during the 2-week treatment (Figure 4-1c).  However, after 8-week 
treatment, LP provided significantly higher brain lithium levels compared to LC (Figure 4-1d).  In 
3XTg-AD mice, no significant difference was observed in both plasma or brain lithium levels after 
28 weeks of LP, LC, or LS treatment (Figure 4-1e).  Of note, the brain to plasma lithium ratio of 
LP tended to be higher after 28-week compared to LC and LS treatment (Figure 4-1f), while the 
difference did not reach significance (LP and LS, p = 0.98; LP and LC, p = 0.84; LS and LC, p = 
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0.85).  Lithium levels showed undetectable levels in both plasma and brain from untreated control 
mice. 
 
Chronic LP treatment reduces β-amyloid plaques in Tg2576 and 3XTg-AD mice 
Lithium treatment has been shown to reduce Aβ generation in vitro, [91] while 
controversial results also exist regarding its ability to reduce Aβ production in vivo [213][214]. 
We determined the effect on -amyloid plaques by chronic treatment with LC or LP in Tg2576 
mice and with LC, LS, or LP in 3XTg-AD mice.  In Tg2576 mice, an 8-week treatment with LP 
significantly reduced A burden (positive area of β-amyloid plaques) compared to LC-treated as 
well as untreated control Tg2576 mice, as determined by IHC using A17-24 specific 4G8 antibody 
(Figures 4-2a and b).  Similarly, LP treatment significantly reduced both soluble and insoluble Aβ 
levels as determined by ELISA (Figure 4-2c).  However, both A burden and Aβ levels did not 
alter after LC treatment.  In 3XTg-AD mice, 28-week LP treatment significantly decreased A 
burden, as determined by IHC using A17-24 specific 4G8 and A1-16 specific 6E10 antibodies 
(Figures 4-2d and e), but A burden was not significantly altered after treatment with LS or LC. 
 
Chronic LP treatment reduces tau phosphorylation through inhibition of GSK3β in Tg2576 
and 3XTg-AD mice 
 
In Tg2576 mice, 8-week LP treatment significantly reduced phosphorylation of tau [p-tau 
(Thr231)] compared to untreated controls, as determined by IHC and WB analyses (Figures 4-3a 
and b). In addition, LP treatment significantly increased GSK3β (Ser9) inhibitory phosphorylation, 
as determined by WB (Figure 4-3c).  However, tau or GSK3 inhibitory phosphorylation was not 
altered by treatment with LC.  In 3XTg-AD mice, 28-week LP treatment significantly reduced tau 
phosphorylation [p-tau (Thr231)] in CA1 as determined by IHC (Figures 4-3d and f).  In addition, 
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LP treatment tended to reduce tau phosphorylation p-tau (Thr231) in CA3, but this decrease was 
not statistically significant for p-tau (Thr231) [(Figures 4-3d and g) (LP and LS, p = 0.771; LP and 
LC, p = 0.31; LS and LC, p = 0.233].  LC or LS treatment did not significantly alter tau 
phosphorylation in CA1 or CA3 as determined by IHC.  In addition, LP treatment significantly 
reduced tau phosphorylation [p-tau (Ser396)], as determined by IHC (Figure 4-3h) and tau 
phosphorylation [p-tau (Ser396, Ser404, Thr181 and Thr231)], as determined by WB (Figures 4-3i and 
j).  LC and LS also reduced tau phosphorylation at several sites, notably p-tau (Ser396 and Thr231), 
albeit less than LP. 
 
LP treatment reduces microglial inflammation, while enhancing microglial A phagocytosis 
and autophagy 
 
In as much as microglial CD40/CD40L signaling can enhance A generation [37] and 
impair A phagocytosis, [210] we determined the effects of LP on CD40 expression, 
CD40/CD40L signaling, and A phagocytosis in primary microglial cells.  Primary microglial 
cells were treated with LP (0-20 mM) in the presence of IFNγ (100 U/ml) and/or CD40 ligand 
(CD40L, 1 µg/ml) for 8 h.  LP treatment significantly inhibited IFN-induced CD40 expression in 
a dose-dependent manner (Figure 4-4b), as determined by FACS analysis, as well as IFN/CD40L-
induced release of pro-inflammatory cytokines (i.e., TNFα and IL-12p70), as determined by 
ELISA (Figure 4-4c).  To assess the effect of LP on microglial A phagocytosis, primary 
microglial cells were pre-incubated with 10 mM LP or vehicle (1% dimethyl sulfoxide) for 6 h 
followed by 1-h incubation with fluorescent-tagged Aβ1-42 (FITC-Aβ1-42).  LP significantly 
increased uptake of Aβ1-42 in primary microglial cells, as evidenced by increased cell-associated 
(intracellular) and decreased extracellular fluorescence (Figure 4-4d).  Sarkar et al. (2005) first 
showed that lithium up-regulates autophagy and clears mutant proteins (huntingtin and α-
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synuclein) by inhibiting inositol monophosphatase [215] Subsequently, several cell culture and 
animal studies demonstrated induction of autophagic pathways by lithium [216] To investigate the 
effect of LP and LC on autophagy, primary microglial cells were treated with LP or LC (10 mM) 
for 18 h, followed by permeabilization and staining with autophagic marker LC3B antibody.  Both 
LP and LC treatment significantly enhanced autophagy (Figure 4-4a). 
 
Chronic LP treatment inhibits peripheral and neural inflammation in Tg2576 mice 
Given that LP could modify β-amyloid plaque pathology in transgenic AD mice, we 
wanted to determine whether reduction of Aβ is associated with an anti-inflammatory effect.  In 
Tg2576 mice, 8-week LP treatment significantly increased plasma levels of anti-inflammatory 
cytokines (i.e., IL-4 and IL-10) compared to untreated controls, as determined by ELISA (Figure 
4e).  In addition, LP treatment increased IL-10 in splenocytes, while reducing pro-inflammatory 
cytokines (i.e., TNFα and IL-12p70), as measured by ELISA (Figure 4-4f).  LP treatment did not 
alter plasma IL-2 or IFN, as determined by ELISA (Figure 4-4e).  LP treatment also increased 
brain levels of anti-inflammatory cytokines (i.e., TGF1 and IL-10) while attenuating the levels 
of sCD40L (Figure 4-4g and h) as analyzed by ELISA.  No cytokine measured was altered by LC 
treatment.  Taken together, these findings indicated that LP dampens pro-inflammatory microglial 
activation, while promoting A phagocytosis and autophagy. 
 
LP treatment decreases GSK3 activity and tau phosphorylation in vitro 
Since LP inhibited tau phosphorylation and increased inhibitory GSK3 phosphorylation 
in vivo, we further investigated these activities of LP in vitro.   HeLa cells overexpressing human 
wild-type tau (HeLa/tau cells), human neuroblastoma SH-SY5Y cells, and primary neuronal cells 
were treated with LP at increasing concentrations (0, 2.5, 5, and 10 mM) for 12 h, followed by 
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analysis of tau and/or GSK3 phosphorylation by WB.  LP significantly increased in inhibitory 
phosphorylation of GSK3β (Ser9) in HeLa/tau cells (Figure 4-5a).  This increase in anti-tau 
phosphorylation was associated with a decrease at 10 mM, as indicated by PHF1 (recognizes 
phospho-Ser396) and phospho-tau (Thr231) immunoreactivity in HeLa/tau cells (Figure 4-5b).  
Similarly, LP (5 and 10 mM) significantly increased inhibitory phosphorylation GSK3β (Ser9) in 
human neuroblastoma SH-SY5Y and primary neuronal cells (Figure 4-5c).  Taken together, these 
findings confirm that LP reduces tau phosphorylation through inactivation of GSK3β. 
 
LP treatment enhances neuronal cell differentiation and chronic treatment prevents cortical 
neuronal and synaptic protein loss 
 
To examine the effect of LP on neuronal cell differentiation, cultured murine 
neuroblastoma N2a cells were treated with LP and LC at 10 mM for 24 h, followed by analysis of 
neuronal markers [i.e., β-tubulin III and phospho-synapsin I (Ser62-67)] by ICC and WB analyses.  
LP-treated N2a cells were significantly enhanced differentiation, as evidenced by increased 
expression of β-tubulin III and phospho-synapsin I (Ser62-67) compared to LC (Figures 4-6a-c).  In 
addition, LP treatment significantly enhanced differentiation of cultured murine and human 
neuronal stem cells (MNSC and HNSC, respectively) compared to LC treatment, as evidenced by 
enhanced neuronal markers (i.e., MAP2 and phospho-synapsin I).  Moreover, LP-treated MNSC 
cells demonstrated increased expression of Tau46, total tau, and MAP2 compared to LC-treated 
these cells (Figures 4-6d-g). Taken together, these findings indicate that LP significantly enhanced 
neuronal stem cell differentiation. 
To examine whether LP treatment can prevent neuronal loss, 5-month old 3XTg-AD mice 
were treated with LP, LC, or LS for 28 weeks, followed by IHC analysis using anti-NeuN antibody.  
Both LP and LS treatment significantly increased the number of NeuN-labeled positive cells in the 
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neocortex region compared to untreated control mice (Figure 4-6h).  In addition, LP- and LS-
treated 3XTg-AD mice showed increased expression of pre- and post-synaptic proteins (i.e., 
synaptophysin and PSD95) by WB analysis (Figure 4-6i).  Collectively, these findings suggest that 
chronic administration of LP or LS to 3XTg-AD mice significantly prevents neuronal loss and 
improves expression of pre- and post-synaptic proteins. 
 
Both acute and chronic LP treatment does not increase COX2 expression 
Previous in vitro and in vivo studies have indicated that lithium chloride inhibits 
constitutive GSK3β activity in the kidney, thereby inducing COX2 expression; producing 
inflammation and toxicity [217][218][219].  To compare the effect of LP and LC on renal GSK3β 
activity and COX2 expression, cultured human renal proximal tubule (HRPT) cells were treated 
with LP or LC at 0, 10, 20, or 30 mM for 12 h.  Interestingly, both LP and LC increased inhibitory 
phosphorylation of GSK3β (Ser9), while only LC increased COX2 expression (Figures 4-7a and 
b).  Therefore, LC-induced COX2 expression is independent of GSK3β activity. 
To compare the effects of LP, LS, and LC treatment on renal COX2 expression in vivo, 6-
week old B6129F2/J mice were fed for 2 weeks with diets containing LP, LC, or LS at low or high 
doses (1.125 or 2.25 mM Li/kg/day).  As shown by WB and IHC analyses, neither LP, LC, nor LS 
treatment alter COX2 expression at low dose, although LC-treated B6129F2/J mice showed a 
tendency to increase.  In contrast, only LC significantly increased COX2 expression at the high 
dose (Figures 4-7c and d).  Further, to test whether chronic administration of lithium induces 
COX2 expression in the context of the pathological condition, transgenic Tg2576 AD mice were 
treated with LP and LC at 2.25 mM Li/kg/day (high dose) for 8 weeks.  As expected, both IHC 
and WB analyses indicated that only LC treatment shows significant increase of COX2 expression 
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(Figures 4-7e-g).  No statistically significant difference was found between LP-treated Tg2576 AD 
mice and untreated controls. 
 
Discussion 
Despite a narrow therapeutic window (0.6-1.5 mM) and the potential for serious adverse 
events, lithium has been used as the first line therapy to reduce manic episodes and suicidality in 
patients with bipolar disorder due to lack of better alternatives [220]. We have previously shown 
that FDA-approved lithium carbonate produces very sharp peak plasma and brain lithium 
concentrations after oral dosing, followed by a rapid decline in rats. In contrast, LISPRO showed 
steady plasma and brain lithium levels out to 48 h without any sharp peak [87].  Based on these 
findings, we hypothesize that LISPRO may prevent the drastic change of lithium levels in the 
plasma seen with current lithium drugs, and maintain stable therapeutic doses and, thus, would 
represent a significant improvement over current lithium medicines for a desired time by slow-
release into the peripheral blood. Similar to above findings, our recent data (8-weeks treatment in 
Tg2576 mice) showed significantly stable plasma lithium levels over the period of time (Figure 4-
1c) as well as higher brain lithium levels compared to Li2CO3 (Figure 4-1d). More importantly, 
B6129F2/J mice treated with LISPRO showed significantly higher brain lithium levels at low 
(1.125 mM/kg/day) and high (2.25 mM/kg/day) concentrations compared to Li2CO3 (Figures 4-
1a-b). Moreover, our recent study also showed comparable levels of lithium in 3XTg-AD mouse 
plasma and brain as result of lithium salicylate, Li2CO3, or LISPRO (28-week treatment).  
Furthermore, the brain to plasma lithium ratio in the LP-treated group was slightly higher (LP and 
LS, p = 0.98; LP and LC, p = 0.84; LS and LC, p = 0.85) versus LS- and LC-treated groups (Figures 
4-1e-f).  Lithium has been employed in treatment of several neurodegenerative diseases including 
AD.  It has been reported that lithium prevents the generation of Aβ peptides by inhibiting GSK3α 
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activity, which interferes with APP γ-secretase cleavage [91][221][222].   In terms of LP, we 
expected that addition of salicylate, which is the primary metabolite derivative of acetyl-salicylic 
acid (aspirin), could work together synergistically to improve the safety and modify the 
pharmacological action of lithium for attenuating AD pathology.  Study data suggest that aspirin 
exerts its effects on the inflammatory cascades, irreversibly inhibiting COX1, and modifying 
enzyme activity of COX2, suppressing production of prostaglandins and thromboxane. Although 
lithium has anti-inflammatory properties, several studies indicate that chronic lithium might induce 
COX2 expression through inhibition of GSK3β activity. Our data also showed that both lithium 
carbonate and LISPRO inactivate GSK3β, but only lithium carbonate activates COX2 whereas 
LISPRO suppresses COX2 due to the anti-inflammatory properties of salicylate anion. A recent 
epidemiological study showed that low-dose aspirin with lithium exert synergistic effects by 
increasing 17-hydroxy-decosahexanoic acid (17-OH-DHA), an anti-inflammatory brain DHA 
metabolite which significantly reduced the risk of disease deterioration in bipolar patients 
compared to other non-steroidal anti-inflammatory drugs and glucocorticoids, a COX2 inhibitor 
[223]. Together, salicylic acid increased brain 17-OH-DHA, [224], and lithium reduced 
neuroinflammation, [225][99] while zwitterionic l-proline significantly reduced the hygroscopic 
property of parent salicylate salt by influencing the solid phase formation. Assuming the above 
hypothesis is true, we wanted to investigate the bioactivities of LISPRO in terms of ameliorating 
AD pathology in cell culture systems and in transgenic (Tg2576 and 3XTg-AD) mouse models.  
We showed that 8-week LISPRO-treated Tg2576 AD mice had significantly reduced soluble and 
insoluble Aβ levels as well as Aβ burden compared to Li2CO3- and control-treated Tg2576 AD 
mice (Figures 4-2a-c).  To examine LISPRO’s effect on Aβ generation in 5-month old 3XTg-AD 
mice, we treated them with LISPRO, lithium salicylate, Li2CO3, and control-diet for 28 weeks with 
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equal dosages of lithium (2.25 mM/kg/day).  We showed that LISPRO treatment significantly 
reduced extracellular Aβ plaques, as evidenced by IHC staining using 4G8 and 6E10 antibodies 
(Figures 4-2d and e).  Taken together, these findings demonstrated that LISPRO suppresses 
generation of both soluble and insoluble Aβ in Tg2576 and 3XTg-AD mouse models. 
Moreover, several lines of evidence demonstrated that lithium is a direct inhibitor of 
GSK3β and also increases the inhibitory serine-phosphorylation of the enzyme [89][226].  Thus, 
we wanted to examine whether LISPRO could reduce tau phosphorylation in cell culture and AD 
mouse models.  Using human HeLa/tau, human neuroblastoma SHSY-5Y, and primary neuronal 
cell lines, we found that LISPRO treatment inhibits phosphorylation of tau at 5-10 mM 
concentrations, which is associated with increasing inhibitory phosphorylation of GSK3β (Ser9) 
(Figures 4-5a-c).  Taken together, these findings indicated that LISPRO inactivates GSK3β 
activity, and thereby reduces tau phosphorylation.  Since lithium is a suitable inhibitor for 
inhibiting GSK3β in vivo, we also examined whether LISPRO-mediated suppression of GSK3β 
activity is associated with attenuation of tau phosphorylation in Tg2576 mice.  In this model, we 
showed that an 8-week LISPRO treatment significantly reduces p-tau (Thr231) phosphorylation 
compared to Li2CO3 and control (Figures 4-3a and b).  These findings were also correlated with 
increased p-GSK3β (Ser9) inhibitory phosphorylation, indicating inactivation of GSK3β activity 
(Figure 4-3c).  To confirm these data obtained in the Tg2576 AD mouse model, we next 
investigated whether chronic administration of LISPRO could also reduce tau phosphorylation in 
3XTg-AD mice.  Thus, we treated 5-month old 3XTg-AD mice with LISPRO, lithium salicylate, 
Li2CO3, or control-diet for 28 weeks with equal doses of lithium (2.25 mM/kg/day).  IHC staining 
using p-tau (Thr231) and p-tau (Ser396) antibodies as well WB analyses using multiple p-tau [Ser396, 
Ser404, Thr181, and Thr231] amino acid residues demonstrated that LISPRO, and in many cases 
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lithium salicylate, significantly attenuates tau phosphorylation compared to Li2CO3 and control 
(Figures 4-3d-j). 
Inflammatory processes are thought to play an active role in AD formation and progression. 
Preclinical as well as postmortem analyses of AD patient brains have provided tons of evidence 
indicating the dysregulation and/or uncontrolled activation of microglial and astrocytic cells, 
activation of complement cascade, inflammatory enzymes such as COX2, inducible nitrate oxide 
synthase, reactive oxygen species, and calcium dysregulation pathways in brain, CSF, and blood 
[227][228][229]. Although it is inconclusive whether these changes are initiating or secondary 
consequences, proinflammatory such as IL-1β, IL-6, TNFα, NO and anti-inflammatory cytokines 
such as IL-4, IL-10, TGFβ elevated in the CSF and blood of AD patients [228][230][231]. Multiple 
lines of evidence showed that lithium down-modulates the pro-inflammatory cytokine responses 
in animal models and is of therapeutic benefits in several neurodegenerative diseases [232][233]. 
Specifically, Nassar and Azab conclude that lithium has anti-inflammatory properties that may 
contribute to its therapeutic activity by down-regulation of COX2, inhibition of IL-1β, TNFα, and 
up-regulation of IL-2 and IL-10 [234]. On the other hand, in contrast to above findings, large 
bodies of evidence indicated that lithium also induces pro-inflammatory cytokines production such 
as IL-4 and IL-6 in certain disease conditions [235][236]. Based on these reports, we sought to 
examine if the efficacy of LISPRO for reducing AD-like pathology in transgenic Tg2576 mice is 
associated with modulation of pro- and anti-inflammatory cytokine responses.  We showed that 
LISPRO treatment significantly increases the expression of anti-inflammatory cytokines such as 
IL-4, IL-10, and TGF-β1, while it decreases the expression of pro-inflammatory cytokines such as 
INFγ, IL-12p70, and sCD40L in Tg2576 mouse brains compared to control- and LC-treated 
Tg2576 mouse brains (Figures 4-4e-h).  Taken together, these findings suggest that LISPRO might 
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reduce Aβ pathology at least in part via up-regulated anti-inflammatory and down-regulated pro-
inflammatory cytokine responses in Tg2576 mice. 
We demonstrated that CD40-CD40L interaction is critical for brain pro-inflammatory 
responses in aggravating AD-like pathology [237]. As LISPRO treatment reduced Aβ production 
in cell culture and transgenic (Tg2576 and 3XTg-AD) mouse models, we next hypothesized that 
reduction of Aβ pathology might correlate with decreased microglial CD40 expression and/or 
increased phagocytosis by microglia.  In this regard, we found that decreased expression of 
microglial CD40 and brain soluble CD40L expression by LISPRO treatment might help attenuate 
Aβ associated pathology, suggesting that disruption of CD40-CD40L signaling could also be 
involved in attenuation of Aβ pathology in Tg2576 and 3XTg-AD mouse models.   As expected, 
LISPRO suppresses IFN-induced CD40 expression (Figures 4b and c) and enhances microglial 
phagocytosis of Aβ (Figure 4-4d) in cultured primary microglial cells.  Moreover, multiple lines 
of evidence demonstrated that lithium enhances autophagy at low doses (10 mM) [215][216]. In 
this regard, we found that LISPRO treatment enhances autophagy markers LC3B in cultured 
primary microglial cells (Figure 4-4a).  Collectively, our data suggest that LISPRO-mediated 
attenuation of Aβ pathology is associated with several therapeutic endpoints including up-
regulated anti-inflammatory and down-regulated pro-inflammatory cytokines, suppression of 
CD40 that disrupts CD40-CD40L signaling, increased microglial phagocytosis of Aβ, and up-
regulated autophagy. 
Furthermore, to investigate whether LISPRO treatment could modulate neuronal cell 
differentiation, cultured mouse neuroblastoma N2a, as well as murine and human stem cells was 
treated with LISPRO, Li2CO3, and control.  Our data from IHC staining and supportive WB 
analyses using β-tubulin III, phospho-synapsin I (Ser62-67), MAP2, and total tau antibodies 
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demonstrated that LISPRO treatment significantly promotes neuronal cell differentiation 
compared to Li2CO3 (Figures 4-6a-g).  Cheng and Chuang reported that lithium increases the 
expression of p53 and Bcl-2 providing neuronal survival [238]. In addition, it has been shown that 
administration of lithium as well as mood-stabilizing agent valproate, increases Bcl-2 levels in the 
cortical region [239]. Based on these findings, we also wanted to examine whether LISPRO could 
prevent cortical neuronal loss in 5-month-old 3XTg-AD mice were treated with LISPRO, lithium 
salicylate, Li2CO3, or control diet for 28 weeks.  Quantitative analysis of neuronal cell numbers 
using the neuronal marker anti-NeuN antibody, displayed that LISPRO and lithium salicylate 
treatments respectively yield an increased survival neurons in the neocortex region of 3XTg-AD 
mice (Fig. 4-6h).  We further examined whether LISPRO treatment could modulate the expression 
of synaptic proteins in 3XTg-AD mice brain, and found that LISPRO and lithium-salicylate 
significantly increase the protein expression of synaptophysin (Pre-synaptic) and PSD95 (Post-
synaptic) in these transgenic mice (Figure 4-6i). 
Finally, one of the major side effects of lithium includes renal toxicity secondary to 
increased expression of COX2 and ensuing inflammation.  It has been shown that acute and chronic 
administration of lithium could enhance COX2 expression by suppressing GSK3β activity in renal 
cell lines and mouse models [217][218]. We observed the effect of LISPRO on COX2 expression 
in renal cells from the Tg2576 AD as well as wild-type B6129F2/J mouse models.  We treated 
human renal proximal tubule cells (HRPT) with LISPRO and Li2CO3.  IHC staining and supportive 
WB data indicated that LISPRO treatment does not enhance COX2 expression in HRPT renal cells 
(Figures 4-7a and b).  To further test the effect of LISPRO treatment on COX2 expression in vivo, 
we orally fed B6129F2/J and Tg2576 mouse lines with LISPRO, lithium salicylate, and Li2CO3 
for 2, and 8 weeks, respectively with low (1.125 mM/kg/day) and high doses (2.25 mM/kg/day).  
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Our IHC and supportive WB findings indicated that LISPRO treatment does not increase COX2 
expression (Figures 4-7c-g). 
In sum, our data supports our hypothesis that LISPRO is a better alternative formulation of 
lithium in terms of safety and efficacy in ameliorating AD pathology in cell culture and two 
different transgenic mouse models.  Nevertheless, further translational research is warranted to 
fully validate LISPRO as a safe and effective disease modifying therapy for AD and other 
neurodegenerative diseases. 
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Figure 4-1 Plasma and brain lithium pharmacokinetics following chronic oral treatment 
with LISPRO (LP), lithium salicylate (LS), and Li2CO3 (LC) in B6129SF2/J, Tg2576 and 
3XTg-AD mice 
(a & b) B6129SF2/J mice (n = 2- 4 mice/group, male) at 2 months of age were treated for 1 or 2 
weeks (wks) with 3 diets containing LP, LC, or LS, yielding lithium at 1.125 or 2.25 mM/kg/day.  
(c & d) Tg2576 mice (n = 8, 4 female/4 male) at 6 months of age were treated for 8 weeks with 2 
diets containing LP or LC, yielding lithium at 2.25 mM/kg/day.  (e & f) Further, 3XTg-AD female 
mice (n = 4 - 8 mice/group) at 5 months of age were treated for 28 weeks with 3 diets containing 
LP, LS or LC, yielding lithium at 2.25 mM/kg/day, or normal mouse chow (Teklad 2018).  Blood 
and brain lithium levels were measured using atomic absorption spectroscopy (AAS).  Brain over 
plasma lithium ratio calculated for each individual 3XTg-AD mouse (f).  All mice received normal 
drinking water and chow ad libitum.  Statistical analysis was carried out using ANOVA with post 
analysis with Fisher’s LSD test (*p < 0.05; **p < 0.01).  There was no significant difference in 
plasma or brain lithium levels between LC- and LS-treated B6129SF2/J mice (p > 0.05).  There 
was no detectable lithium in plasma and brain homogenates in control Teklad 2018 diet-fed 
B6129SF2/J, Tg2576, and 3XTg-AD mice (Ctrl, data not shown). 
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Figure 4-2 Oral LP treatment reduces β-amyloid pathology in Tg2576 and 3XTg-AD mice 
Tg2576 mice at 8 months of age (n = 9; 5 male/4 female) and 3XTg-AD female mice at 5 months 
of age (n = 4 - 8 mice/group) were treated for 8 or 28 weeks, respectively, with diets containing 
LP, LS or LC, yielding lithium at 2.25 mM/kg/day, or normal mouse chow as indicated.  These 
dosages were chosen to give brain lithium concentrations of 0.25 - 0.50 mM, which fall in a range 
of clinical therapy for AD. 7, 15  All mice received chow and normal drinking water ad libitum.  
Mouse brain tissue sections and homogenates were prepared from each mouse after treatment.  (a 
and d) Half-brain coronal sections were analyzed by anti-Aβ antibody (4G8) staining.  (b and e) 
Percentage of 4G8 positive plaques (mean ± SEM) was quantified by image analysis as described 
previously.  (c) Total soluble and insoluble Aβ1-40, 42 peptides from homogenates were analyzed 
by ELISA and represented as picograms of Aβ peptides per mg of total protein.  LP but not LC 
treatment markedly reduced total soluble and insoluble Aβ1-40,42 levels.  A t-test for two samples 
and one-way ANOVA-test for multiple independent samples revealed significant differences 
between LP and LC ( b and c) and among LP, LS and LC compared with control diet (Ctrl) (e, *p 
< 0.05, **p < 0.01).  There was no notable or significant difference in both 4G8 positive Aβ 
plaques and cerebral soluble/insoluble Aβ1-40,42 levels in brain sections and homogenates between 
LC-treated and control Teklad 2018 diet-fed Tg2576 mice (Ctrl, p > 0.05). 
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Figure 4-3 Oral LP treatment reduces tau hyper-phosphorylation in Tg2576 and 3XTg-AD 
mice   
 
Representative micrographs showing IHC staining of brain sections from Tg2576 and 3XTg-AD 
mice orally treated for 8 and 28 weeks, respectively, with diets containing LP, LS or LC, yielding 
lithium at 2.25 mM/kg/day, or control Teklad 2018 diet, as detailed in Figure 4-1 above.  Shown 
are IHC staining and quantification of p-tau (Thr231, a, d) and p-tau (Ser396, e) immunoreactivity 
in CA3 of Tg2576 (a) and CA1/CA3 of 3XTg-AD mice brain sections (d and e).  Percentage of p-
tau (Thr231) or p-tau (Ser396) positive areas (mean ± SEM) was quantified by image analysis in 
CA1/CA3 of 3XTg-AD mice (f - h).  ANOVA with post hoc analyses using Fisher’s LSD test for 
multiple samples reveals significant differences in phosphorylated tau between LP treated and 
control mince (*p < 0.05, **p < 0.01).  The mouse brain homogenates were subjected to western 
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blot (WB) analysis with antibodies against p-tau (Thr231), p-tau (Ser396), p-tau (Ser404), p-tau 
(Thr181), total tau, GAPDH (b and i), pGSK3 (Ser9) or total-GSK3β (c).  As shown below WB, 
densitometry analysis shows the band density ratios of p-tau to total tau (b, bottom panel) or 
GAPDH (j) and pGSK3β to total GSK3β (c, bottom panel).  Statistical t-test analyses of WB data 
revealed a significant decrease in the ratios of p-tau (Thr231) to total tau (b) and increase in pGSK3β 
(Ser9) to total GSK3β (c) in LP compared with LC-treated Tg2576 mice (**p < 0.01).  One-way 
ANOVA and post hoc analyses revealed significant differences in the ratio of p-tau to GAPDH (j) 
compared to control treatment (Ctrl, *p < 0.05, **p < 0.01).  Similar results from both 
immunochemistry staining and WB analyses were also obtained with PHF-1 antibody (data not 
shown) in the LISPRO-treated Tg2576 mice.  There was no notable and significant difference in 
both p-tau (Thr231) and inactivated p-GSK3β (Ser9) levels in brain homogenates between LC- and 
control Teklad 2018 diet-fed Tg2576 mice (p > 0.05). 
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Figure 4-4 LP inhibits peripheral and neuroinflammation, while promoting microglial 
autophagy and A phagocytosis 
(a) For determination of microglial autophagy, mouse primary microglial cells were pretreated 
with LP, LC, LiCl, or L-proline at 10 mM or PBS (Ctrl) for 18 h, followed by permeabilization, 
staining with LC3B rabbit polyclonal antibody, and visualization with Alexa Fluor® 647 goat anti-
rabbit IgG (LC3B antibody kit, Molecular Probes®).  The fluorescence intensity of the 
autophagosomes (Autosome) and the cytosol were quantified using Slidebook™ digital 
microscopy software (mean ± SD).  Both LP and LC treatments significantly enhanced microglial 
autophagy (**p < 0.01).  Note that there was no significance difference in the fluorescence 
intensity of the autophagosomes and the cytosol between LC, LP, and LiCl (p > 0.05).  L-proline 
failed to promote any notable autophagy.  In addition, mouse primary microglial cells were treated 
with LP (0-20 mM) in the presence of IFNγ (100 U/ml) or/and CD40 ligand (CD40L, 1 µg/ml) for 
8 h and then examined for pro-inflammatory microglial activation as assessed by flow cytometric 
(FACS) analysis and ELISA.  (b) FACS analysis showed LP induced significant dose dependent 
decreases in IFNγ-induced CD40 expression.  Data are represented as mean percentage of CD40 
expressing (CD40 Exp) cells (± SEM) from two independent experiments.  (c) Microglial cell 
culture supernatants were collected and subjected to cytokine ELISA as indicated.  Data are 
represented as mean pg of TNFα or IL-12p70 per mg of total cellular protein (± SEM) from three 
independent experiments. 
For determination of microglial A phagocytosis, primary microglial cell were pre-treated 
with LP at 10 mM or vehicle (1% DMSO in medium) for 6 h and then incubated with 1 µM FITC-
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Aβ1-42 for 1 h (d).  Cellular supernatants and lysates were analyzed for extracellular (Extra, top 
panel) and cell-associated (Cell-Asso, bottom panel) FITC-Aβ1-42 using a fluorometer.  Data are 
represented as the relative fold of mean fluorescence change (mean ± SEM), calculated as the 
mean fluorescence for each sample at 37°C divided by mean fluorescence at 4°C (n = 4 for each 
condition presented) (**p < 0.01).  LDH assay showed no significant increase in cell toxicity 
induced by LISPRO up to 20 mM in primary microglial cells (data not shown). 
 
For determination of peripheral and neuroinflammation, blood plasma (e), splenocyte 
cultured media (f) and brain homogenates (g and h) from LP- and LC-treated and untreated Tg2576 
mice (Ctrl) were subjected to cytokine and sCD40L ELISA.  Data are presented as mean ± SEM 
values of cytokines (pg/ml plasma or medium) (e and f) or fold increase of brain tissue-derived 
cytokines or sCD40L for LC or LP-treated over untreated mice (g and h, n = 9 for LP- and LC-
treated mice; n = 6 mice for untreated mice, *p < 0.05; **p < 0.01).  There was no notable or 
significant difference in cytokine levels in plasma and splenocyte cultured media between LC-
treated and control untreated mice (p > 0.05). 
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Figure 4-5 LP decreases tau phosphorylation while increasing inhibitory GSK3β (Ser9) 
phosphorylation in cultured cells 
Human tau stably transfected HeLa cells (HeLa/tau cells) (a and b), human neuroblastoma (SH-
SY5Y) cells (c, left panel), and primary neuronal cells (c, right panel) were treated with LP at the 
indicated concentrations (0-10 mM) for 12 h, followed by analysis of cell lysates by WB.  
Inhibitory phosphorylation status of GSK3β was detected by anti-phospho-GSK3β (Ser9) and total 
GSK3 antibodies (a).  Phosphorylation status of tau was detected by anti-phospho-tau [p-tau 
(Thr231)] and PHF1 antibodies as used previously (b).  Total tau (phosphorylated and non-
phosphorylated) was detected by tau-46 (b).  WB results are representative of two independent 
experiments for pGSK3β (Ser9) and total GSK3β, and three experiments respectively for PHF1, p-
tau (Thr231) and total tau with triplicates for each treatment condition.  Densitometry analysis 
below each WB figure panel shows the band density ratio of pGSK3β (Ser9) to total GSK3β as 
well as p-tau (Thr231) to total tau.  A t-test revealed a significant increase in the ratio of pGSK3β 
(Ser9) to total GSK3β and decrease in p-tau to total tau for HeLa/tau cells treated with 10 mM 
LISPRO compared to control (0 mM) (*p < 0.05; **p < 0.01).  In addition, a significant increase 
in the ratio of pGSK3β (Ser9) to total GSK3β was observed for both SH-SY5Y cells and 
differentiated neuronal cells treated with either 5 or 10 mM LISPRO compared to control (0 mM) 
(*p < 0.05) (c).  The secreted Aβ1-40,42 peptides were undetectable by Aβ ELISA of the conditioned 
media from HeLa/tau cells with or without LISPRO treatment (data not shown). 
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Figure 4-6 LISPRO markedly promotes neuronal cell differentiation and prevent neuronal 
and synaptic protein loss in 3XTg-AD mice 
Murine neuroblastoma (N2a cells, a), murine neuronal stem cells (MNSC, d) and human neural 
stem cells (HNSC, H9-Derived, f) were treated with LP, LC, LiCl, or L-proline (10 mM) for 24 h, 
4 days, or 14 days respectively.  These cells were then permeabilized with 0.05% Triton X-100 for 
5 min, washed, and stained with mouse anti-β-tubulin III monoclonal antibody, rabbit anti-
phospho-synapsin I (Ser62 and Ser67) polyclonal antibody, mouse anti-MAP2 monoclonal 
antibody, mouse anti-total tau (tau46) antibody or rabbit anti-GFAP polyclonal antibody overnight 
at 4 °C.  Alexa Fluor® 488 goat anti-mouse IgG (green) was used to detect β-tubulin III, MAP2 
and total tau and Alexa Fluor® 594 donkey anti-rabbit IgG (red) were used to detect phospho-
synapsin I and GFAP, respectively (a and d).  DAPI staining was used to detect nuclear DNA. 
Confocal images were taken by Olympus Fluoview™ FV1000 laser scanning confocal 
microscope.  In parallel, N2a cells (b), MNSC (e) and HNSC (g) were treated with LP, LC, LiCl, 
or L-proline at 10 mM, lysed with cell lysis buffer, and then subjected to WB analysis of β-tubulin 
III,  phospho-synapsin I, MAP2, total tau and GFAP.  As indicated below each WB panel, the band 
density ratios of β-tubulin III and phospho-synapsin I (p-synapsin I) to β-actin (c), MAP2, total 
tau and phospho-synapsin I to β-actin (e) and MAP2 and GFAP to β-actin (g) are presented as 
mean ± SEM  These data are representative of three independent experiments with similar results 
(*p < 0.05; **p < 0.01).  There was no notable or significant difference in β-tubulin III, phospho-
synapsin I, MAP2, total tau and GFAP immunofluorescence and WB analysis between LC, LiCl, 
or L-proline treatment (p > 0.05) for all three differentiated N2a cells, MNSC and HNSC 
respectively. 
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The brain tissue sections and homogenates prepared from LP-, LS-, or LC-treated, or 
untreated control 3XTg-AD mice, were subjected to IHC staining and WB analyses of neuronal 
and pre- and post-synaptic proteins, using NeuN, synaptophysin and PSD95 antibodies, 
respectively.  No statistically significant but increased changes in total number of immunoreactive 
(NeuN) positive cells were observed in LP- and LS-treated compared with untreated control mice 
(h).  (i) However, synaptophysin (Synapto) and PSD95 protein levels were significantly elevated 
in LP- and LS-treated mice compared with LC-treated and untreated control mice.  As indicated 
below IHC and WB panels, percentage of NeuN immunoreactive positive cells, synaptophysin, 
and PSD95 to GAPDH band density ratios were determined by image analysis (mean ± SEM).  
Data were analyzed by a one-way ANOVA and post testing with Fisher’s LSD test (*p < 0.05; 
**p < 0.01). 
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Figure 4-7 LISPRO does not increase COX2 expression in vitro and in vivo 
Human primary renal proximal tubule cells (ATCC® PCS-400-010TM) were cultured in 
InVitroGRO medium (BioreclamationIVT) and treated with LP, LC, LiCl, or L-proline at 0 to 30 
mM for 12 h.  These cells were then lysed with cell lysis buffer and analyzed by WB for COX2, 
total GSK3β and phospho GSK3β (Ser9 and Thr390) expression using anti-COX2 antibody (a) and 
anti-phospho- and total GSK3β antibodies (b).  Note that there were no notable differences in 
COX2 expression or GSK3β phosphorylation between LC and LiCl treatments.  L-proline 
treatment induced no change in COX2 expression and GSK3β phosphorylation. 
 
B6129F2/J male mice (weighing 20-25 g, 2-month old) were treated with 3 diets containing 
LP, LC, or LS, or control Teklad 2018 diet, for 1 or 2 weeks, yielding lithium at 1.125 or 2.25 
mM/kg/day.  All mice received normal drinking water and chow ad libitum.  (c) Kidneys were 
collected after treatment and analyzed by IHC for COX2 expression in the renal medulla.  (d) In 
addition, the kidney microsomal proteins were extracted to assess COX2 expression by WB 
analysis.  COX2 to -actin band density ratio of WB were determined by ImageJ analysis (mean 
± SEM) in duplicates from six mice in each group.  Statistical analysis was carried out using 
ANOVA (*p < 0.05, n = 6 for LP, LC and LS; n = 3 for control diet).  Furthermore, Tg2576 mice 
were treated with 2 diets containing LP or LP, yielding lithium at 2.25 mM/kg/day for 8 weeks.  
(e) Kidneys were collected after treatment and analyzed by IHC for COX2 expression in the renal 
medulla.  (f) The kidney microsomal proteins were extracted to assess COX2 expression by WB.  
(g) Quantification of COX2 to β- actin band density ratio of WB among ctrl, LP and LC treatments 
were determined by ImageJ analysis. Statistical analysis was carried out using ANOVA followed 
post hoc by Fishers LSD (*p < 0.05, **p < 0.01, n = 9 per treatment). 
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CHAPTER 5 
 
Ionic co-crystal of lithium salicylate proline (LISPRO), a novel formulation of 
lithium, prevents cognitive and neuropsychiatric behavioral deficits in the 
APPswe/PS1dE9 transgenic mouse model of Alzheimer’s disease 
 
 
Chapter synopsis 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive 
decline of cognition and associated neuropsychiatric symptoms including weight loss, anxiety, 
agitation, depression, irritation, and aggressiveness.  To date, no pharmacological or non-
pharmacological intervention has yet been shown to delay or stop progression of the disease.  
Lithium carbonate (Li2CO3), a drug widely used for treating bipolar disorder, has been shown to 
effect neuroprotection in a number of models of neurodegenerative disease, but may induce 
inflammation and toxicity in its current formulation.  Recently we have shown that a novel ionic 
co-crystal of lithium salicylate l-proline (LISPRO) is an improved alternative formulation of 
lithium as compared to lithium carbonate or lithium salicylate in terms of safety and efficacy in 
ameliorating AD pathology in cell culture and transgenic mouse models.  The present study was 
designed to evaluate and compare the efficacy of LISPRO (LP) with lithium carbonate (LC) and 
lithium salicylate (LS) for ameliorating cognitive impairments and associated neuropsychiatric 
signs, including depression, anxiety, irritability, and impaired locomotor function, in 
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APPSWE/PS1dE9 mice, a commonly used transgenic model of AD.  Female APPSWE/PS1dE9 mice 
at 4 months of age were orally treated with LP, LS, or LC for 9 months at 2.25 mmol lithium/kg/day 
followed by determination of body weight, growth of internal organs, and cognitive and non-
cognitive behavior. Untreated age-matched non-transgenic littermates (B6C3F1/J) served as wild-
type (WT) controls.  No significant differences in body weight, brain, heart, lung, spleen, liver or 
kidney were found between lithium treated- and untreated APPSWE/PS1dE9 cohorts.  LP treatment 
improved cognitive function, as shown by lower escape latency during training and probe trial of 
the Morris water maze (MWM) test and longer contextual freezing time during the fear 
conditioning test.  LP treatment also reduced depression, as assessed by tail suspension test, and 
irritability, as assessed by touch escape test.  Moreover, LP treatment afforded superior protection 
against cognitive impairment as determined by contextual fear conditioning test and irritability in 
comparison with LC or LS treatment.  However, lithium treatment did not alter anxiety or 
locomotor activity as assessed by open field, elevated plus maze or accelerated rotarod test.  We 
suggest that chronic LISPRO treatment prevent cognitive deficits, depression and irritability in 
female APPSWE/PS1dE9 mice, and is superior in improving associative learning and memory and 
irritability compared with lithium salicylate or carbonate treatments, supporting the potential of 
this lithium formulation for the treatment of AD. 
 
Background 
Alzheimer’s disease (AD) is characterized pathologically by the accumulation of neuritic 
plaques [1] and neurofibrillary tangles [2]  in the brain and clinically by a progressive decline in 
cognitive function.  As total neuronal volumes positively correlated with memory and cognitive 
function [240], the degeneration of neural synapses especially in the hippocampus and cortical 
regions is also positively correlated with cognitive decline in patients with AD [241][242].  It is 
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widely believed that abnormal accumulation of plaques and tangles consisting of amyloid-β (Aβ) 
[194] and hyperphosphorylated tau [195] proteins, respectively, promotes neurodegeneration 
[243] which may be involved in the development of cognitive and neuropsychiatric problems 
[244].  More recently, soluble oligomeric forms of Aβ and tau have been shown as the most toxic 
form of Aβ and tau aggregate to produce cognitive deficits in the absence of Aβ plaques or 
insoluble intraneuronal tangles [245][246][247].  In addition, other emotional problems, such as 
depression, anxiety, apathy, irritation, agitation and aggression, gradually develop in patients with 
AD [248].  No single drug has been shown to be effective in improving both cognitive and non-
cognitive problems.  
Lithium salts were initially used in the treatment of gout (including “brain gout”) as early 
as 1859 and then recognized for its beneficial effects on mood by the late 1800’s [198].  Despite 
having a narrow therapeutic window that requires routine blood monitoring to avoid lithium 
toxicity and associated side effects, lithium salts are still considered even today as the gold standard 
by many clinicians for preventing the reoccurrence of mania and suicidality in bipolar patients 
[249][250].  Based in part on evidence that lithium therapy may prevent cognitive decline in 
bipolar disorder, a growing body of studies using diverse preclinical and clinical models have 
provided evidence for potential disease modifying properties of lithium in treating 
neurodegenerative diseases, including AD [251].  Overall, the available evidence suggest that the 
neuroprotective effects of lithium found in diverse preclinical models of neurodegeneration 
translate into therapeutic benefits in cognitive function and reduced biomarkers in clinical trials of 
mild cognitively impaired amnestic and AD patients at lower lithium doses than those typically 
used for mood stabilization [252].  Other studies also suggest that long-term lithium treatment 
inhibits or slows down the core pathophysiologic features of AD in preclinical as well in human 
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study [253][254].  Notably, in a recent review of 28 psychiatric medications, including 
antipsychotics, anticonvulsants and antidepressants, lithium had the most replicated evidence for 
neuroprotection in the widest range of neurodegenerative disease models [255].  Despite these 
potential benefits of lithium pharmaceutics, safety issues remain.  Indeed, current Food and Drug 
Administration (FDA)-approved lithium pharmaceutics have a narrow therapeutic window, 
producing a sharp peak in the serum blood levels which can cause adverse side effects.  In addition, 
due to competition for sodium reuptake, high levels of lithium can accumulate in the kidney under 
certain conditions resulting in renal inflammation and toxicity [256]. 
To improve lithium’s therapeutic profile, we have recently investigated the safety, 
pharmacokinetics, and therapeutic efficacy of LISPRO, a novel ionic co-crystal of lithium 
salicylate and l-proline [87], in comparison with lithium carbonate and lithium salicylate in 
preclinical models of AD [150].  We found that 8- as well as 28-week oral treatment with LISPRO 
produced superior reduction of hippocampal brain pathology, including A plaque deposition, tau 
hyperphosphorylation, neuroinflammation, and neurodegeneration, in transgenic Alzheimer’s-like 
mice models.  Similarly, in cell culture studies, LISPRO reduced tau hyperphosphorylation, 
microglial inflammation and glycogen synthase kinase 3-beta activity and was superior to lithium 
carbonate in enhancing neuronal stem cell differentiation.  In addition, pharmacokinetic studies 
indicated that LISPRO treatment provided significantly higher brain lithium levels and more 
steady plasma lithium levels in both normal and transgenic Alzheimer’s-like mice when compared 
to lithium carbonate.  Moreover, a 2-week oral treatment of lithium carbonate in normal mice 
increased proinflammatory cyclooxygenase-2 expression in the kidneys, while the molar 
equivalent of lithium administered as LISPRO did not [150].  The purpose of this follow-up study 
was to compare the effects of chronic oral treatment of LISPRO with lithium carbonate and lithium 
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salicylate on behavioral impairment and various AD-associated neuropsychiatric symptoms, 
including depression, irritation, anxiety and impaired locomotion, as well as physical growth and 
development of internal organs in APPswe/PS1dE9 double transgenic mice, the most widely used 
preclinical animal model in evaluating drug safety and efficacy for AD.  For consistency, we 
employed the same chronic dosing regimen of LISPRO that was used in our prior study [150]. 
 
Materials and methods 
Animals and treatment 
Twelve-week-old (3 months of age) female transgenic (Tg) APPswe/PS1dE9 mice [B6C3-
Tg (APPswe/PS1dE9)85Dbo/Mmjax; Stock #034829; n = 28) and wild-type (WT) non-transgenic 
control littermates (Non-Tg Ctrl, B6C3F1/J; n = 10) were obtained from Jackson Laboratory (Bar 
Harbor, ME) and housed 3-4 mouse per cage before starting treatment.  APPswe/PS1dE9 mice 
express human amyloid precursor protein (APP) with the K670N/M671L (Swedish) mutation and 
human presenilin 1 (PS1) with the deltaE9 mutation, both under control of the prion promoter.  
The Swedish mutation results in an increase in BACE1 cleavage of APP and the deltaE9 mutation 
increases γ-secretase activity.  These mice  show plaque deposits at 6 months of age, and increasing 
cognitive impairment at 12 months of age [257][258].   APPSWE/PS1dE9 mice were randomly 
assigned into four treatment groups, and starting at 4 months of age received normal chow (Tg-
Ctrl, Lithium, 0%, n = 8) or chow that contained lithium carbonate (LC, 0.05%, equivalent to 83 
mg/kg/day, n = 6), lithium salicylate (LS, 0.20%, equivalent to 325 mg/kg/day, n = 6) or lithium 
salicylate proline co-crystal (LP, 0.35%, equivalent to 583 mg/kg/day, n = 8) for 9-months. This 
gave a dose of lithium at 2.25 mmol lithium/kg/day for each formulation.  This dosage was chosen 
to give brain lithium concentrations of 0.25-0.5 mmol/L, which fall in the range of clinical therapy 
for AD [150] [200].  Non-transgenic wild type (WT) littermates cohort (Non-Tg Ctrl, n = 10) were 
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fed normal chow diet as a control.  At the end of 8-months treatment (12 months of age) 
comprehensive cognitive and non-cognitive evaluations (Figure 5-1) were conducted by 
individuals blind to genotype and treatment group [160].  All animal experiments were performed 
in accordance with the guidelines of the National Institutes of Health and were approved by USF 
Institutional Animal Care and Use Committee (IACUC reference number: IS000002240). 
 
Behavioral assays 
Morris water maze 
The Morris Water Maze (MWM) is used to investigate hippocampal spatial memory 
impairments in rodents.  The apparatus consists of a circular tank (150 × 85 cm) filled with water 
(25 ± 2 0C).  The circular tank was divided into four invisible quadrants (North, South, East, West) 
using ANY-MazeTM video recording software.  To increase the tracking sensitivity, white paint 
solution was mixed in the water to provide contrast to the dark color of the mouse and facilitate 
tracking of mouse movement. In the study reported here, a hidden platform was placed 1 cm 
beneath the water level in North East zone during the training period (4 trials) for two consecutive 
days, during which time individual mouse was placed in the tank and were allowed to find the 
platform.   Over multiple trials wherein the mouse is placed in the tank at different locations, the 
mouse learns to find the hidden platform within 60 s by using distal spatial learning cues, here 
consisting of colored objects placed on the walls outside of the water tank but in view of the mouse.  
If the mouse failed to locate the hidden platform within 60 s, it was guided to the platform and 
allowed to stay there for 10 - 20 s.  Spatial memory was evaluated by assessing the average latency 
time (in seconds) and path length of a mouse before reaching the hidden platform.  Twenty-four 
hours following the end of the last trial each mouse was given a 60 s probe trial, which determines 
the ability of the mouse to retrieve learned information. During probe trial, the hidden platform is 
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removed, and parameters such as escape latency (time to reach the previous platform position), 
time spent in the platform quadrant, crossings over the platform and total distance travelled were 
recorded using automated ANY-MazeTM video software. 
 
Fear conditioning 
Fear Conditioning (FC) assesses the ability of rodents to learn and memorize the 
association between environmental cues (context) and aversive stimuli (cued).  This test is used to 
investigate hippocampal- (contextual), as well as amygdala-dependent (cued) memory functions, 
as indicated by the freezing response (complete absence of movement except respiration).  The 
mouse learns rapidly in an environment where the aversive stimulus consists of conditioned (white 
tone) and unconditioned stimuli (shock).  The experimental set-up consists of a transparent 
Plexiglas box with a photo beam detection system and an electric shock generator wired to a grid 
in the floor on the box.  On Day 1 a mouse was placed in the chamber and allowed to explore 
freely for 6 min during which baseline freezing time (conditioning) was observed using automated 
video recording software.  After 3 min, an auditory stimulus (80 dB tone) was given for 30 s 
followed by a 0.35 mA mild foot shock for 2s.  Two minutes later another conditioned-
unconditioned pairing was given.  The mouse was then removed from the chamber and returned 
to the home cage.  At Days 2, 7, and 21, each mouse was placed back to the chamber for 6 min 
without any shock and the freezing time was recorded (contextual response).  Similarly, the mouse 
was the placed in the chamber for 6 min after changing contextual cues with a few drops of vanilla 
extract, the auditory stimulus (80 dB tone) was delivered during the last 3 min, and freezing time 
was recorded (cued response).    
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Elevated plus maze 
Elevated Plus Maze (EPM) is used extensively with the open field test to assess anxiety-
like behavior.  The apparatus is elevated 50 cm above the ground and consists of four arms of 60 
x 20 cm at 90o, two open and two closed with elevated walls of 40 cm, and a central square of 10 
× 10 cm dimension.  In this study, each mouse was placed in the center of the maze facing an open 
arm and the video tracking software is used to record arm entries for 5 min.  Mice that stay in the 
closed arms of the EPM are thought to be exhibiting anxiety-like behavior, whereas those 
frequently exploring open arms are considered to be exhibiting less anxiety behavior. 
 
Open field test 
The Open Field (OF) test is used to evaluate anxiety-like behavior by placing the mouse in a cubic 
(1m x 1m x 1m) box with walls to prevent the escape of the mouse.  The open field is comprised 
of peripheral and central areas marked with a grid and square crossings. Video tracking software 
is used to separate the open field into peripheral and central areas of the grid.  The mouse is placed 
in the center of the open field and allowed to freely move for 10 min under adequate lighting 
without any background noise and odors, while tracking total distance travelled and times spent in 
the open and periphery using video tracking software.  The amount of time spent or number of 
entries into central area is indicative of reduced level of anxiety, while more time spent in the 
periphery indicates higher anxiety level. 
 
 
Tail suspension test 
Depression-related behaviors and antidepressant activity of drugs can be studied in the 
mouse using tail suspension test.  In this test, a mouse is suspended above a surface by anchoring 
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the tail with tape and is observed for its efforts to escape for 300 s. The duration of periods of 
attempts to escape (agitation) and immobility is recorded with a stopwatch.   
 
Touch escape test 
The Touch Escape test is a non-cognitive behavior test used to analyze the irritability of 
the animal in response to touch as summarized by SHIRPA (Smithkline Beecham, Harwell, 
Imperial College, Royal London Hospital, Phenotype assessment) [259]. To determine Touch 
Escape, each mouse was taken from the home cage and placed on a table.  The evaluator brushed 
the sides and back of the mouse from behind starting from the upper front of the thorax then slowly 
moving caudally to its tail while evaluating its irritability.  A Touch Escape score from 0 to 2 was 
determined with the following scale: “0” included freezing, or no progression or regression of 
movement from the evaluator’s hand, score “1” comprised of startle responses like agitation, small 
jump, jerk, twitching followed by a small amount of progression away from the evaluator, score 
“2” included jumping or quick progressive movements away from the evaluator and/or biting.  
 
Accelerated rotarod test 
Briefly, mice were placed on a rotating rod beam, which underwent an acceleration from 
4 to 40 rotations per minute (RPM) over 5 min for three consecutive trials separated by a 60 min 
interval, and latencies to fall as well as maximal speed before falling were determined.  The amount 
of time a mouse remains on the accelerating rotating beam is an index of motor coordination.  
 
Statistical analysis 
All data are presented as mean ± SEM.  We used t-test for two groups’ comparison, while 
comparison between more than two groups was analyzed by ANOVA followed by Tukey’s honest 
significant difference post hoc analyses.  Alpha was set at 0.05 for all analyses.  Statistical analyses 
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were performed using the Statistical Package for the Social Sciences (SPSS), release 24.0 (IBM, 
Armonk, NY). 
 
Results 
LISPRO did not affect body weight in female APPSWE/PS1dE9 mice 
Among the long-term adverse effects, lithium therapy is associated with weight gain in a 
subset of bipolar patients through an unknown mechanism.  But contradictory results also exist 
regarding effects of  lithium treatment on weight gain or loss in both rodents and humans [260]. 
To investigate whether LP, LS, and LC treatment had any effect on weight gain in APPSWE/PS1dE9 
mice, body weights of mice were measured at the beginning (4 months age) as well as at the end 
(13 months of age) of the treatment.  Nontransgenic WT control mice weighed significantly more 
than untreated transgenic APPSWE/PS1dE9 cohort both before and after the treatment period 
(Figure 5-2), presumably due to a significantly greater deposition of fat tissue in nontransgenic 
WT compared with transgenic APPSWE/PS1dE9 mice.  However, no statistically significant 
difference in body weight was found between untreated transgenic APPSWE/PS1dE9 mice 
receiving normal chow and those receiving LP, LS, or LC treatment for 9 months [Before 
treatment, Age = 4 months, F (4, 36) =13.142; p < 0.001; Non-Tg Ctrl vs. Tg-Ctrl: p < 0.001; LP 
vs. Tg-Ctrl: p = 0.933; LP vs. LC: p = 1.000; LP vs. LS: p = 0.790. After treatment, Age = 13 
months, F (4, 36) =18.359; p < 0.001; Non-Tg vs. Tg-Ctrl: p < 0.001; LP vs. Tg-Ctrl: p = 0.992; 
LP vs. LC: p = 0.995; LP vs. LS: p = 0.937.] 
 
LISPRO did not adversely affect the growth of internal organs in APPSWE/PS1dE9 mice 
Lithium treatment has been shown to influence the functions of endocrine hormones 
regulating growth and development of internal organs in mice [261].  Therefore, we wanted to 
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examine if long-term lithium treatment would adversely affect the growth of internal organs in 
female transgenic APPSWE/PS1dE9 AD mice.  To our knowledge, no such data is available on the 
long-term effect of LP, LC, and LS treatments on organ development in these mice. At sacrifice, 
post-hoc analysis showed statistically significant decrease in weights of brain (Figure 5-3a, left 
panel), liver (Figure 5-3b, left panel) and kidneys (Figure 5-3b, center panel) in untreated 
transgenic APPSWE/PS1dE9 cohort compared with non-transgenic WT control mice.  However, 
the weights of heart, lung and spleen were not significantly different between untreated transgenic 
APPSWE/PS1dE9 and nontransgenic WT control.  In addition, lithium treatment did not significantly 
alter the weight of any organ in transgenic mice, indicating no adverse effect of lithium treatment 
on growth of these organs.  [Brain, F (4, 36) = 2.889; p = 0.038; Non-Tg Ctrl vs. Tg-Ctrl: p = 
0.066; LP vs. Tg-Ctrl: p = 0.967; LP vs. LC: p = 0.688; LP vs. LS: p = 0.992.  Heart, F (4, 36) = 
2.048; p = 0.111; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.763; LP vs. Tg-Ctrl: p = 0.630; LP vs. LC: p = 
0.592; LP vs. LS: p = 0.943.  Lung, F (4, 36) = 0.815; p = 0.525; Non-Tg Ctrl vs. Tg-Ctrl: p = 
1.000; LP vs. Tg-Ctrl: p = 0.947; LP vs. LC: p = 0.873; LP vs. LS: p = 1.000.  Liver, F (4, 36) 
=16.049; p = 0.0001; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.0001; LP vs. Tg-Ctrl: p = 0.442; LP vs. LC: 
p = 0.999; LP vs. LS: p = 1.000.  Kidneys, F (4, 36) = 13.551; p = 0.0001; Non-Tg Ctrl vs. Tg-
Ctrl: p = 0.0001; LP vs. Tg-Ctrl: p = 0.998; LP vs. LC: p = 0.675; LP vs. LS: p = 0.983.  Spleen, 
F (4, 36) = 2.813; p = 0.042; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.711; LP vs. Tg-Ctrl: p = 0.366; LP vs. 
LC: p = 0.324; LP vs. LS: p = 0.377.] 
   
Improvement of spatial memory deficits in female APPSWE/PS1dE9 mice by LISPRO 
treatment 
 
Within the medial temporal lobes, the hippocampus has been considered to be critical for 
spatial memory function and is therefore the focus of this study.  In our previous study, we found 
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that LISPRO treatment prevents the progression of amyloid deposition in the hippocampus and 
cortex in Tg2576 and 3xTg-AD mice models [150]. Due to abundant amyloid deposition in the 
cortex and hippocampus by twelve months of age, the transgenic APPSWE/PS1dE9 mouse model 
of AD also shows spatial and stress-induced memory deficits.  To examine whether long-term 
LISPRO treatment ameliorates spatial learning and memory deficits in this AD model, the MWM 
test was conducted after 8-months of treatment, when the mice were approximately 12 months of 
age.  All groups showed a gradual decrease in escape latency to find the hidden platform in second 
and third trials of training (Trial 1 vs. Trial 2 and Trial 2 vs. Trial 3: p < 0.05; in all five groups; 
Figure 5-4a), indicating the learning ability of all mice throughout the training period. At probe 
trial, untreated transgenic APPSWE/PS1dE9 mice showed longer escape latencies compared to non-
transgenic WT control mice, confirming an AD-associated learning and memory deficit as 
determined by the MWM test (Figure 5-4b).  In addition, LP-treatment significantly reduced the 
time to find the target platform compared with the untreated transgenic APPSWE/PS1dE9 mice, 
suggesting that LISPRO ameliorates spatial memory deficits in these mice.  Although LP treatment 
reduced the latency to find the target platform compared with LC and LS treatment, this difference 
was not statistically significant.   Thus, long-term treatment with LISPRO, LC, or LS protects 
against memory loss in transgenic APPSWE/PS1dE9 mice. Transgenic mice also spent significantly 
less time in the target quadrant compared with nontransgenic WT control mice, but this time was 
not altered with lithium treatment (Figure 5-4c).  Swimming distance and speed was not 
significantly different between untreated and lithium treated transgenic and WT control mice 
(Figure 5-4d & e).  [Latency at probing, F (4, 34) = 7.801; p = 0.0001, Non-Tg Ctrl vs. Tg-Ctrl: p 
= 0.0001; LP vs. Tg-Ctrl: p = 0.003; LP vs. LC: p = 0.228; LP vs. LS: p = 0.251.  Time in target 
quadrant, F (4, 34) = 3.824; p = 0.013; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.015; LP vs. Tg-Ctrl:  p = 
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0.437; LP vs. LC: p = 0.840; LP vs. LS: p = 0.720.  Swimming distance, F (4, 34) = 0.389; p = 
0.815; Non-Tg Ctrl vs. Tg-Ctrl: p = 1.000; LP vs. Tg-Ctrl:  p = 1.000; LP vs. LC: p = 0.869, LP 
vs. LS: p = 1.000.  Swimming speed, F (4, 34) = 0.265; p = 0.898; Non-Tg Ctrl vs. Tg-Ctrl: p = 
0.949; LP vs. Tg-Ctrl:  p = 1.000; LP vs. LC: p = 0.996, LP vs. LS: p = 0.999.] 
 
LISPRO treatment ameliorated contextual associative memory deficits in female 
APPSWE/PS1dE9 mice 
 
FC test is used to examine associative learning and memory in rodent models of AD by 
measuring their freezing behavior. APPSWE/PS1dE9 mice show impaired contextual FC memory 
at 3 months of age, whereas cued FC is found to be normal [262]. To examine the effect of LISPRO 
treatment on hippocampal- and amygdala-dependent memory, we examined both contextual and 
cued fear conditioning in female APPSWE/PS1dE9 mice at 12 months of age after 8 months of 
treatment.  At day 1, the baseline freezing responses were recorded where mice were exposed to 
conditioned stimulus (mild foot shock) paired with an unconditioned stimulus (audio tone).  Total 
baseline freezing time was not significantly different between non-transgenic WT and untreated 
or lithium treated transgenic APPSWE/PS1dE9 mice (Figure 5-5a).   The contextual freezing 
response was then recorded without tone at 1, 7, and 21 days after conditioning.  Freezing times 
were not significantly different between lithium treated and untreated transgenic APPSWE/PS1dE9 
mice after 1 and 7 days of conditioning (p > 0.05 in all case; data not shown).  However, untreated 
transgenic APPSWE/PS1dE9 mice exhibited significantly less freezing to the context compared 
with nontransgenic WT control mice after 21 days of conditioning (Figure 5-5b).  More 
importantly, LP-treatment significantly increased freezing times compared to untreated or LC or 
LS-treated transgenic APPSWE/PS1dE9 mice at this time point.  In addition, we also investigated 
cued FC, consisting of an audio tone without any foot shock application at days 1, 7, and 21 days 
 134 
 
after conditioning training.  No statistically significant differences in freezing time were observed 
among treatment groups for cued FC at any day after training (Figure 5-5c).  Taken together, these 
results indicated that LISPRO improves contextual memory deficits with no change in cued FC, 
suggesting prevention of hippocampal with maintenance of amygdala-dependent cognitive 
impairment in female APPSWE/PS1dE9 mice. [Baseline conditioning, F (4, 36) = 0.508, p = 0.730; 
Non-Tg Ctrl vs. Tg-Ctrl: p = 0.998; LP vs. Tg-Ctrl: p = 0.998; LP vs. LC: p = 0.970; LP vs. LS: p 
= 0.993.  Contextual FC 21 days, F (4, 36) = 6.828, p = 0.0001; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.007; 
LP vs. Tg-Ctrl: p = 0.031; LP vs. LC: p = 0.039; LP vs. LS: p = 0.044.  Cued FC, F (4, 36) = 1.445, 
p = 0.241; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.174; LP vs. Tg-Ctrl: p = 0.910; LP vs. LC: p = 1.000; 
LP vs. LS: p = 0.999.] 
 
LISPRO did not reduce anxiety-like behavior in female APPSWE/PS1dE9 mice 
It is estimated that more than eighty percent of dementia patients show non-cognitive 
psychological changes including apathy, depression, anxiety, agitation, and irritability during the 
progression of AD [263]. Thus, in this study, we examined anxiety by the open field and elevated 
plus maze tests.  APPSWE/PS1dE9 transgenic mice did not exhibit enhanced anxiety compared with 
WT mice as determined by the open field test, reflected as reduced time in center, center entries 
or distance traveled in center or enhanced time in periphery or distance traveled in periphery.  The 
transgenic mice also did not exhibit impaired locomotor activity, reflected as altered total time 
mobile.  In addition, no measure of anxiety or locomotor activity was altered by lithium treatment 
in the transgenic mice.  [Time spent in center, F (4, 36) = 2.985, p = 0.034; Non-Tg Ctrl vs. Tg-
Ctrl: p = 0.973; LP vs. Tg-Ctrl: p = 0.189; LP vs. LC: p = 0.964; LP vs. LS: p = 1.000; Figure 5-
6a.  Time spent in periphery, F (4, 36) = 0.528, p = 0.716; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.998; LP 
vs. Tg-Ctrl: p = 0.953; LP vs. LC: p = 0.958; LP vs. LS: p = 1.000; Figure 5-6b.  Center entries, F 
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(4, 36) = 0.522; p = 0.720, Non-Tg Ctrl vs. Tg-Ctrl: p = 0.721; LP vs. Tg-Ctrl: p = 0.999; LP vs. 
LC: p = 0.965; LP vs. LS: p = 0.982; Figure 5-6c.  Distance travelled in the center, F (4, 36) = 
1.242, p = 0.314; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.665; LP vs. Tg-Ctrl: p = 0.596; LP vs. LC: p = 
0.990; LP vs. LS: p = 0.421; Figure 5-6d.  Distance travelled in periphery, F (4, 36) = 5.369, p = 
0.002; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.485; LP vs. Tg-Ctrl: p = 0.880; LP vs. LC: p = 0.481; LP vs. 
LS: p = 0.931; Figure 5-6e.  Total time mobile, F (4, 36) = 4.053, p = 0.009, Non-Tg Ctrl vs. Tg-
Ctrl: p = 0.360; LP vs. Tg-Ctrl: p = 0.995; LP vs. LC: p = 0.392; LP vs. LS:  p = 0.996; Figure 5-
6f.]  
In contrast to the open field test, transgenic APPSWE/PS1dE9 mice exhibited significantly 
enhanced anxiety compared with non-transgenic WT control mice, reflected as reduced time spent 
in the open arms of the elevated plus maze test.  However, this level of anxiety was not significantly 
altered by LC, LS or LP treatment. In addition, no significant difference was found between 
nontransgenic WT and untreated and lithium-treated transgenic mice in time spent in closed arms 
or open or closed arm entries.  Overall, these results suggest that LISPRO, LC, or LS have no 
effect on anxiety-like or locomotor behavior in female APPSWE/PS1dE9 mice.  [Time spent in open 
arms, F (4, 36) = 5.913, p = 0.001, Non-Tg Ctrl vs. Tg-Ctrl: p = 0.020; LP vs. Tg-Ctrl: p = 0.946; 
LP vs. LC: p = 1.000; LP vs. LS: p = 0.983; Figure 5-6g.  Time spent in closed arms, F (4, 36) = 
2.307, p = 0.056; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.054; LP vs. Tg-Ctrl: p = 0.977; LP vs. LC: p = 
0.494; LP vs. LS: p = 1.000; Figure 5-6h.  Open arms entries, F (4, 36) = 1.630; p = 0.190; Non-
Tg Ctrl vs. Tg-Ctrl: p = 0.600; LP vs. Tg-Ctrl: p = 0.996; LP vs. LC: p = 0.976; LP vs. LS: p = 
1.000; Figure 5-6i.  Closed arm entries, F (4, 36) = 2.756; p = 0.044; Non-Tg Ctrl vs. Tg-Ctrl: p = 
0.680; LP vs. Tg-Ctrl: p = 0.580; LP vs. LC: p = 1.000; LP vs. LS: p = 0.759; Figure 5-6j.] 
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LISPRO prevented depression-like behavior in female APPSWE/PS1dE9 mice 
The prevalence of depression among AD patients has been reported to be 10 to 50% [264]. 
Therefore, we assessed whether 12-months old APPSWE/PS1dE9 mice with advance state of 
disease progression show depressive-like behavior and whether LISPRO treatment could reverse 
this effect as tested by tail suspension test. Mice were individually suspended by the tail from a 
horizontal stand and immobility time was recorded as an index of depressive-like behavior (Figure 
5-7a).  While transgenic APPSWE/PS1dE9 mice exhibited increased immobility time compared 
with non-transgenic WT control mice, lithium treatment with LC, LS, or LP reduced immobility 
time compared in the untreated transgenic mice.  No statistically significant difference in 
immobility time was found between LP, LC, or LS treatment. These data suggest that lithium 
treatment as LISPRO or carbonate and salicylate salt of lithium reduces depression as a secondary 
effect in the treatment of AD.  [F (4, 36) = 41.093; p = 0.001; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.0001, 
LP vs. Tg-Ctrl: p = 0.0001; LP vs. LC: p = 0.999; LP vs. LS: p = 0.971; Figure 5-7a.] 
 
LISPRO reduced irritability in female APPSWE/PS1dE9 mice 
The prevalence of irritability among AD patients was reported from 13-23% in clinical 
studies.  In addition, transgenic APPSWE/PS1dE9 mice show an increased hypersensitivity to touch 
indicative of enhanced irritability [265].   Therefore, we examined whether LISPRO treatment 
reduces irritability in transgenic APPSWE/PS1dE9 mice as determined by the touch escape test 
(Figure 5-7b) While transgenic APPSWE/PS1dE9 mice showed higher irritability compared to non-
transgenic WT control mice, as shown by its irritability score, LP treatment reduced irritability 
compared to untreated transgenic APPSWE/PS1dE9 mice.  In addition, LP treatment produced 
superior reduction of irritability compared with LC, but not LS, treatment.  [F (4, 36) = 6.272, p = 
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0.001; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.013; LP vs. Tg-Ctrl: p = 0.0001; LP vs. LC: p = 0.038; LP 
vs. LS: p = 0.132; Figure 5-7b.]    
 
LISPRO did not did not alter motor function but lithium carbonate and salicylate treatment 
improved motor function compared to LISPRO treatment in female APPSWE/PS1dE9 mice 
 
Mild tremor and weakness is one of the common side effects for patients receiving chronic 
lithium treatment [266].  Therefore, we determined whether or not long-term LISPRO treatment 
changes motor coordination and performance in transgenic APPSWE/PS1dE9 mice, as determined 
using the accelerated rotarod test.  All mice showed learning of motor functions as indicated by 
longer time spent on the rod and higher speed at fall over the course of three consecutive trials 
(Trial 1 vs. Trial 2: p < 0.05, within each cohort; Trial 2 vs. Trial 3: p < 0.05, within each cohort 
except LS, Figure 5-8c & d).  There was no significant difference in time spent on the rod or speed 
at fall (RPM) between nontransgenic WT and untreated and LP-treated transgenic 
APPSWE/PS1dE9 mice.  However, LC and LS treatment significantly increased motor function 
compared to LP treatment as shown by increased latency to fall and higher speed at fall.  Therefore, 
LP treatment did not alter motor function in APPSWE/PS1dE9 mice, but LC and LS treatment 
showed improved motor function compared to LP treatment.  [Latency to fall, F (4, 107) = 3.633; 
p = 0.008; Non-Tg Ctrl vs. Tg-Ctrl: p = 0.943; LP vs. Tg-Ctrl: p = 0.623; LP vs. LC: p = 0.018; 
LP vs. LS: p = 0.024; Figure 5-8a.  Speed at fall, F (4, 107) = 3.587; p = 0.009; Non-Tg Ctrl vs. 
Tg-Ctrl: p = 0.962; LP vs. Tg-Ctrl: p = 0.568; LP vs. LC: p = 0.016; LP vs. LS: p = 0.028; Figure 
5-8b.] 
 
Discussion 
Currently available medications approved by the FDA for the treatment of Alzheimer’s 
disease only mildly reduce certain cognitive symptoms, but do not prevent the disease or slow its 
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progression.  However, a growing body of both translational and preclinical evidence suggests that 
lithium may potentially have significant disease modifying therapeutic benefits for patients with 
mild cognitive impairment or early stage AD [200][92].  Although a few studies reported no effect 
of lithium chloride on A levels [267][268] or even neurodegeneration induced by tau suppression 
[269], the overriding evidence indicates that lithium treatment effectively reduces extracellular β-
amyloid [150][270] and tau hyperphosphorylation in cell culture and animal models of AD 
[267][271]. Likewise, intracerebroventricular injection of Aβ in zebrafish embryo impairs 
cognition which was successfully reversed by lithium administration [271]. Lithium has been 
shown to ameliorate neuropathology and restore hippocampal neurogenesis in Ts65Dn mice, a 
transgenic model of Down Syndrome, in which chromosome 21 with its APP gene is inherited in 
triplicate [272]. Gelfo et al. (2017) recently investigated the potential beneficial effects of a 30-
day oral lithium treatment (0.24% lithium in diet) in preventing neuropathology and cognitive 
dysfunction following basal forebrain cholinergic neurodegeneration in rats.   While lithium 
treatment did not affect choline acetyltransferase and caspase-3 activity, it significantly rescued 
memory deficits suggesting that lithium’s therapeutic effects were not dependent on the 
cholinergic system [273]. Using a rat hippocampal neuron model, Dwivedi et al. (2015) reported 
that lithium-induced neuroprotection is associated with epigenetic modification of brain-derived 
neurotrophic factor (BDNF) gene promoter and altered expression of apoptotic-regulatory proteins 
[274].  
In an initial open label feasibility and tolerability clinical trial in mild to moderate AD 
patients, no significant effects of lithium on cognition were observed after 1 year of treatment 
[275]. In another single blind multi-center trial in mild to moderate AD patients, no significant 
effects on cognition were observed after 10 weeks [276]. However, in these early clinical studies, 
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the dosage was titrated to reach a target serum lithium level based on the prophylaxis range (0.5-
0.8 mmol/L) typically used for the maintenance of bipolar disorder.  In a more recent double-blind 
placebo controlled disease modification trial, subjects with mild cognitive impairment (MCI) who 
received lower levels of lithium (0.25-0.5 mmol/L) had significantly lower conversion rates to AD 
than those receiving placebo [200]. Moreover, those who had received lithium had significantly 
lower CSF phospho-tau levels as well as better compliance and performance on the cognitive 
subscale of the Alzheimer's disease Assessment Scale [200].   In another double-blind, placebo 
control trial, microdoses (300 µg) of lithium daily for 15 months prevented cognitive decline in 
AD patients as measured by the mini-mental state examination (MMSE) compared to placebo, 
with the benefits starting after 6 months and persisting until the end of trial [202].  In addition, 
chronic lithium treatment has been also shown to increase the serum levels of BDNF in patients 
with early AD [277], which could be responsible for cognitive enhancement. 
Despite the therapeutic potential for lithium in the treatment of AD neuropathology and 
cognitive impairment, lithium formulations currently available exhibit a narrow therapeutic 
window with an increased risk of side effects and noncompliance in elderly populations [278].  
With the goal of improving lithium’s therapeutic profile, we have been investigating the safety, 
pharmacokinetics, and therapeutic efficacy of LISPRO, a novel ionic co-crystal of lithium 
salicylate and l-proline, compared with lithium carbonate and lithium salicylate across a host of 
preclinical models of AD. Employing the same chronic dosage regimen found to reduce AD-like 
neuropathology in our previous study, the major findings of the present study was that chronic 8-
month oral treatment with LISPRO ameliorated spatial (Figure 5-4b) and contextual memory 
deficits (Figure 5-5b) typically found in female APPSWE/PS1dE9 mice at 12 months of age, without 
adversely effecting body or internal organ development (Figure 5-3a-b), anxiety (Figure 5-6) or 
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motor function (Figure 5-8). This improved spatial and associative memory function could be 
mediated through restoration of pre-and post-synaptic protein functions, which is shown in our 
previous study [150].  A further electrophysiological study is necessary to reveal the protective 
synaptic functions of LISPRO treatment. 
In addition, LISPRO reduced depressive like behavior as assessed in the tail suspension 
test and irritability as assessed in the touch escape test.  Similar to our previous study which found 
LISPRO to have a superior therapeutic profile for several neuropathological endpoints in cellular 
and animal models, LISPRO exhibited superior improvement in contextual memory deficits 
(Figure 5-5b), and amelioration of irritability (Figure 5-7b), compared with molar equivalent doses 
of lithium carbonate or lithium salicylate.  All three formulation LISPRO, carbonate and salicylate 
pharmaceutics of lithium, significantly improved spatial memory deficits (Figure 5-4b) and 
depressive-like behavioral symptoms (Figure 5-7a) in female transgenic APPSWE/PS1dE9 mice 
measured by tail suspension test (Figure 5-7a). Lithium carbonate and salicylate showed improved 
motor function coordination compared to LISPRO as assessed by accelerated rotarod test (Figure 
5-8). 
Secondary symptoms such as agitation and psychosis are common in AD and are associated 
with increased patient distress, increased caregiver burden, more rapid cognitive decline, greater 
risk of institutionalization and mortality, and increased health care costs.  Unfortunately, currently 
available medications used often off-label to target these secondary symptoms have been reported 
to have long term adverse effects.  For example, the FDA issued a black box warning in 2005 that 
antipsychotics significantly increased all-cause mortality in dementia. Moreover, valproic acid, a 
mood stabilizer used often off-label to treat agitation across diverse patient populations was found 
to significantly accelerate brain atrophy as determined by magnetic resonance imaging as well as 
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cognitive impairment following 1-year treatment in AD patients [279]. Therefore, the ability of 
chronic treatment with LISPRO to safely reduce AD-like neuropathology and cognitive deficits 
but also depressive like behavior and irritability in APPSWE/PS1dE9 mice has intriguing 
implications if these preclinical findings translate into clinically meaningful therapeutic benefits. 
 
 
 
 
 
 
 
 
 
 142 
 
 
 
Figure 5-1 Outline of study design.   
Female APPSWE/PS1dE9 mice at 4 months of age were fed with either regular chow (Tg-Ctrl, n = 
8) or chow that contained lithium carbonate (LC, 0.05% equivalent to 83 mg/kg/day, n = 6), 
lithium salicylate (LS, 0.20% equivalent to 325 mg/kg/day, n = 6) or lithium salicylate proline co-
crystal, LISPRO (LP, 0.35% equivalent to 583 mg/kg/day, n = 8) for 9 months.  In addition, aged-
matched non-transgenic background control mice (B6C3F1/J, Non-Tg Ctrl, n = 10) were fed 
regular chow for 9 months as control.  Each treatment group was subject to a battery of behavioral 
tests at 12 months of age and mice were sacrificed at 13 months of age. 
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Figure 5-2 Lithium treatment did not affect body weight gain in female APPSWE/PS1dE9 
mice. 
Female transgenic APPSWE/PS1dE9 mice were fed with either regular chow (Tg-Ctrl) or chow that 
contained lithium carbonate (LC), lithium salicylate (LS) or lithium salicylate proline co-crystal, 
LISPRO (LP), as described for Diagram 1.  In addition, age-matched non-transgenic WT mice 
(B6C3F1/J, Non-Tg Ctrl) were fed normal chow as control.   Each treatment group was subjected 
to body weight measurement at the beginning of treatment (4 months) and at the time of sacrifice 
(13 months).  Lithium treatment (LC, LS, or LP) for nine months had no effect on weight gain 
compared to transgenic APPSWE/PS1dE9 mice (p > 0.05 = ns).  But, non-transgenic WT cohort 
control showed significant difference of body weight compared to transgenic cohort before (Non-
Tg vs. Tg-Ctrl: ***p < 0.001) and after (Non-Tg vs. Tg-Ctrl: ***p < 0.001) the treatment. Data 
shown as means ± SEM.  [p > 0.05 = non-significant = ns; *p < 0.05; **p < 0.01; ***p < 0.001] 
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Figure 5-3 LISPRO treatments did not affect growth of internal organs in APPSWE/PS1dE9 
mice. 
The weight of brain (a, left upper panel), heart (a, middle upper panel), lung (a, right upper panel), 
liver (b, left lower panel), kidney(s) (b, middle lower panel), and spleen (b, right lower panel) were 
determined at time of sacrifice in female APPSWE/PS1dE9 cohort fed normal chow (Tg-Ctrl) or 
chow containing LC, LS, or LP as well as aged-matched non-transgenic WT control cohort fed 
normal chow (Non-Tg Ctrl), as described for Diagram 1.  No significant differences in the weight 
of internal organs were observed after 9-months treatment with LP, LC, or LS compared with 
untreated APPSWE/PS1dE9 mice (p > 0.05 = ns).  Data shown as means ± SEM.  [p > 0.05 = non-
significant = ns; *p < 0.05; **p < 0.01; ***p < 0.001] 
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Figure 5-4 Spatial memory deficits in APPSWE/PS1dE9 mice are improved by chronic 
LISPRO treatment.   
Female APPSWE/PS1dE9 and non-transgenic WT control mice were fed normal chow or chow 
containing LC, LS, or LP as described for Diagram 1 followed by MWM testing.  (a) Latency to 
find the hidden platform was determined during the training period during four trials.  During the 
training period, the untreated transgenic APPSWE/PS1dE9 cohort (Tg-Ctrl) took significantly more 
time to find the platform compared with the non-transgenic control mice (Non-Tg Ctrl), indicating 
a deficit in spatial learning.  All three lithium treatments (LC, LS, and LP) significantly reduced 
spatial learning deficit (**p < 0.01), as indicated by reduced latency, compared with the previous 
trial within the same cohort.  (b) Latency to find platform target was determined during the probe 
trial of MWM, performed 24 h after the last training trial.  Transgenic APPSWE/PS1dE9 cohort 
took more time to find the target platform than the non-transgenic WT cohort (**p < 0.01) and LP 
treatment reversed this learning deficit (**p < 0.01).  (c) Time spent in target quadrant was 
determined for probe trial. No significant differences were found in time spent in target quadrant 
for lithium treated- and transgenic cohort (p > 0.05 = ns).  In addition, no statistically significant 
differences were found in (d) total swimming distance travelled (p > 0.05 = ns) and (e) mean 
swimming speed (p > 0.05 = ns) during the probe trials. (f) Swim tracking plot during probe trial.  
Data shown as means ± SEM.  [p > 0.05 = non-significant = ns; *p < 0.05; **p < 0.01; ***p < 
0.001] 
 146 
 
 
 
Figure 5-5 LISPRO improves associative-learning and memory on contextual fear 
conditioning in female APPSWE/PS1dE9 mice.   
Female transgenic APPSWE/PS1dE9 and non-transgenic WT control cohort were fed with normal 
chow or chow containing LC, LS, or LP as described for Diagram 1, followed by contextual and 
cued fear conditioning testing.  (a) No statistically significant differences for freezing time were 
found during the conditioning training between non-transgenic WT control (Non-Tg Ctrl) and 
transgenic APPSWE/PS1dE9 control (Tg-Ctrl) or treated with LC, LS, or LP (p > 0.05 = ns).  (b) 
No statistically significant difference in contextual freezing times were found among transgenic 
APPSWE/PS1dE9 mice untreated or treated with LC, LS, or LP at 2 or 7 days after conditioning (p 
> 0.05).  However, contextual freezing time after 21 days-conditioning was significantly longer 
for transgenic APPSWE/PS1dE9 mice treated with LP compared with transgenic APPSWE/PS1dE9 
cohort control (*p < 0.05), LC (*p < 0.05), and LS (*p < 0.05) cohort.  (c) No statistically 
significant difference in cued freezing time was found among nontransgenic WT control and 
transgenic APPSWE/PS1dE9 cohort control or treated with LC, LS, or LP (p > 0.05 = ns, in all case) 
in the same time period recorded.  Data shown as means ± SEM. [p > 0.05 = non-significant = ns; 
*p < 0.05; **p < 0.01; ***p < 0.001] 
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Figure 5-6 LISPRO does not improve anxiety-like behavior or locomotor activity in 
APPSWE/PS1dE9 mice.   
Female APPSWE/PS1dE9 mice (Tg-Ctrl) exhibited statistically non-significant anxiety-like 
behavior and locomotor impairment as shown by (c) reduced center entries (p > 0.05) and (d) 
reduced time spent mobile (p > 0.05), respectively, compared with non-transgenic WT cohort 
control during open field testing.  No statistically significant differences were observed among 
transgenic APPSWE/PS1dE9 cohort or treated with LC, LS, or LP in (a) time spent in center or (b) 
periphery, (c) number of center entries, (d) distance travelled in center or (e) periphery or (f) total 
mobile time.  Likewise, transgenic APPSWE/PS1dE9 cohort exhibited anxiety as shown by 
statistically significant reduced (g) time spent (*p < 0.05) and (i) statistically non-significant but 
reduced entries in open arms in elevated plus maze test (p > 0.05).  Similarly, no statistically 
significant differences were observed among transgenic APPSWE/PS1dE9 cohort or treated with 
LC, LS, or LP in (g) time spent and entries (g & i) in open or (h & j) closed arms (p > 0.05; in all 
case).  Data shown as means ± SEM. [p > 0.05 = non-significant = ns; *p < 0.05; **p < 0.01; ***p 
< 0.001] 
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Figure 5-7 LISPRO reduces depressive-like behavior and irritability in APPSWE/PS1dE9 
mice. 
Female transgenic APPSWE/PS1dE9 cohort (Tg-Ctrl) exhibited depressive-like behavior compared 
with nontransgenic WT cohort control (Non-Tg Ctrl vs. Tg-Ctrl: ***p < 0.001) as shown by 
increased immobility time in tail suspension test, which was reduced by LC, LS, and LP treatment 
(a, Tg-Ctrl vs. LP: ***p < 0.001).  In addition, transgenic APPSWE/PS1dE9 cohort exhibited 
increased irritability as shown by increased irritability score in touch escape test compared to 
nontransgenic WT cohort control (Non-Tg Ctrl vs. Tg-Ctrl: *p < 0.05) , which was reversed by 
LP, and LS treatment (b, **p < 0.01).  In addition, a statistically significant reduction in irritability 
score was found between LP and LC treatment (**p < 0.01).  Data shown as means ± SEM.  [p > 
0.05 = non-significant = ns; *p < 0.05; **p < 0.01; ***p < 0.001] 
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Figure 5-8 Not LISPRO but carbonate and salicylate treatment showed improved motor 
function compared to LISPRO in female APPSWE/PS1dE9 mice. 
 
Female transgenic APPSWE/PS1dE9 cohort control (Tg Ctrl) did not exhibit altered motor 
coordination compared with nontransgenic WT cohort control (Non-Tg Ctrl), as determined by (a) 
latency to fall (Non-Tg Ctrl vs. Tg-Ctrl: p > 0.05 = ns) or (b) RPM at fall (Non-Tg Ctrl vs. Tg-
Ctrl: p > 0.05 = ns) throughout three consecutive trials of accelerated rotarod testing.  In addition, 
motor coordination did not differ between transgenic APPSWE/PS1dE9 and LP treated cohort (LP 
vs. Tg-Ctrl: p > 0.05 = ns). Both LC and LS treatment showed improved motor function compared 
to LISPRO during (a) latency at fall (LP vs. LC: p < 0.01; LP vs. LS: p < 0.01) and (b) lower speed 
at fall [LP vs. LC: p < 0.01; LP vs. LS: p < 0.01).  Both non-transgenic WT control and transgenic 
treated or control exhibited enhanced motor function learning compared with the previous trials as 
determined by (c) increased latency to fall and (d) increased maximum speed at fall over three 
consecutive trials.  Data shown as means ± SEM.  [p > 0.05 = non-significant = ns; *p < 0.05; **p 
< 0.01; ***p < 0.001] 
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CHAPTER 6 
 
DISCUSSION 
 
               AD is the most common cause of dementia among the elderly. APP is strongly implicated 
in dysregulated amyloidogenic processing, synthesis, and subsequent release of Aβ peptides. The 
aggregation of Aβ peptides as plaques and accumulation of hyperphosphorylated tau as 
neurofibrillary tangles are two core AD neuropathological features. Neuronal dysfunction and cell 
death occurs as a result of protein misfolding and aggregations. Progressive neurodegeneration in 
the cortex and hippocampus causes atrophy (shrinkage) and ventricular enlargement, particularly 
involving the frontal, parietal, and temporal lobes. The disease progress is associated with gradual 
cognitive deterioration and associated decline in different aspects of daily life activities which 
include working memory, language, and executive functions such as organization and planning. 
To date, no effective disease-modifying treatments exist for AD. Currently available treatments of 
AD include acetylcholinesterase inhibitor and NMDA- receptor antagonist, which are safe and 
reported to show mild to moderate symptomatic benefits in several independent studies. However, 
these drugs do not stop the deterioration of cognitive functions in AD patients. Therapeutic 
approaches that lower or inhibit the formation of Aβ and restrain the pathological transformation 
of tau are capable of slowing down disease progression. The development of novel drugs for AD 
with strong disease-modifying approaches is one of the biggest unmet clinical needs in global 
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health care system. Thus, the search for novel biological and pharmacological approaches targeting 
the molecular events underlying the pathogenesis has been a major goal of our research.  
              Research in recent years has indicated that blood circulatory system can modulate brain 
physiology and pathology in normal aging and neurodegenerative conditions such as AD. Factors 
those are required for maintenance of tissue homeostasis start to decrease, while factors involved 
in injury-repair and inflammation increase as we get older [40]. In a study of parabiosis, a 
surgically connecting shared blood system of 3- and 18- month- old mouse study showed increased 
number of neural stem cells, increased activity of synapses, increased expression of genes involved 
in formation of new memories, and decreased inflammation in this model of old mouse brain [41]. 
The same group also discovered that soluble factors responsible for this beneficial effect in young-
old parabiosis mouse model, as no evidence of blood cells entry was found in the brain [75]. More 
interestingly, studies on a mouse model for aging have shown that intravenously transfused young 
human plasma rejuvenate age-related changes in old mice brain and improve cognitive function as 
assessed via Barnes maze test [156]. Such results indicate that soluble factors in young blood 
possess enormous potential to reverse age-related impairments in the brain structure and cognitive 
functions. Beyond aging studies, one of our collaborators also performed a parabiosis study by 
joining transgenic APPswe/PS1dE9 amyloid and WT aged-matched background control mice. The 
study data show that peripheral system plays crucial role in the clearance of Aβ in transgenic 
APPswe/PS1dE9 AD mice [157]. Recent advances in cord blood research emphasize the 
therapeutic possibility of HUCBC in several CNS disorders including AD. HUCBC possess anti-
inflammatory and immune modulatory potential with self-renewal capabilities. We hypothesized 
that HUCBS may also possess anti-inflammatory immunomodulatory therapeutic potential for AD 
and other dementias. The study outlined in this PhD dissertation is the first to demonstrate that 
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HUCBS contain α-secretase-like enzyme that has significant potential to produce sAPPα compared 
to adult and aged blood serum (Chapter 2). In this study, we have isolated and purified a fraction 
enriched in α-secretase like enzyme (termed as α-CBSF) from HUCBS with thousand-fold more 
sAPPα producing capacity than the original fraction. Identification and purification of this novel 
enzyme has enormous therapeutic significance for subset of patients suffering from AD with low 
levels of sAPPα. The neuroprotective functions of sAPPα in neuronal environment have been 
evidenced by several independent studies [56]. As outlined in the introduction, sAPPα has 
neurotrophic and neuroprotective properties by preventing neuronal cell death in AD brain. 
Additionally, others and we have shown that sAPPα decrease amyloid [42] and tau pathology [43] 
by inhibiting BACE1 and GSK3β enzyme in rodent models. While the neuroprotective and anti-
AD effect of sAPPα is well established, αCBSF infusion for 6 weeks via osmotic minipump 
showed improvement of cognitive functions and reduction of amyloid load in cerebral cortex and 
hippocampus in transgenic 5XFAD mice. In further studies, we tried to identify the heat-sensitive 
protein factor(s) from αCBSF. Our study identified a novel role for complement protein C1 in the 
cell culture system. Multi-step fractionation followed by LC-MS/MS analyses of αCBSF has 
identified several proteins compared to AgBSF, each of which could potentially generate sAPP 
by cleaving APP in cellular system. Utilizing in vitro CHO/APPwt, N2a/APPwt, and TgAPPwt 
primary neuronal cell lines, we found that α-secretase-like enzyme produce sAPP may be 
mediated by complement protein C1 (Chapter 3). This result indicates that complement protein C1 
might play a crucial role in the brain during APP processing and progression of AD. Although our 
preliminary data suggest that complement protein C1 is a novel candidate for APP cleavage in 
cellular condition, further investigation is needed to translate these findings in preclinical models 
brain. 
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Lithium has a long history in treating bipolar disorder and other psychiatric conditions. In 
1859, Lange used lithium as a prophylactic for depressive illness. After a long break, Cade in 1949 
reintroduced lithium salts to treat manic-depressive illness, currently known as bipolar disorder. 
Subsequently in 1954, Schou and colleagues conducted the first randomized controlled trial and 
showed that lithium salt has better anti-manic treatment effects compared to electroconvulsive 
therapy [198]. Despite the strong evidence that lithium salt has neuroprotective potential to treat 
several diseases, currently available lithium pharmaceutics exhibit a narrow therapeutic window 
with an increased risk of side effects and noncompliance in elderly populations [278]. To examine 
lithium’s therapeutic profile, we have investigated the safety, pharmacokinetics, and therapeutic 
efficacy of LISPRO, in comparison with lithium carbonate and the parent lithium salicylate salts 
in preclinical models of AD.  Pharmacokinetic studies indicated that LISPRO provided 
significantly higher brain lithium levels and more steady plasma lithium levels in both normal and 
transgenic Alzheimer’s-like mice when compared to lithium carbonate. We predict that LISPRO 
might prevent the drastic change of lithium levels in the plasma seen with current lithium drugs, 
maintain stable therapeutic doses and, thus, would represent a significant improvement over 
current lithium medicines for a desired time by slow-release into the peripheral blood. While 
examining the inflammatory safety profiles, a 2-week oral treatment of lithium carbonate in normal 
mice increased proinflammatory cyclooxygenase-2 expression in the kidneys, while the molar 
equivalent of lithium administered as LISPRO did not.  Although lithium has anti-inflammatory 
properties, several studies indicate that chronic administration of lithium might induce COX2 
expression through inhibition of GSK3β activity. Our data also showed that both lithium carbonate 
and LISPRO inactivate GSK3β, but only lithium carbonate activates COX2 whereas LISPRO 
suppresses COX2 due to the anti-inflammatory properties of the salicylate anion. While 
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investigating the therapeutic efficacy, we found that 8- as well as 28-week treatment with LISPRO 
produced superior reduction of hippocampal brain pathology, including A plaque deposition, 
neuroinflammation, and neurodegeneration in transgenic Alzheimer’s-like mice models [150]. It 
has been reported that lithium prevents the generation of Aβ peptides by inhibiting GSK3α activity, 
which interferes with APP γ-secretase cleavage. Addition of salicylate, which is the primary 
metabolite derivative of acetyl-salicylic acid, improves the safety and might modify the 
pharmacological action of lithium.  Moreover, several lines of evidence demonstrated that lithium 
is a direct inhibitor of GSK3β and also increases the inhibitory serine-phosphorylation. Using 
human HeLa/tau, human neuroblastoma SHSY-5Y, and primary neuronal cell lines, we found that 
LISPRO inhibits phosphorylation of tau, which is associated with increasing inhibitory 
phosphorylation of GSK3β (Ser9). Additionally, both 8- and 28-week LISPRO treatment 
significantly reduces p-tau (Thr231) phosphorylation compared to Li2CO3 and control in Tg2576 
and 3XTg-AD mice tested using immunohistochemistry [p-tau (Thr231) and p-tau (Ser396)] and 
western blot analyses [p-tau (Ser396, Ser404, Thr181, and Thr231)], and in many cases lithium 
salicylate, significantly attenuates tau phosphorylation compared to lithium carbonate and control.  
Taken together, these findings indicated that LISPRO inactivates GSK3β activity, and thereby 
reduces tau phosphorylation, microglial inflammation, GSK3β activity, and was superior to 
lithium carbonate in enhancing neuronal stem cell differentiation (Chapter 4). While examining 
the effect of LISPRO and other two lithium drugs on behavioral functions, we found that LISPRO 
exhibited superior improvement in contextual memory deficits, and amelioration of irritability, 
compared with molar equivalent doses of lithium carbonate or lithium salicylate.  All three 
formulations LISPRO, carbonate and salicylate pharmaceutics of lithium, significantly improved 
spatial memory deficits and depressive-like behavioral symptoms in transgenic APPswe/PS1dE9 
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mice measured by tail suspension test. Lithium carbonate and salicylate showed improved motor 
function coordination compared to LISPRO as assessed by accelerated rotarod test (Chapter 5). 
Therefore, it is evident that chronic treatment with LISPRO can not only safely reduce AD-like 
neuropathology and cognitive deficits, but also reduce the depressive like behavior and irritability 
in APPswe/PS1dE9 mice. These preclinical findings/results have intriguing implications if they 
translate into clinically meaningful therapeutic benefits. 
  
 157 
 
 
 
 
 
 
REFERENCES 
[1] J. Hardy and D. Allsop, “Amyloid deposition as the central event in the aetiology of 
Alzheimer’s disease,” Trends Pharmacol Sci, vol. 12, no. 10, pp. 383–388, 1991. 
[2] M. Goedert, M. G. Spillantini, and R. A. Crowther, “Tau proteins and neurofibrillary 
degeneration,” Brain Pathol, vol. 1, no. 4, pp. 279–286, 1991. 
[3] J. J. Palop and L. Mucke, “Amyloid-β–induced neuronal dysfunction in Alzheimer’s 
disease: from synapses toward neural networks,” Nat. Neurosci., vol. 13, no. 7, pp. 812–
818, Jul. 2010. 
[4] Alzheimer’s Association. 2018, “2018 Alzheimer’s Disease Facts and Figures Includes a 
Special Report on the Financial and Personal Benefits of Early Diagnosis,” Alzheimers 
Dement , vol. 14, no. 3, pp. 367–429, 2018. 
[5] C. Haass and D. J. Selkoe, “Cellular processing of beta-amyloid precursor protein and the 
genesis of amyloid beta-peptide.,” Cell, vol. 75, no. 6, pp. 1039–42, Dec. 1993. 
[6] J. Kang et al., “The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-
surface receptor,” Nature, vol. 325, no. 6106, pp. 733–736, Feb. 1987. 
[7] T. Jefferson et al., “Metalloprotease Meprin β Generates Nontoxic N-terminal Amyloid 
Precursor Protein Fragments in Vivo,” J. Biol. Chem., vol. 286, no. 31, pp. 27741–27750, 
Aug. 2011. 
[8] J. Bien et al., “The Metalloprotease Meprin β Generates Amino Terminal-truncated 
Amyloid β Peptide Species,” J. Biol. Chem., vol. 287, no. 40, pp. 33304–33313, Sep. 2012. 
[9] C. Schönherr et al., “Generation of aggregation prone N-terminally truncated amyloid β 
peptides by meprin β depends on the sequence specificity at the cleavage site,” Mol. 
Neurodegener., vol. 11, no. 1, p. 19, Dec. 2016. 
[10] M. Willem et al., “η-Secretase processing of APP inhibits neuronal activity in the 
hippocampus,” Nature, vol. 526, no. 7573, pp. 443–447, Oct. 2015. 
[11] S. G. Younkin, “Evidence that Aβ42 is the real culprit in Alzheimer’s disease,” Ann. 
Neurol., vol. 37, no. 3, pp. 287–288, Mar. 1995. 
[12] T. Iwatsubo, D. M. A. Mann, A. Odaka, N. Suzuki, and Y. Ihara, “Amyloid β protein (Aβ) 
deposition: Aβ42(43) precedes Aβ40 in down Syndrome,” Ann. Neurol., vol. 37, no. 3, pp. 
294–299, Mar. 1995. 
[13] T. Maurice, B. P. Lockhart, and A. Privat, “Amnesia induced in mice by centrally 
administered beta-amyloid peptides involves cholinergic dysfunction.,” Brain Res., vol. 
706, no. 2, pp. 181–93, Jan. 1996. 
[14] J. Cleary, J. M. Hittner, M. Semotuk, P. Mantyh, and E. O’Hare, “Beta-amyloid(1-40) 
effects on behavior and memory.,” Brain Res., vol. 682, no. 1–2, pp. 69–74, Jun. 1995. 
[15] B. A. Yankner, L. R. Dawes, S. Fisher, L. Villa-Komaroff, M. L. Oster-Granite, and R. L. 
Neve, “Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer’s 
disease.,” Science, vol. 245, no. 4916, pp. 417–20, Jul. 1989. 
[16] L. Mucke and D. J. Selkoe, “Neurotoxicity of Amyloid  -Protein: Synaptic and Network 
Dysfunction,” Cold Spring Harb. Perspect. Med., vol. 2, no. 7, pp. a006338–a006338, Jul. 
 158 
 
2012. 
[17] T. L. Spires-Jones and B. T. Hyman, “The Intersection of Amyloid Beta and Tau at 
Synapses in Alzheimer’s Disease,” Neuron, vol. 82, no. 4, pp. 756–771, May 2014. 
[18] P. T. Nelson et al., “Correlation of Alzheimer Disease Neuropathologic Changes With 
Cognitive Status: A Review of the Literature,” J. Neuropathol. Exp. Neurol., vol. 71, no. 5, 
pp. 362–381, May 2012. 
[19] S. T. Ferreira, M. V. Lourenco, M. M. Oliveira, and F. G. De Felice, “Soluble amyloid-β 
oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease,” Front. 
Cell. Neurosci., vol. 9, p. 191, May 2015. 
[20] M. E. Larson and S. E. Lesné, “Soluble Aβ oligomer production and toxicity,” J. 
Neurochem., vol. 120, pp. 125–139, Jan. 2012. 
[21] C. M. Waterman-Storer, “Microtubules and microscopes: how the development of light 
microscopic imaging technologies has contributed to discoveries about microtubule 
dynamics in living cells.,” Mol. Biol. Cell, vol. 9, no. 12, pp. 3263–71, Dec. 1998. 
[22] J. Avila et al., “Tau Structures.,” Front. Aging Neurosci., vol. 8, p. 262, 2016. 
[23] A. Mietelska-Porowska, U. Wasik, M. Goras, A. Filipek, and G. Niewiadomska, “Tau 
Protein Modifications and Interactions: Their Role in Function and Dysfunction,” Int. J. 
Mol. Sci., vol. 15, no. 3, pp. 4671–4713, Mar. 2014. 
[24] L. Martin, X. Latypova, and F. Terro, “Post-translational modifications of tau protein: 
Implications for Alzheimer’s disease,” Neurochem. Int., vol. 58, no. 4, pp. 458–471, Mar. 
2011. 
[25] M. Pevalova, P. Filipcik, M. Novak, J. Avila, and K. Iqbal, “Post-translational modifications 
of tau protein.,” Bratisl. Lek. Listy, vol. 107, no. 9–10, pp. 346–53, 2006. 
[26] P. T. Nelson, H. Braak, and W. R. Markesbery, “Neuropathology and cognitive impairment 
in Alzheimer disease: a complex but coherent relationship.,” J. Neuropathol. Exp. Neurol., 
vol. 68, no. 1, pp. 1–14, Jan. 2009. 
[27] R. Cacace, K. Sleegers, and C. Van Broeckhoven, “Molecular genetics of early-onset 
Alzheimer’s disease revisited,” Alzheimer’s Dement., vol. 12, no. 6, pp. 733–748, Jun. 2016. 
[28] F. K. Wiseman et al., “A genetic cause of Alzheimer disease: mechanistic insights from 
Down syndrome.,” Nat. Rev. Neurosci., vol. 16, no. 9, pp. 564–74, Sep. 2015. 
[29] S. L. Rosenthal and M. I. Kamboh, “Late-Onset Alzheimer’s Disease Genes and the 
Potentially Implicated Pathways.,” Curr. Genet. Med. Rep., vol. 2, no. 2, pp. 85–101, 2014. 
[30] J. Cummings, G. Lee, T. Mortsdorf, A. Ritter, and K. Zhong, “Alzheimer’s disease drug 
development pipeline: 2017.,” Alzheimer’s Dement. (New York, N. Y.), vol. 3, no. 3, pp. 
367–384, Sep. 2017. 
[31] F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto, “Alzheimer’s 
disease: clinical trials and drug development.,” Lancet. Neurol., vol. 9, no. 7, pp. 702–16, 
Jul. 2010. 
[32] A. D. Bachstetter et al., “Peripheral injection of human umbilical cord blood stimulates 
neurogenesis in the aged rat brain,” BMC Neurosci., vol. 9, no. 1, p. 22, Feb. 2008. 
[33] D. Ilic, C. Miere, and E. Lazic, “Umbilical cord blood stem cells: clinical trials in non-
hematological disorders,” Br. Med. Bull., vol. 102, no. 1, pp. 43–57, Jun. 2012. 
[34] J. D. Newcomb, P. R. Sanberg, S. K. Klasko, and A. E. Willing, “Umbilical cord blood 
research: current and future perspectives.,” Cell Transplant., vol. 16, no. 2, pp. 151–8, 2007. 
 
 
 159 
 
[35] P. R. Sanberg et al., “The Treatment of Neurodegenerative Disorders Using Umbilical Cord 
Blood and Menstrual Blood-Derived Stem Cells,” Cell Transplant., vol. 20, no. 1, pp. 85–
94, Feb. 2011. 
[36] B. R. Achyut, N. R. S. Varma, and A. S. Arbab, “Application of Umbilical Cord Blood 
Derived Stem Cells in Diseases of the Nervous System,” J. Stem Cell Res. Ther., vol. 4, no. 
5, 2014. 
[37] W. V. Nikolic et al., “Peripherally Administered Human Umbilical Cord Blood Cells 
Reduce Parenchymal and Vascular beta-Amyloid Deposits in Alzheimer Mice,” Stem Cells 
Dev., vol. 17, no. 3, pp. 423–439, Jun. 2008. 
[38] D. Darlington et al., “Human Umbilical Cord Blood-Derived Monocytes Improve 
Cognitive Deficits and Reduce Amyloid-β Pathology in PSAPP Mice,” Cell Transplant., 
vol. 24, no. 11, pp. 2237–2250, Nov. 2015. 
[39] Y. Xing, Y. Wu, L. Wang, and X. Meng, “Human umbilical cord blood cell transplantation 
improves cardiac function in a myoardial infarction rat model but induces intestinal graft 
versus host disease.,” Cell. Mol. Biol. (Noisy-le-grand)., vol. 60, no. 2, pp. 6–12, Jun. 2014. 
[40] S. A. Villeda et al., “The ageing systemic milieu negatively regulates neurogenesis and 
cognitive function,” Nature, vol. 477, no. 7362, pp. 90–94, Sep. 2011. 
[41] S. A. Villeda et al., “Young blood reverses age-related impairments in cognitive function 
and synaptic plasticity in mice,” Nat. Med., vol. 20, no. 6, pp. 659–663, Jun. 2014. 
[42] D. Obregon et al., “Soluble amyloid precursor protein-alpha modulates beta-secretase 
activity and amyloid-beta generation,” Nat Commun, vol. 3, p. 777, 2012. 
[43] J. Deng et al., “Soluble amyloid precursor protein alpha inhibits tau phosphorylation 
through modulation of GSK3beta signaling pathway,” J Neurochem, vol. 135, no. 3, pp. 
630–637, 2015. 
[44] L. Lannfelt, H. Basun, L. O. Wahlund, B. A. Rowe, and S. L. Wagner, “Decreased alpha-
secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s 
disease.,” Nat. Med., vol. 1, no. 8, pp. 829–32, Aug. 1995. 
[45] K. Sennvik, J. Fastbom, M. Blomberg, L. O. Wahlund, B. Winblad, and E. Benedikz, 
“Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal 
fluid of Alzheimer’s disease patients.,” Neurosci. Lett., vol. 278, no. 3, pp. 169–72, Jan. 
2000. 
[46] Y. Goodman and M. P. Mattson, “Secreted Forms of β-Amyloid Precursor Protein Protect 
Hippocampal Neurons against Amyloid β-Peptide-Induced Oxidative Injury,” Exp. Neurol., 
vol. 128, no. 1, pp. 1–12, Jul. 1994. 
[47] M. Gralle, M. G. Botelho, and F. S. Wouters, “Neuroprotective Secreted Amyloid Precursor 
Protein Acts by Disrupting Amyloid Precursor Protein Dimers,” J. Biol. Chem., vol. 284, 
no. 22, pp. 15016–15025, May 2009. 
[48] A. Ishida, K. Furukawa, J. N. Keller, and M. P. Mattson, “Secreted form of beta-amyloid 
precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP 
in hippocampal slices.,” Neuroreport, vol. 8, no. 9–10, pp. 2133–7, Jul. 1997. 
[49] M. Hick et al., “Erratum to: Acute function of secreted amyloid precursor protein fragment 
APPsα in synaptic plasticity,” Acta Neuropathol., vol. 129, no. 1, pp. 161–162, Jan. 2015. 
[50] W. Araki et al., “Trophic effect of beta-amyloid precursor protein on cerebral cortical 
neurons in culture.,” Biochem. Biophys. Res. Commun., vol. 181, no. 1, pp. 265–71, Nov. 
1991. 
 
 160 
 
[51] N. Gakhar-Koppole et al., “Activity requires soluble amyloid precursor protein α to promote 
neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK 
pathway,” Eur. J. Neurosci., vol. 28, no. 5, pp. 871–882, Sep. 2008. 
[52] I. Ohsawa, C. Takamura, T. Morimoto, M. Ishiguro, and S. Kohsaka, “Amino-terminal 
region of secreted form of amyloid precursor protein stimulates proliferation of neural stem 
cells.,” Eur. J. Neurosci., vol. 11, no. 6, pp. 1907–13, Jun. 1999. 
[53] M. P. Demars, A. Bartholomew, Z. Strakova, and O. Lazarov, “Soluble amyloid precursor 
protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal 
origin,” Stem Cell Res. Ther., vol. 2, no. 4, p. 36, Aug. 2011. 
[54] T. Saitoh et al., “Secreted form of amyloid beta protein precursor is involved in the growth 
regulation of fibroblasts.,” Cell, vol. 58, no. 4, pp. 615–22, Aug. 1989. 
[55] C. U. Pietrzik et al., “From differentiation to proliferation: the secretory amyloid precursor 
protein as a local mediator of growth in thyroid epithelial cells.,” Proc. Natl. Acad. Sci. U. 
S. A., vol. 95, no. 4, pp. 1770–5, Feb. 1998. 
[56] A. Habib, D. Sawmiller, and J. Tan, “Restoring Soluble Amyloid Precursor Protein alpha 
Functions as a Potential Treatment for Alzheimer’s Disease,” J Neurosci Res, vol. 95, no. 
4, pp. 973–991, 2017. 
[57] M. P. Mattson, B. Cheng, A. R. Culwell, F. S. Esch, I. Lieberburg, and R. E. Rydel, 
“Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted 
forms of the beta-amyloid precursor protein.,” Neuron, vol. 10, no. 2, pp. 243–54, Feb. 
1993. 
[58] K. Furukawa, S. W. Barger, E. M. Blalock, and M. P. Mattson, “Activation of K+ channels 
and suppression of neuronal activity by secreted β-amyloid-precursor protein,” Nature, vol. 
379, no. 6560, pp. 74–78, Jan. 1996. 
[59] K. Furukawa and M. P. Mattson, “Secreted amyloid precursor protein alpha selectively 
suppresses N-methyl-D-aspartate currents in hippocampal neurons: involvement of cyclic 
GMP.,” Neuroscience, vol. 83, no. 2, pp. 429–38, Mar. 1998. 
[60] S. W. Barger, R. R. Fiscus, P. Ruth, F. Hofmann, and M. P. Mattson, “Role of cyclic GMP 
in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid 
precursor.,” J. Neurochem., vol. 64, no. 5, pp. 2087–96, May 1995. 
[61] V. L. Smith-Swintosky, L. C. Pettigrew, S. D. Craddock, A. R. Culwell, R. E. Rydel, and 
M. P. Mattson, “Secreted forms of beta-amyloid precursor protein protect against ischemic 
brain injury.,” J. Neurochem., vol. 63, no. 2, pp. 781–4, Aug. 1994. 
[62] M. P. Bowes, E. Masliah, D. A. C. Otero, J. A. Zivin, and T. Saitoh, “Reduction of 
Neurological Damage by a Peptide Segment of the Amyloid β/A4 Protein Precursor in a 
Rabbit Spinal Cord Ischemia Model,” Exp. Neurol., vol. 129, no. 1, pp. 112–119, Sep. 1994. 
[63] E. Thornton, R. Vink, P. C. Blumbergs, and C. Van Den Heuvel, “Soluble amyloid 
precursor protein α reduces neuronal injury and improves functional outcome following 
diffuse traumatic brain injury in rats,” Brain Res., vol. 1094, no. 1, pp. 38–46, Jun. 2006. 
[64] F. Corrigan et al., “The neuroprotective domains of the amyloid precursor protein, in 
traumatic brain injury, are located in the two growth factor domains,” Brain Res., vol. 1378, 
pp. 137–143, Mar. 2011. 
[65] F. Corrigan, R. Vink, P. C. Blumbergs, C. L. Masters, R. Cappai, and C. van den Heuvel, 
“sAPPα rescues deficits in amyloid precursor protein knockout mice following focal 
traumatic brain injury,” J. Neurochem., vol. 122, no. 1, pp. 208–220, Jul. 2012. 
 
 161 
 
[66] F. Corrigan et al., “The neuroprotective activity of the amyloid precursor protein against 
traumatic brain injury is mediated via the heparin binding site in residues 96-110,” J. 
Neurochem., vol. 128, no. 1, pp. 196–204, Jan. 2014. 
[67] G. Cheng, Z. Yu, D. Zhou, and M. P. Mattson, “Phosphatidylinositol-3-Kinase–Akt Kinase 
and p42/p44 Mitogen-Activated Protein Kinases Mediate Neurotrophic and 
Excitoprotective Actions of a Secreted Form of Amyloid Precursor Protein,” Exp. Neurol., 
vol. 175, no. 2, pp. 407–414, Jun. 2002. 
[68] S. Jimenez et al., “Age-dependent Accumulation of Soluble Amyloid β (Aβ) Oligomers 
Reverses the Neuroprotective Effect of Soluble Amyloid Precursor Protein-α (sAPPα) by 
Modulating Phosphatidylinositol 3-Kinase (PI3K)/Akt-GSK-3β Pathway in Alzheimer 
Mouse Model,” J. Biol. Chem., vol. 286, no. 21, pp. 18414–18425, May 2011. 
[69] N. Milosch et al., “Holo-APP and G-protein-mediated signaling are required for sAPPα-
induced activation of the Akt survival pathway,” Cell Death Dis., vol. 5, no. 8, pp. e1391–
e1391, Aug. 2014. 
[70] Q. Guo, N. Robinson, and M. P. Mattson, “Secreted beta-amyloid precursor protein 
counteracts the proapoptotic action of mutant presenilin-1 by activation of NF-kappaB and 
stabilization of calcium homeostasis.,” J. Biol. Chem., vol. 273, no. 20, pp. 12341–51, May 
1998. 
[71] S. M. Greenberg, W. Q. Qiu, D. J. Selkoe, A. Ben-Itzhak, and K. S. Kosik, “Amino-terminal 
region of the beta-amyloid precursor protein activates mitogen-activated protein kinase.,” 
Neurosci. Lett., vol. 198, no. 1, pp. 52–6, Sep. 1995. 
[72] D. Kögel, R. Schomburg, E. Copanaki, and J. H. M. Prehn, “Regulation of gene expression 
by the amyloid precursor protein: inhibition of the JNK/c-Jun pathway,” Cell Death Differ., 
vol. 12, no. 1, pp. 1–9, Jan. 2005. 
[73] T. D. Stein, N. J. Anders, C. DeCarli, S. L. Chan, M. P. Mattson, and J. A. Johnson, 
“Neutralization of Transthyretin Reverses the Neuroprotective Effects of Secreted Amyloid 
Precursor Protein (APP) in APPSw Mice Resulting in Tau Phosphorylation and Loss of 
Hippocampal Neurons: Support for the Amyloid Hypothesis,” J. Neurosci., vol. 24, no. 35, 
pp. 7707–7717, Sep. 2004. 
[74] D. Hartl et al., “Soluble Alpha-APP (sAPPalpha) Regulates CDK5 Expression and Activity 
in Neurons,” PLoS One, vol. 8, no. 6, p. e65920, Jun. 2013. 
[75] J. M. Castellano et al., “Human umbilical cord plasma proteins revitalize hippocampal 
function in aged mice,” Nature, vol. 544, no. 7651, pp. 488–492, Apr. 2017. 
[76] B. Dean, “Understanding the role of inflammatory-related pathways in the pathophysiology 
and treatment of psychiatric disorders: evidence from human peripheral studies and CNS 
studies.,” Int. J. Neuropsychopharmacol., vol. 14, no. 7, pp. 997–1012, Aug. 2011. 
[77] J. M. Frischer et al., “The relation between inflammation and neurodegeneration in multiple 
sclerosis brains.,” Brain, vol. 132, no. Pt 5, pp. 1175–89, May 2009. 
[78] Q. Wang, Y. Liu, and J. Zhou, “Neuroinflammation in Parkinson’s disease and its potential 
as therapeutic target,” Transl. Neurodegener., vol. 4, no. 1, p. 19, Dec. 2015. 
[79] I. G. Barbosa, R. Machado-Vieira, J. C. Soares, and A. L. Teixeira, “The immunology of 
bipolar disorder.,” Neuroimmunomodulation, vol. 21, no. 2–3, pp. 117–22, 2014. 
[80] M. T. Heneka et al., “Neuroinflammation in Alzheimer’s disease,” Lancet Neurol., vol. 14, 
no. 4, pp. 388–405, Apr. 2015. 
 
 
 162 
 
[81] H. Neumann, M. R. Kotter, and R. J. M. Franklin, “Debris clearance by microglia: an 
essential link between degeneration and regeneration.,” Brain, vol. 132, no. Pt 2, pp. 288–
95, Feb. 2009. 
[82] D. J. Loane and A. Kumar, “Microglia in the TBI brain: The good, the bad, and the 
dysregulated.,” Exp. Neurol., vol. 275 Pt 3, no. 0 3, pp. 316–327, Jan. 2016. 
[83] D. Sawmiller et al., “Luteolin Reduces Alzheimer’s Disease Pathologies Induced by 
Traumatic Brain Injury,” Int. J. Mol. Sci., vol. 15, no. 1, pp. 895–904, Jan. 2014. 
[84] D. Sawmiller et al., “Diosmin reduces cerebral Aβ levels, tau hyperphosphorylation, 
neuroinflammation, and cognitive impairment in the 3xTg-AD mice,” J. Neuroimmunol., 
vol. 299, pp. 98–106, Oct. 2016. 
[85] K. Rezai-Zadeh et al., “Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid 
precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice,” 
J Neurosci, vol. 25, no. 38, pp. 8807–8814, 2005. 
[86] M. Vendrame et al., “Infusion of Human Umbilical Cord Blood Cells in a Rat Model of 
Stroke Dose-Dependently Rescues Behavioral Deficits and Reduces Infarct Volume,” 
Stroke, vol. 35, no. 10, pp. 2390–2395, Aug. 2004. 
[87] A. J. Smith et al., “Improving Lithium Therapeutics by Crystal Engineering of Novel Ionic 
Cocrystals,” Mol. Pharm., vol. 10, no. 12, pp. 4728–4738, Dec. 2013. 
[88] C. J. Phiel and P. S. Klein, “M OLECULAR T ARGETS OF L ITHIUM A CTION,” Annu. 
Rev. Pharmacol. Toxicol., vol. 41, no. 1, pp. 789–813, Apr. 2001. 
[89] P. S. Klein and D. A. Melton, “A molecular mechanism for the effect of lithium on 
development.,” Proc. Natl. Acad. Sci. U. S. A., vol. 93, no. 16, pp. 8455–9, Aug. 1996. 
[90] M. A. Mines and R. S. Jope, “Glycogen synthase kinase-3: a promising therapeutic target 
for fragile x syndrome.,” Front. Mol. Neurosci., vol. 4, p. 35, 2011. 
[91] C. J. Phiel, C. A. Wilson, V. M.-Y. Lee, and P. S. Klein, “GSK-3α regulates production of 
Alzheimer’s disease amyloid-β peptides,” Nature, vol. 423, no. 6938, pp. 435–439, May 
2003. 
[92] O. V Forlenza, V. J. De-Paula, and B. S. Diniz, “Neuroprotective effects of lithium: 
implications for the treatment of Alzheimer’s disease and related neurodegenerative 
disorders,” ACS Chem Neurosci, vol. 5, no. 6, pp. 443–450, 2014. 
[93] T. Engel, P. Goñi-Oliver, J. J. Lucas, J. Avila, and F. Hernández, “Chronic lithium 
administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau 
hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary 
tangles do not revert,” J. Neurochem., vol. 99, no. 6, pp. 1445–1455, Dec. 2006. 
[94] J. A. Quiroz, R. Machado-Vieira, C. A. Zarate, H. K. Manji, and H. K. Manji, “Novel 
insights into lithium’s mechanism of action: neurotrophic and neuroprotective effects.,” 
Neuropsychobiology, vol. 62, no. 1, pp. 50–60, 2010. 
[95] W. J. Ryves and A. J. Harwood, “Lithium Inhibits Glycogen Synthase Kinase-3 by 
Competition for Magnesium,” Biochem. Biophys. Res. Commun., vol. 280, no. 3, pp. 720–
725, Jan. 2001. 
[96] J. S. Rao, H.-J. Lee, S. I. Rapoport, and R. P. Bazinet, “Mode of action of mood stabilizers: 
is the arachidonic acid cascade a common target?,” Mol. Psychiatry, vol. 13, no. 6, pp. 585–
596, Jun. 2008. 
[97] D. L. Murphy, C. Donnelly, and J. Moskowitz, “Inhibition by lithium of prostaglandin E1 
and norepinephrine effects on cyclic adenosine monophosphate production in human 
platelets.,” Clin. Pharmacol. Ther., vol. 14, no. 5, pp. 810–4. 
 163 
 
[98] M. C. Chang and C. R. Jones, “Chronic lithium treatment decreases brain phospholipase A2 
activity.,” Neurochem. Res., vol. 23, no. 6, pp. 887–92, Jun. 1998. 
[99] M. Basselin et al., “Lithium modifies brain arachidonic and docosahexaenoic metabolism 
in rat lipopolysaccharide model of neuroinflammation.,” J. Lipid Res., vol. 51, no. 5, pp. 
1049–56, May 2010. 
[100] S. Hong, K. Gronert, P. R. Devchand, R.-L. Moussignac, and C. N. Serhan, “Novel 
Docosatrienes and 17 S -Resolvins Generated from Docosahexaenoic Acid in Murine Brain, 
Human Blood, and Glial Cells,” J. Biol. Chem., vol. 278, no. 17, pp. 14677–14687, Apr. 
2003. 
[101] B. Voutsinos-Porche et al., “Temporal patterns of the cerebral inflammatory response in the 
rat lithium–pilocarpine model of temporal lobe epilepsy,” Neurobiol. Dis., vol. 17, no. 3, 
pp. 385–402, Dec. 2004. 
[102] C. J. Yuskaitis and R. S. Jope, “Glycogen synthase kinase-3 regulates microglial migration, 
inflammation, and inflammation-induced neurotoxicity,” Cell. Signal., vol. 21, no. 2, pp. 
264–273, Feb. 2009. 
[103] S. Moncada and J. P. Bolanos, “Nitric oxide, cell bioenergetics and neurodegeneration,” J. 
Neurochem., vol. 97, no. 6, pp. 1676–1689, Jun. 2006. 
[104] G. Bagetta, R. Massoud, P. Rodinò, G. Federici, and G. Nisticò, “Systemic administration 
of lithium chloride and tacrine increases nitric oxide synthase activity in the hippocampus 
of rats.,” Eur. J. Pharmacol., vol. 237, no. 1, pp. 61–4, Jun. 1993. 
[105] M. Ghasemi and A. R. Dehpour, “The NMDA receptor/nitric oxide pathway: a target for 
the therapeutic and toxic effects of lithium,” Trends Pharmacol. Sci., vol. 32, no. 7, pp. 
420–434, Jul. 2011. 
[106] G. Wegener et al., “Combined chronic treatment with citalopram and lithium does not 
modify the regional neurochemistry of nitric oxide in rat brain.,” J. Physiol. Pharmacol., 
vol. 55, no. 3, pp. 575–86, Sep. 2004. 
[107] S. Maruta et al., “Effects of intraperitoneally injected lithium, imipramine and diazepam on 
nitrate levels in rat amygdala,” Psychiatry Clin. Neurosci., vol. 59, no. 3, pp. 358–361, Jun. 
2005. 
[108] E. S. Kleinerman, R. D. Knowles, M. B. Blick, and L. A. Zwelling, “Lithium chloride 
stimulates human monocytes to secrete tumor necrosis factor/cachectin.,” J. Leukoc. Biol., 
vol. 46, no. 5, pp. 484–92, Nov. 1989. 
[109] M. Hull, E. Lee, T. Lee, N. Anand, V. LaLone, and N. Parameswaran, “Lithium chloride 
induces TNFα in mouse macrophages via MEK-ERK-dependent pathway.,” J. Cell. 
Biochem., vol. 115, no. 1, pp. 71–80, Jan. 2014. 
[110] M. Martin, K. Rehani, R. S. Jope, and S. M. Michalek, “Toll-like receptor–mediated 
cytokine production is differentially regulated by glycogen synthase kinase 3,” Nat. 
Immunol., vol. 6, no. 8, pp. 777–784, Aug. 2005. 
[111] Y. Wang et al., “Inhibiting glycogen synthase kinase-3 reduces endotoxaemic acute renal 
failure by down-regulating inflammation and renal cell apoptosis.,” Br. J. Pharmacol., vol. 
157, no. 6, pp. 1004–13, Jul. 2009. 
[112] K. Kang et al., “Lithium pretreatment reduces brain injury after intracerebral hemorrhage 
in rats,” Neurol. Res., vol. 34, no. 5, pp. 447–454, Jun. 2012. 
[113] E. M. Knijff et al., “An imbalance in the production of IL-1β and IL-6 by monocytes of 
bipolar patients: restoration by lithium treatment,” Bipolar Disord., vol. 9, no. 7, pp. 743–
753, Nov. 2007. 
 164 
 
[114] M. H. Rapaport and H. K. Manji, “The effects of lithium on ex vivo cytokine production.,” 
Biol. Psychiatry, vol. 50, no. 3, pp. 217–24, Aug. 2001. 
[115] T. F. Tay, M. Maheran, S. L. Too, M. S. Hasidah, G. Ismail, and N. Embi, “Glycogen 
synthase kinase-3β inhibition improved survivability of mice infected with Burkholderia 
pseudomallei.,” Trop. Biomed., vol. 29, no. 4, pp. 551–67, Dec. 2012. 
[116] S. Kishter, F. A. Hoffman, and P. A. Pizzo, “Production of and response to interleukin-2 by 
cultured T cells: effects of lithium chloride and other putative modulators.,” J. Biol. 
Response Mod., vol. 4, no. 2, pp. 185–94, Apr. 1985. 
[117] M. B. Sztein et al., “In vitro effects of thymosin and lithium on lymphoproliferative 
responses of normal donors and HIV seropositive male homosexuals with AIDS-related 
complex.,” Clin. Immunol. Immunopathol., vol. 44, no. 1, pp. 51–62, Jul. 1987. 
[118] M. Maes et al., “In vitro immunoregulatory effects of lithium in healthy volunteers.,” 
Psychopharmacology (Berl)., vol. 143, no. 4, pp. 401–7, Apr. 1999. 
[119] E. Rocha, M. Achaval, P. Santos, and R. Rodnight, “Lithium treatment causes gliosis and 
modifies the morphology of hippocampal astrocytes in rats.,” Neuroreport, vol. 9, no. 17, 
pp. 3971–4, Dec. 1998. 
[120] G. M. Gilad and V. H. Gilad, “Astroglia growth retardation and increased microglia 
proliferation by lithium and ornithine decarboxylase inhibitor in rat cerebellar cultures: 
Cytotoxicity by combined lithium and polyamine inhibition,” J. Neurosci. Res., vol. 85, no. 
3, pp. 594–601, Feb. 2007. 
[121] E. M. Toledo and N. C. Inestrosa, “Activation of Wnt signaling by lithium and rosiglitazone 
reduced spatial memory impairment and neurodegeneration in brains of an 
APPswe/PSEN1ΔE9 mouse model of Alzheimer’s disease,” Mol. Psychiatry, vol. 15, no. 
3, pp. 272–285, Mar. 2010. 
[122] K. P. Hoeflich, J. Luo, E. A. Rubie, M.-S. Tsao, O. Jin, and J. R. Woodgett, “Requirement 
for glycogen synthase kinase-3β in cell survival and NF-κB activation,” Nature, vol. 406, 
no. 6791, pp. 86–90, Jul. 2000. 
[123] S. Ghosh and M. S. Hayden, “New regulators of NF-κB in inflammation,” Nat. Rev. 
Immunol., vol. 8, no. 11, pp. 837–848, Nov. 2008. 
[124] L. Wang, L. Zhang, X. Zhao, M. Zhang, W. Zhao, and C. Gao, “Lithium Attenuates IFN-β 
Production and Antiviral Response via Inhibition of TANK-Binding Kinase 1 Kinase 
Activity,” J. Immunol., vol. 191, no. 8, pp. 4392–4398, Oct. 2013. 
[125] P. Zhang, J. Katz, and S. M. Michalek, “Glycogen synthase kinase-3β (GSK3β) inhibition 
suppresses the inflammatory response to Francisella infection and protects against tularemia 
in mice,” Mol. Immunol., vol. 46, no. 4, pp. 677–687, Feb. 2009. 
[126] E. Beurel and R. S. Jope, “Glycogen synthase kinase-3 promotes the synergistic action of 
interferon-γ on lipopolysaccharide-induced IL-6 production in RAW264.7 cells,” Cell. 
Signal., vol. 21, no. 6, pp. 978–985, Jun. 2009. 
[127] M. Bouskila, M. F. Hirshman, J. Jensen, L. J. Goodyear, and K. Sakamoto, “Insulin 
promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal muscle,” 
Am. J. Physiol. Metab., vol. 294, no. 1, pp. E28–E35, Jan. 2008. 
[128] K. Hughes, E. Nikolakaki, S. E. Plyte, N. F. Totty, and J. R. Woodgett, “Modulation of the 
glycogen synthase kinase-3 family by tyrosine phosphorylation.,” EMBO J., vol. 12, no. 2, 
pp. 803–8, Feb. 1993. 
[129] V. Stambolic and J. R. Woodgett, “Mitogen inactivation of glycogen synthase kinase-3 beta 
in intact cells via serine 9 phosphorylation.,” Biochem. J., vol. 303 ( Pt 3), pp. 701–4, Nov. 
 165 
 
1994. 
[130] E.-M. Hur and F.-Q. Zhou, “GSK3 signalling in neural development,” Nat. Rev. Neurosci., 
vol. 11, no. 8, pp. 539–551, Aug. 2010. 
[131] M. Hetman, J. E. Cavanaugh, D. Kimelman, and Z. Xia, “Role of glycogen synthase kinase-
3beta in neuronal apoptosis induced by trophic withdrawal.,” J. Neurosci., vol. 20, no. 7, 
pp. 2567–74, Apr. 2000. 
[132] K. M. Jacobs, S. R. Bhave, D. J. Ferraro, J. J. Jaboin, D. E. Hallahan, and D. Thotala, “GSK-
3: A Bifunctional Role in Cell Death Pathways,” Int. J. Cell Biol., vol. 2012, pp. 1–11, 2012. 
[133] J. Jo et al., “Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving 
caspase-3, Akt1 and GSK-3β,” Nat. Neurosci., vol. 14, no. 5, pp. 545–547, May 2011. 
[134] P. T. T. Ly et al., “Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-
associated phenotypes.,” J. Clin. Invest., vol. 123, no. 1, pp. 224–35, Jan. 2013. 
[135] M. K. King, M. Pardo, Y. Cheng, K. Downey, R. S. Jope, and E. Beurel, “Glycogen synthase 
kinase-3 inhibitors: Rescuers of cognitive impairments.,” Pharmacol. Ther., vol. 141, no. 
1, pp. 1–12, Jan. 2014. 
[136] K. Spittaels et al., “Glycogen synthase kinase-3beta phosphorylates protein tau and rescues 
the axonopathy in the central nervous system of human four-repeat tau transgenic mice.,” 
J. Biol. Chem., vol. 275, no. 52, pp. 41340–9, Dec. 2000. 
[137] A. Takashima, “GSK-3 is essential in the pathogenesis of Alzheimer’s disease.,” J. 
Alzheimers. Dis., vol. 9, no. 3 Suppl, pp. 309–17, 2006. 
[138] C. Hooper, R. Killick, and S. Lovestone, “The GSK3 hypothesis of Alzheimer’s disease,” 
J. Neurochem., vol. 104, no. 6, pp. 1433–1439, Mar. 2008. 
[139] J. Avila, G. León-Espinosa, E. García, V. García-Escudero, F. Hernández, and J. DeFelipe, 
“Tau Phosphorylation by GSK3 in Different Conditions,” Int. J. Alzheimers. Dis., vol. 2012, 
pp. 1–7, May 2012. 
[140] D. F. Seals and S. A. Courtneidge, “The ADAMs family of metalloproteases: multidomain 
proteins with multiple functions,” Genes Dev., vol. 17, no. 1, pp. 7–30, Jan. 2003. 
[141] M. Deuss, K. Reiss, and D. Hartmann, “Part-time alpha-secretases: the functional biology 
of ADAM 9, 10 and 17.,” Curr. Alzheimer Res., vol. 5, no. 2, pp. 187–201, Apr. 2008. 
[142] G. Murphy, “The ADAMs: signalling scissors in the tumour microenvironment,” Nat. Rev. 
Cancer, vol. 8, no. 12, pp. 932–941, Dec. 2008. 
[143] E. E. Gardiner, D. Karunakaran, Y. Shen, J. F. Arthur, R. K. Andrews, and M. C. Berndt, 
“Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family 
metalloproteinases,” J. Thromb. Haemost., vol. 5, no. 7, pp. 1530–1537, Jul. 2007. 
[144] M. Bender et al., “Differentially regulated GPVI ectodomain shedding by multiple platelet-
expressed proteinases,” Blood, vol. 116, no. 17, pp. 3347–3355, Oct. 2010. 
[145] P. J. Gough, K. J. Garton, P. T. Wille, M. Rychlewski, P. J. Dempsey, and E. W. Raines, 
“A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell 
surface expression of CXC chemokine ligand 16.,” J. Immunol., vol. 172, no. 6, pp. 3678–
85, Mar. 2004. 
[146] M. J. Mohan et al., “The tumor necrosis factor-alpha converting enzyme (TACE): a unique 
metalloproteinase with highly defined substrate selectivity.,” Biochemistry, vol. 41, no. 30, 
pp. 9462–9, Jul. 2002. 
[147] R. Postina, “A closer look at alpha-secretase.,” Curr. Alzheimer Res., vol. 5, no. 2, pp. 179–
86, Apr. 2008. 
 
 166 
 
[148] M. A. Israel et al., “Probing sporadic and familial Alzheimer’s disease using induced 
pluripotent stem cells,” Nature, vol. 482, no. 7384, pp. 216–220, Feb. 2012. 
[149] A. J. Smith et al., “Plasma and brain pharmacokinetics of previously unexplored lithium 
salts,” RSC Adv., vol. 4, no. 24, pp. 12362–12365, 2014. 
[150] A. Habib et al., “LISPRO mitigates β-amyloid and associated pathologies in Alzheimer’s 
mice,” Cell Death Dis., vol. 8, no. 6, p. e2880, Jun. 2017. 
[151] B. G. Mockett, M. Richter, W. C. Abraham, and U. C. Müller, “Therapeutic Potential of 
Secreted Amyloid Precursor Protein APPsα,” Front. Mol. Neurosci., vol. 10, p. 30, Feb. 
2017. 
[152] V. J. Spilman P, Jagodzinska B, Bredesen DE, “Enhancement of sAPPα as a Therapeutic 
Strategy for Alzheimer’s and Other Neurodegenerative Diseases,” Alzheimer’s 
Neurodegener. Dis., vol. 1, no. 1, pp. 1–10, Aug. 2015. 
[153] D. Darlington et al., “Multiple low-dose infusions of human umbilical cord blood cells 
improve cognitive impairments and reduce amyloid-beta-associated neuropathology in 
Alzheimer mice,” Stem Cells Dev, vol. 22, no. 3, pp. 412–421, 2013. 
[154] J. Middeldorp et al., “Preclinical Assessment of Young Blood Plasma for Alzheimer 
Disease,” JAMA Neurol., vol. 73, no. 11, p. 1325, Nov. 2016. 
[155] L. Katsimpardi et al., “Vascular and Neurogenic Rejuvenation of the Aging Mouse Brain 
by Young Systemic Factors,” Science (80). vol. 344, no. 6184, pp. 630–634, May 2014. 
[156] J. M. Castellano et al., “In vivo assessment of behavioral recovery and circulatory exchange 
in the peritoneal parabiosis model,” Sci. Rep., vol. 6, no. 1, p. 29015, Sep. 2016. 
[157] Y. Xiang et al., “Physiological amyloid-beta clearance in the periphery and its therapeutic 
potential for Alzheimer’s disease,” Acta Neuropathol., vol. 130, no. 4, pp. 487–499, Oct. 
2015. 
[158] H. Oakley et al., “Intraneuronal beta-Amyloid Aggregates, Neurodegeneration, and Neuron 
Loss in Transgenic Mice with Five Familial Alzheimer’s Disease Mutations: Potential 
Factors in Amyloid Plaque Formation,” J. Neurosci., vol. 26, no. 40, pp. 10129–10140, Oct. 
2006. 
[159] S. Oddo et al., “Triple-transgenic model of Alzheimer’s disease with plaques and tangles: 
intracellular Abeta and synaptic dysfunction.,” Neuron, vol. 39, no. 3, pp. 409–21, Jul. 2003. 
[160] D. Sawmiller et al., “Beneficial effects of a pyrroloquinolinequinone-containing dietary 
formulation on motor deficiency, cognitive decline and mitochondrial dysfunction in a 
mouse model of Alzheimer’s disease,” Heliyon, vol. 3, no. 4, p. e00279, 2017. 
[161] R. D. Shytle et al., “Optimized turmeric extracts have potent anti-amyloidogenic effects.,” 
Curr. Alzheimer Res., vol. 6, no. 6, pp. 564–71, Dec. 2009. 
[162] C. Hundhausen et al., “Regulated shedding of transmembrane chemokines by the 
disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes.,” J. 
Immunol., vol. 178, no. 12, pp. 8064–72, Jun. 2007. 
[163] T. Isozaki et al., “Evidence That CXCL16 Is a Potent Mediator of Angiogenesis and Is 
Involved in Endothelial Progenitor Cell Chemotaxis: Studies in Mice With K/BxN Serum-
Induced Arthritis,” Arthritis Rheum., vol. 65, no. 7, pp. 1736–1746, Jul. 2013. 
[164] C. Peters-Libeu et al., “sAβPPα is a Potent Endogenous Inhibitor of BACE1,” J. 
Alzheimer’s Dis., vol. 47, no. 3, pp. 545–555, Aug. 2015. 
[165] C. Haass and D. J. Selkoe, “Soluble protein oligomers in neurodegeneration: lessons from 
the Alzheimer’s amyloid beta-peptide,” Nat Rev Mol Cell Biol, vol. 8, no. 2, pp. 101–112, 
2007. 
 167 
 
[166] P. Eikelenboom and F. C. Stam, “Immunoglobulins and complement factors in senile 
plaques. An immunoperoxidase study,” Acta Neuropathol, vol. 57, no. 2–3, pp. 239–242, 
1982. 
[167] P. Damien and D. S. Allan, “Regenerative Therapy and Immune Modulation Using 
Umbilical Cord Blood-Derived Cells,” Biol Blood Marrow Transpl., vol. 21, no. 9, pp. 
1545–1554, 2015. 
[168] A. H. Habib  Mori T. Tian, J. Zeng, J. Fan, S. Giunta, B. Sanberg, P. Sawmiller, D. and Tan, 
J., “Human Umbilical Cord Blood Serum-derived alpha-Secretase: Functional Testing in 
Alzheimer’s Disease Mouse Models,” Cell Transplant., vol. x, no. y, pp. 1–18, 2018. 
[169] H. Rus, C. Cudrici, and F. Niculescu, “The role of the complement system in innate 
immunity,” Immunol Res, vol. 33, no. 2, pp. 103–112, 2005. 
[170] B. Stevens et al., “The classical complement cascade mediates CNS synapse elimination,” 
Cell, vol. 131, no. 6, pp. 1164–1178, 2007. 
[171] R. Veerhuis, H. M. Nielsen, and A. J. Tenner, “Complement in the brain,” Mol Immunol, 
vol. 48, no. 14, pp. 1592–1603, 2011. 
[172] R. A. van Schaarenburg et al., “C1q Deficiency and Neuropsychiatric Systemic Lupus 
Erythematosus,” Front Immunol, vol. 7, p. 647, 2016. 
[173] N. M. Thielens, F. Tedesco, S. S. Bohlson, C. Gaboriaud, and A. J. Tenner, “C1q: A fresh 
look upon an old molecule,” Mol Immunol, vol. 89, pp. 73–83, 2017. 
[174] K. B. Reid and R. R. Porter, “Subunit composition and structure of subcomponent C1q of 
the first component of human complement,” Biochem J, vol. 155, no. 1, pp. 19–23, 1976. 
[175] K. Pisalyaput and A. J. Tenner, “Complement component C1q inhibits beta-amyloid- and 
serum amyloid P-induced neurotoxicity via caspase- and calpain-independent 
mechanisms,” J Neurochem, vol. 104, no. 3, pp. 696–707, 2008. 
[176] M. E. Benoit and A. J. Tenner, “Complement protein C1q-mediated neuroprotection is 
correlated with regulation of neuronal gene and microRNA expression,” J Neurosci, vol. 
31, no. 9, pp. 3459–3469, 2011. 
[177] D. A. Fraser, A. K. Laust, E. L. Nelson, and A. J. Tenner, “C1q differentially modulates 
phagocytosis and cytokine responses during ingestion of apoptotic cells by human 
monocytes, macrophages, and dendritic cells,” J Immunol, vol. 183, no. 10, pp. 6175–6185, 
2009. 
[178] H. Rus, C. Cudrici, S. David, and F. Niculescu, “The complement system in central nervous 
system diseases,” Autoimmunity, vol. 39, no. 5, pp. 395–402, 2006. 
[179] M. I. Fonseca et al., “Treatment with a C5aR antagonist decreases pathology and enhances 
behavioral performance in murine models of Alzheimer’s disease,” J Immunol, vol. 183, 
no. 2, pp. 1375–1383, 2009. 
[180] D. A. Fraser, K. Pisalyaput, and A. J. Tenner, “C1q enhances microglial clearance of 
apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine 
production,” J Neurochem, vol. 112, no. 3, pp. 733–743, 2010. 
[181] M. E. Benoit, M. X. Hernandez, M. L. Dinh, F. Benavente, O. Vasquez, and A. J. Tenner, 
“C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse 
models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity,” 
J Biol Chem, vol. 288, no. 1, pp. 654–665, 2013. 
[182] D. A. Loeffler, D. M. Camp, and D. A. Bennett, “Plaque complement activation and 
cognitive loss in Alzheimer’s disease,” J Neuroinflammation, vol. 5, p. 9, 2008. 
 
 168 
 
[183] J. J. Alexander, A. J. Anderson, S. R. Barnum, B. Stevens, and A. J. Tenner, “The 
complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -
degeneration,” J Neurochem, vol. 107, no. 5, pp. 1169–1187, 2008. 
[184] C. Gaboriaud, W. L. Ling, N. M. Thielens, I. Bally, and V. Rossi, “Deciphering the fine 
details of c1 assembly and activation mechanisms: ‘mission impossible’?,” Front Immunol, 
vol. 5, p. 565, 2014. 
[185] J. Rogers et al., “Peripheral clearance of amyloid beta peptide by complement C3-dependent 
adherence to erythrocytes,” Neurobiol Aging, vol. 27, no. 12, pp. 1733–1739, 2006. 
[186] M. Maier, Y. Peng, L. Jiang, T. J. Seabrook, M. C. Carroll, and C. A. Lemere, “Complement 
C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration 
and modulation of the microglia/macrophage phenotype in amyloid precursor protein 
transgenic mice,” J Neurosci, vol. 28, no. 25, pp. 6333–6341, 2008. 
[187] P. Gasque, Y. D. Dean, E. P. McGreal, J. VanBeek, and B. P. Morgan, “Complement 
components of the innate immune system in health and disease in the CNS,” 
Immunopharmacology, vol. 49, no. 1–2, pp. 171–186, 2000. 
[188] F. H. Brennan, A. J. Anderson, S. M. Taylor, T. M. Woodruff, and M. J. Ruitenberg, 
“Complement activation in the injured central nervous system: another dual-edged sword?,” 
J Neuroinflammation, vol. 9, p. 137, 2012. 
[189] Y. Shen and S. Meri, “Yin and Yang: complement activation and regulation in Alzheimer’s 
disease,” Prog Neurobiol, vol. 70, no. 6, pp. 463–472, 2003. 
[190] A. Afagh, B. J. Cummings, D. H. Cribbs, C. W. Cotman, and A. J. Tenner, “Localization 
and cell association of C1q in Alzheimer’s disease brain,” Exp Neurol, vol. 138, no. 1, pp. 
22–32, 1996. 
[191] M. Li, R. R. Ager, D. A. Fraser, N. O. Tjokro, and A. J. Tenner, “Development of a 
humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid 
induced complement activation,” Mol Immunol, vol. 45, no. 11, pp. 3244–3252, 2008. 
[192] M. I. Fonseca, J. Zhou, M. Botto, and A. J. Tenner, “Absence of C1q leads to less 
neuropathology in transgenic mouse models of Alzheimer’s disease,” J Neurosci, vol. 24, 
no. 29, pp. 6457–6465, 2004. 
[193] S. D. Webster, A. J. Yang, L. Margol, W. Garzon-Rodriguez, C. G. Glabe, and A. J. Tenner, 
“Complement component C1q modulates the phagocytosis of Abeta by microglia,” Exp 
Neurol, vol. 161, no. 1, pp. 127–138, 2000. 
[194] C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, and K. 
Beyreuther, “Amyloid plaque core protein in Alzheimer disease and Down syndrome,” Proc 
Natl Acad Sci U S A, vol. 82, no. 12, pp. 4245–4249, 1985. 
[195] I. Grundke-Iqbal, K. Iqbal, Y. C. Tung, M. Quinlan, H. M. Wisniewski, and L. I. Binder, 
“Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer 
cytoskeletal pathology,” Proc Natl Acad Sci U S A, vol. 83, no. 13, pp. 4913–4917, 1986. 
[196] A. Serrano-Pozo, M. P. Frosch, E. Masliah, and B. T. Hyman, “Neuropathological 
Alterations in Alzheimer Disease,” Cold Spring Harb. Perspect. Med., vol. 1, no. 1, pp. 
a006189–a006189, Sep. 2011. 
[197] A. Lleo, “Current Therapeutic Options for Alzheimers Disease,” Curr. Genomics, vol. 8, 
no. 8, pp. 550–558, Dec. 2007. 
[198] E. Shorter, “The history of lithium therapy,” Bipolar Disord, vol. 11 Suppl 2, pp. 4–9, 2009. 
[199] J. F. Hayes et al., “Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During 
Maintenance Mood Stabilizer Treatment,” JAMA Psychiatry, vol. 73, no. 6, p. 630, Jun. 
 169 
 
2016. 
[200] O. V Forlenza, B. S. Diniz, M. Radanovic, F. S. Santos, L. L. Talib, and W. F. Gattaz, 
“Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive 
impairment: randomised controlled trial,” Br J Psychiatry, vol. 198, no. 5, pp. 351–356, 
2011. 
[201] F. K. Goodwin, B. Fireman, G. E. Simon, E. M. Hunkeler, J. Lee, and D. Revicki, “Suicide 
Risk in Bipolar Disorder During Treatment With Lithium and Divalproex,” JAMA, vol. 290, 
no. 11, p. 1467, Sep. 2003. 
[202] M. A. Nunes, T. A. Viel, and H. S. Buck, “Microdose lithium treatment stabilized cognitive 
impairment in patients with Alzheimer’s disease,” Curr Alzheimer Res, vol. 10, no. 1, pp. 
104–107, 2013. 
[203] V. D. Davenport, “Distribution of Parenterally Administered Lithium in Plasma, Brain, and 
Muscle of Rats,” Am. J. Physiol. Content, vol. 163, no. 3, pp. 633–641, Nov. 1950. 
[204] M. S. Ebadi, V. J. Simmons, M. J. Hendrickson, and P. S. Lacy, “Pharmacokinetics of 
lithium and its regional distribution in rat brain.,” Eur. J. Pharmacol., vol. 27, no. 3, pp. 
324–9, Aug. 1974. 
[205] C. Livingstone and H. Rampes, “Lithium: a review of its metabolic adverse effects,” J. 
Psychopharmacol., vol. 20, no. 3, pp. 347–355, May 2006. 
[206] M. Schou, P. C. Baastrup, P. Grof, P. Weis, and J. Angst, “Pharmacological and clinical 
problems of lithium prophylaxis.,” Br. J. Psychiatry, vol. 116, no. 535, pp. 615–9, Jun. 
1970. 
[207] T. Town et al., “Reduced Th1 and enhanced Th2 immunity after immunization with 
Alzheimer’s beta-amyloid(1-42).,” J. Neuroimmunol., vol. 132, no. 1–2, pp. 49–59, Nov. 
2002. 
[208] J. Tan et al., “Role of CD40 ligand in amyloidosis in transgenic Alzheimer’s mice,” Nat. 
Neurosci., vol. 5, no. 12, pp. 1288–1293, Dec. 2002. 
[209] K. Rezai-Zadeh et al., “Flavonoid-mediated presenilin-1 phosphorylation reduces 
Alzheimer’s disease beta-amyloid production.,” J. Cell. Mol. Med., vol. 13, no. 3, pp. 574–
88, Mar. 2009. 
[210] K. P. Townsend et al., “CD40 signaling regulates innate and adaptive activation of 
microglia in response to amyloid beta-peptide,” Eur. J. Immunol., vol. 35, no. 3, pp. 901–
910, Mar. 2005. 
[211] J. Saura, J. M. Tusell, and J. Serratosa, “High-yield isolation of murine microglia by mild 
trypsinization,” Glia, vol. 44, no. 3, pp. 183–189, Dec. 2003. 
[212] Y. Zhu et al., “Mutant presenilin-1 deregulated peripheral immunity exacerbates 
Alzheimer-like pathology,” J. Cell. Mol. Med., vol. 15, no. 2, pp. 327–338, Feb. 2011. 
[213] F. Yu, Y. Zhang, and D.-M. Chuang, “Lithium Reduces BACE1 Overexpression, Beta 
Amyloid Accumulation, and Spatial Learning Deficits in Mice with Traumatic Brain 
Injury,” J. Neurotrauma, vol. 29, no. 13, pp. 2342–2351, Sep. 2012. 
[214] T. L. Sudduth, J. G. Wilson, A. Everhart, C. A. Colton, and D. M. Wilcock, “Lithium 
Treatment of APPSwDI/NOS2−/− Mice Leads to Reduced Hyperphosphorylated Tau, 
Increased Amyloid Deposition and Altered Inflammatory Phenotype,” PLoS One, vol. 7, 
no. 2, p. e31993, Feb. 2012. 
[215] S. Sarkar et al., “Lithium induces autophagy by inhibiting inositol monophosphatase,” J. 
Cell Biol., vol. 170, no. 7, pp. 1101–1111, Sep. 2005. 
 
 170 
 
[216] Y. Motoi, K. Shimada, K. Ishiguro, and N. Hattori, “Lithium and Autophagy,” ACS Chem. 
Neurosci., vol. 5, no. 6, pp. 434–442, Jun. 2014. 
[217] T.-H. Kwon, “Dysregulation of Renal Cyclooxygenase-2 in Rats with Lithium-induced 
Nephrogenic Diabetes Insipidus,” Electrolyte Blood Press., vol. 5, no. 2, p. 68, Dec. 2007. 
[218] R. Rao et al., “Lithium treatment inhibits renal GSK-3 activity and promotes 
cyclooxygenase 2-dependent polyuria,” Am. J. Physiol. Physiol., vol. 288, no. 4, pp. F642–
F649, Apr. 2005. 
[219] R. Rao, C.-M. Hao, and M. D. Breyer, “Hypertonic Stress Activates Glycogen Synthase 
Kinase 3β-mediated Apoptosis of Renal Medullary Interstitial Cells, Suppressing an NFκB-
driven Cyclooxygenase-2-dependent Survival Pathway,” J. Biol. Chem., vol. 279, no. 6, pp. 
3949–3955, Feb. 2004. 
[220] A. Cipriani, K. Hawton, S. Stockton, and J. R. Geddes, “Lithium in the prevention of suicide 
in mood disorders: updated systematic review and meta-analysis.,” BMJ, vol. 346, p. f3646, 
Jun. 2013. 
[221] G. Alvarez, J. R. Muñoz-Montaño, J. Satrústegui, J. Avila, E. Bogónez, and J. Díaz-Nido, 
“Regulation of tau phosphorylation and protection against beta-amyloid-induced 
neurodegeneration by lithium. Possible implications for Alzheimer’s disease.,” Bipolar 
Disord., vol. 4, no. 3, pp. 153–65, Jun. 2002. 
[222] G. Alvarez, J. R. Muñoz-Montaño, J. Satrústegui, J. Avila, E. Bogónez, and J. Díaz-Nido, 
“Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration.,” 
FEBS Lett., vol. 453, no. 3, pp. 260–4, Jun. 1999. 
[223] P. Stolk et al., “Is aspirin useful in patients on lithium? A pharmacoepidemiological study 
related to bipolar disorder,” Prostaglandins, Leukot. Essent. Fat. Acids, vol. 82, no. 1, pp. 
9–14, Jan. 2010. 
[224] C. N. Serhan et al., “Resolvins: a family of bioactive products of omega-3 fatty acid 
transformation circuits initiated by aspirin treatment that counter proinflammation signals.,” 
J. Exp. Med., vol. 196, no. 8, pp. 1025–37, Oct. 2002. 
[225] M. Basselin, N. E. Villacreses, H.-J. Lee, J. M. Bell, and S. I. Rapoport, “Chronic lithium 
administration attenuates up-regulated brain arachidonic acid metabolism in a rat model of 
neuroinflammation,” J. Neurochem., vol. 102, no. 3, pp. 761–772, Mar. 2007. 
[226] R. S. Jope, “Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes,” 
Trends Pharmacol. Sci., vol. 24, no. 9, pp. 441–443, Sep. 2003. 
[227] W. S. Griffin et al., “Glial-neuronal interactions in Alzheimer’s disease: the potential role 
of a ‘cytokine cycle’ in disease progression.,” Brain Pathol., vol. 8, no. 1, pp. 65–72, Jan. 
1998. 
[228] N. Abbas et al., “Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and 
down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice.,” J. 
Neuroimmunol., vol. 126, no. 1–2, pp. 50–7, May 2002. 
[229] G. C. Brown and A. Bal-Price, “Inflammatory Neurodegeneration Mediated by Nitric 
Oxide, Glutamate, and Mitochondria,” Mol. Neurobiol., vol. 27, no. 3, pp. 325–355, Jun. 
2003. 
[230] W. S. Griffin et al., “Brain interleukin 1 and S-100 immunoreactivity are elevated in Down 
syndrome and Alzheimer disease.,” Proc. Natl. Acad. Sci. U. S. A., vol. 86, no. 19, pp. 7611–
5, Oct. 1989. 
[231] E. A. van der Wal, F. Gómez-Pinilla, and C. W. Cotman, “Transforming growth factor-beta 
1 is in plaques in Alzheimer and Down pathologies.,” Neuroreport, vol. 4, no. 1, pp. 69–72, 
 171 
 
Jan. 1993. 
[232] M. Sy et al., “Inflammation Induced by Infection Potentiates Tau Pathological Features in 
Transgenic Mice,” Am. J. Pathol., vol. 178, no. 6, pp. 2811–2822, Jun. 2011. 
[233] V. De-Paula et al., “Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity 
in Cultured Cortical and Hippocampal Neurons,” Molecules, vol. 20, no. 11, pp. 19878–
19885, Nov. 2015. 
[234] A. Nassar and A. N. Azab, “Effects of Lithium on Inflammation,” ACS Chem. Neurosci., 
vol. 5, no. 6, pp. 451–458, Jun. 2014. 
[235] E. Beurel and R. S. Jope, “Inflammation and lithium: clues to mechanisms contributing to 
suicide-linked traits,” Transl. Psychiatry, vol. 4, no. 12, pp. e488–e488, Dec. 2014. 
[236] S. S. Valvassori et al., “Lithium modulates the production of peripheral and cerebral 
cytokines in an animal model of mania induced by dextroamphetamine,” Bipolar Disord., 
vol. 17, no. 5, pp. 507–517, Aug. 2015. 
[237] B. Giunta, K. Rezai-Zadeh, and J. Tan, “Impact of the CD40-CD40L dyad in Alzheimer’s 
disease.,” CNS Neurol. Disord. Drug Targets, vol. 9, no. 2, pp. 149–55, Apr. 2010. 
[238] R. W. Chen and D. M. Chuang, “Long term lithium treatment suppresses p53 and Bax 
expression but increases Bcl-2 expression. A prominent role in neuroprotection against 
excitotoxicity.,” J. Biol. Chem., vol. 274, no. 10, pp. 6039–42, Mar. 1999. 
[239] G. Chen et al., “The mood-stabilizing agents lithium and valproate robustly increase the 
levels of the neuroprotective protein bcl-2 in the CNS.,” J. Neurochem., vol. 72, no. 2, pp. 
879–82, Feb. 1999. 
[240] J. H. Morrison and P. R. Hof, “Selective vulnerability of corticocortical and hippocampal 
circuits in aging and Alzheimer’s disease,” Prog Brain Res, vol. 136, pp. 467–486, 2002. 
[241] C. A. Davies, D. M. Mann, P. Q. Sumpter, and P. O. Yates, “A quantitative morphometric 
analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients 
with Alzheimer’s disease,” J Neurol Sci, vol. 78, no. 2, pp. 151–164, 1987. 
[242] S. T. DeKosky and S. W. Scheff, “Synapse loss in frontal cortex biopsies in Alzheimer’s 
disease: correlation with cognitive severity,” Ann Neurol, vol. 27, no. 5, pp. 457–464, 1990. 
[243] L. Crews and E. Masliah, “Molecular mechanisms of neurodegeneration in Alzheimer’s 
disease,” Hum Mol Genet, vol. 19, no. R1, pp. R12-20, 2010. 
[244] C. G. Lyketsos et al., “Neuropsychiatric symptoms in Alzheimer’s disease,” Alzheimers 
Dement, vol. 7, no. 5, pp. 532–539, 2011. 
[245] S. Gandy, “Testing the amyloid hypothesis of Alzheimer’s disease in vivo.,” Lancet. 
Neurol., vol. 9, no. 4, pp. 333–5, Apr. 2010. 
[246] K. R. Patterson et al., “Characterization of prefibrillar Tau oligomers in vitro and in 
Alzheimer disease,” J Biol Chem, vol. 286, no. 26, pp. 23063–23076, 2011. 
[247] K. J. Kopeikina, B. T. Hyman, and T. L. Spires-Jones, “Soluble forms of tau are toxic in 
Alzheimer’s disease.,” Transl. Neurosci., vol. 3, no. 3, pp. 223–233, Sep. 2012. 
[248] K. L. Lanctot et al., “Neuropsychiatric signs and symptoms of Alzheimer’s disease: New 
treatment paradigms,” Alzheimers Dement (N Y), vol. 3, no. 3, pp. 440–449, 2017. 
[249] S. Sportiche et al., “Clinical factors associated with lithium response in bipolar disorders,” 
Aust. N. Z. J. Psychiatry, vol. 51, no. 5, pp. 524–530, 2017. 
[250] P. V Nunes, O. V Forlenza, and W. F. Gattaz, “Lithium and risk for Alzheimer’s disease in 
elderly patients with bipolar disorder,” Br J Psychiatry, vol. 190, pp. 359–360, 2007. 
[251] O. V Forlenza, V. J. de Paula, R. Machado-Vieira, B. S. Diniz, and W. F. Gattaz, “Does 
Lithium Prevent Alzheimer’s Disease?,” Drugs Aging, vol. 29, no. 5, pp. 335–342, 2012. 
 172 
 
[252] O. V Forlenza, I. Aprahamian, V. J. de Paula, and T. Hajek, “Lithium, a Therapy for AD: 
Current Evidence from Clinical Trials of Neurodegenerative Disorders,” Curr Alzheimer 
Res, vol. 13, no. 8, pp. 879–886, 2016. 
[253] X. Zhang et al., “Long-term treatment with lithium alleviates memory deficits and reduces 
amyloid-beta production in an aged Alzheimer’s disease transgenic mouse model,” J 
Alzheimers Dis, vol. 24, no. 4, pp. 739–749, 2011. 
[254] V. A. Fajardo, V. A. Fajardo, P. J. LeBlanc, and R. E. K. MacPherson, “Examining the 
Relationship between Trace Lithium in Drinking Water and the Rising Rates of Age-
Adjusted Alzheimer’s Disease Mortality in Texas,” J Alzheimers Dis, vol. 61, no. 1, pp. 
425–434, 2018. 
[255] E. C. Lauterbach and M. F. Mendez, “Psychopharmacological Neuroprotection in 
Neurodegenerative Diseases, Part III: Criteria-Based Assessment: A Report of the ANPA 
Committee on Research,” J. Neuropsychiatry Clin. Neurosci., vol. 23, no. 3, pp. 242–260, 
2011. 
[256] B. Shine, R. F. McKnight, L. Leaver, and J. R. Geddes, “Long-term effects of lithium on 
renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data,” Lancet, 
vol. 386, no. 9992, pp. 461–468, 2015. 
[257] M. Garcia-Alloza et al., “Characterization of amyloid deposition in the APPswe/PS1dE9 
mouse model of Alzheimer disease,” Neurobiol Dis, vol. 24, no. 3, pp. 516–524, 2006. 
[258] C. Janus, A. Y. Flores, G. Xu, and D. R. Borchelt, “Behavioral abnormalities in 
APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple 
behavioral domains,” Neurobiol Aging, vol. 36, no. 9, pp. 2519–2532, 2015. 
[259] D. C. Rogers et al., “Use of SHIRPA and discriminant analysis to characterise marked 
differences in the behavioural phenotype of six inbred mouse strains,” Behav Brain Res, 
vol. 105, no. 2, pp. 207–217, 1999. 
[260] S. K. Praharaj, “Metformin for Lithium-induced Weight Gain: A Case Report,” Clin. 
Psychopharmacol. Neurosci., vol. 14, no. 1, pp. 101–103, 2016. 
[261] C. F. Giusti, S. R. Amorim, R. A. Guerra, and E. S. Portes, “Endocrine disturbances related 
to the use of lithium,” Arq Bras Endocrinol Metab., vol. 56, no. 3, pp. 153–158, 2012. 
[262] C. Bonardi, F. de Pulford, D. Jennings, and M.-C. Pardon, “A detailed analysis of the early 
context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to 
preclinical Alzheimer’s disease,” Behav. Brain Res., vol. 222, no. 1, pp. 89–97, Sep. 2011. 
[263] C. G. Lyketsos, O. Lopez, B. Jones, A. L. Fitzpatrick, J. Breitner, and S. DeKosky, 
“Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: 
results from the cardiovascular health study,” Jama, vol. 288, no. 12, pp. 1475–1483, 2002. 
[264] J. H. Park et al., “Depression in vascular dementia is quantitatively and qualitatively 
different from depression in Alzheimer’s disease,” Dement Geriatr Cogn Disord, vol. 23, 
no. 2, pp. 67–73, 2007. 
[265] M. Filali, R. Lalonde, and S. Rivest, “Cognitive and non-cognitive behaviors in an 
APPswe/PS1 bigenic model of Alzheimer’s disease,” Genes Brain Behav, vol. 8, no. 2, pp. 
143–148, 2009. 
[266] M. Gitlin, “Lithium side effects and toxicity: prevalence and management strategies,” Int J 
Bipolar Disord, vol. 4, 2016. 
[267] A. Caccamo, S. Oddo, L. X. Tran, and F. M. LaFerla, “Lithium reduces tau phosphorylation 
but not A beta or working memory deficits in a transgenic model with both plaques and 
tangles,” Am J Pathol, vol. 170, no. 5, pp. 1669–1675, 2007. 
 173 
 
[268] C. Feyt et al., “Lithium chloride increases the production of amyloid-beta peptide 
independently from its inhibition of glycogen synthase kinase 3,” J Biol Chem, vol. 280, no. 
39, pp. 33220–33227, 2005. 
[269] P. Lei et al., “Lithium suppression of tau induces brain iron accumulation and 
neurodegeneration,” Mol Psychiatry, vol. 22, no. 3, pp. 396–406, 2017. 
[270] L. Trujillo-Estrada et al., “In vivo modification of Abeta plaque toxicity as a novel 
neuroprotective lithium-mediated therapy for Alzheimer’s disease pathology,” Acta 
Neuropathol Commun, vol. 1, p. 73, 2013. 
[271] L. R. Nery et al., “Brain Intraventricular Injection of Amyloid-beta in Zebrafish Embryo 
Impairs Cognition and Increases Tau Phosphorylation, Effects Reversed by Lithium,” PLoS 
One, vol. 9, no. 9, 2014. 
[272] P. Bianchi, E. Ciani, A. Contestabile, S. Guidi, and R. Bartesaghi, “Lithium Restores 
Neurogenesis in the Subventricular Zone of the Ts65Dn Mouse, a Model for Down 
Syndrome,” Brain Pathol., vol. 20, no. 1, pp. 106–118, 2010. 
[273] F. Gelfo et al., “Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic 
Depletion: Effects on Memory Impairment and Neurodegeneration,” J. Alzheimers Dis., 
vol. 56, no. 4, pp. 1505–1518, 2017. 
[274] T. Dwivedi and H. Zhang, “Lithium-induced neuroprotection is associated with epigenetic 
modification of specific BDNF gene promoter and altered expression of apoptotic-
regulatory proteins,” Front Neurosci, vol. 8, p. 457, 2014. 
[275] A. Macdonald, K. Briggs, M. Poppe, A. Higgins, L. Velayudhan, and S. Lovestone, “A 
feasibility and tolerability study of lithium in Alzheimer’s disease,” Int. J. Geriatr. 
Psychiatry, vol. 23, no. 7, pp. 704–711, 2008. 
[276] H. Hampel et al., “Lithium Trial in Alzheimer’s Disease: A Randomized, Single-Blind, 
Placebo-Controlled, Multicenter 10-Week Study,” J. Clin. Psychiatry, vol. 70, no. 6, pp. 
922–931, 2009. 
[277] T. Leyhe et al., “Increase of BDNF Serum Concentration in Lithium Treated Patients with 
Early Alzheimer’s Disease,” J. Alzheimers Dis., vol. 16, no. 3, pp. 649–656, 2009. 
[278] A. Nilsson and R. Axelsson, “Psychopathology during long-term lithium treatment of 
patients with major affective disorders. A prospective study,” Acta Psychiatr Scand, vol. 
80, no. 4, pp. 375–388, 1989. 
[279] A. S. Fleisher et al., “Chronic divalproex sodium use and brain atrophy in Alzheimer 
disease,” Neurology, vol. 77, no. 13, pp. 1263–1271, 2011. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 174 
 
 
 
 
 
 
APPENDIX A 
 
 
IACUC APPROVAL FOR ANIMAL STUDY 
 
 
 
 
 175 
 
 
 
 
 
 
APPENDIX B 
 
 
IACUC APPROVAL FOR ANIMAL STUDY 
 
 
 
 
 
 176 
 
 
 
 
 
 177 
 
 
 
 
 
 
APPENDIX C 
 
 
COPYRIGHT PERMISSIONS 
 
 
 
 
 178 
 
 
 
 
 
 179 
 
 
 
 
 
 180 
 
 
 
 
 
 181 
 
 
 
 
 
 182 
 
 
 
 
 
 183 
 
 
 184 
 
 
 185 
 
 
